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2Abstract
Acute lymphoblastic leukaemia (ALL) is the most common cancer in children, and is
characterised by the proliferation of immature lymphoid cells in the bone marrow.
The fusion gene TEL/AML1, generated by the chromosome translocation t(12;21), is
the most common single genetic aberration in B-lineage ALL, and is formed from
the transcription factors TEL and AML1 (coded for by the genes ETV6 and RUNX1,
respectively). However, it is still not clear how the presence of TEL/AML1 causes
the development of leukaemia. In addition, the importance of a common secondary
mutation in TEL/AML1+ leukaemia, the loss of the untranslocated ETV6 allele, is
still subject to debate.
The role of TEL/AML1 in malignant haematopoiesis has been previously studied in
a variety of models, include in vivo mouse models, in vitro TEL/AML1+ cell lines,
and ex vivo patient samples. Each of these models has contributed great amounts to
our knowledge about TEL/AML1+ leukaemia; however, each type of model has its
disadvantages. Here, a new model is presented which aims to complement these
other models, based upon human embryonic stem cells (hESCs) expressing a
TEL/AML1 transgene. These transgenic hESCs were shown to be capable of
multipotent haematopoietic development, including towards B lymphocytes.
The consequence of the loss of TEL in TEL/AML1+ leukaemia is not fully known.
Here I provide two insights into this frequent secondary mutation. Firstly, a gene
expression microarray revealed the transcriptional role of TEL and illuminated how
its loss might contribute to progression of TEL/AML1+ leukaemia. Secondly, the
functional role of TEL in proliferation and apoptosis was further investigated, which
provided further insight about the clonal evolution of TEL/AML1+ leukaemia. In
addition, new discoveries were made of potential partners for heterodimeric
transcription factor complexes and targets for TEL repression, which provide new
avenues for future studies.
Taken together, the data presented in this thesis provides the basis for renewed study
into TEL/AML1+ leukaemia which could address remaining questions about the
disease.
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Chapter 1: Introduction
1.1 General features of leukaemia
1.1.1 Disease & Classification
The leukaemias are a group of cancers of the bone marrow involving the
proliferation of immature leukocytes called ‘blasts’, and make up about 2.5% of
cancers in the United Kingdom, with an incidence of about 1 in 10,000 (Office of
National Statistics, Cancer Registrations, 2008). Leukaemia can be classified as
either acute or chronic; acute leukaemias are fast progressing and are the most
common leukaemias in children, whereas chronic leukaemias can take months or
years to progress, involving more mature blasts, and commonly occur in adults.
These can be further subdivided into the haematopoietic lineage of the leukaemic
blasts, either lymphoid or myeloid. Combining these classifications gives the four
major groups of leukaemias (making up over 80% of all leukaemias), which are
Chronic Myelogenous Leukaemia (CML), Chronic Lymphocytic Leukaemia (CLL),
Acute Myelogenous Leukaemia (AML), and Acute Lymphoblastic Leukaemia
(ALL).
1.1.2 Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia (ALL) is a disease typified by the proliferation of
immature lymphocytes (termed lymphoblasts) in the bone marrow. The symptoms of
the disease probably result from the ‘crowding-out’ of normal haematopoietic cells
by these malignant lymphoblasts, and include anaemia, fatigue, frequent infections
and fever, and bruising caused by the loss of platelets. In addition, leukaemia blasts
infiltrate other organs, including the central nervous system (CNS), lymph nodes,
spleen, and liver. According to the Haematological Malignancy Research Network,
the incidence of ALL is roughly 1 in 100,000 in the United Kingdom, and peaks in
2-10 year olds, where it accounts for 80% of all leukaemias in this age group.
Lymphoid leukaemias can be either of B-cell, T-cell, or Natural Killer (NK)-cell
lineage, with B-cell lineage leukaemias making up approximately 88% of all
lymphoid leukaemias, and T-cell ALL accounting for 15 to 25% of ALLs
(Hoffbrand et al 2006; Knight 2010).
CHAPTER 1: INTRODUCTION
15
1.1.3 Subtypes of B-lineage ALL
The most common single genetic cause of childhood B-lineage ALL is the
chromosome translocation t(12;21)(p13;q22), generating a fusion between two
transcription factors: the gene ETV6 (coding for the protein TEL) and RUNX1
(coding for AML1), often referred to as TEL/AML1. Affecting roughly 25% of
patients (1 in 10,000 children under the age of 15), the prognosis of TEL/AML1+
leukaemia is good, with around 90% of children cured (Moorman 2012). The
frequency of TEL/AML1 fusions in adult ALL is low, representing about 3% of
adult ALL cases (Kwong & Wong 1997; Lee et al 2005).
The fusion protein BCR-ABL1, resulting from the t(9;22)(q34;q11.2) translocation
(otherwise known as the ‘Philadelphia chromosome’), is more commonly associated
with adult ALL than childhood ALL, representing 30% and 3% of cases,
respectively. BCR-ABL1 is associated with a poor prognosis in ALL, despite being
associated with a good prognosis in CML (Knight 2010).
Other chromosome abnormalities associated with B-ALL include
t(1;19)(q23;p13)/E2A-PBX1, t(v;11q23)/rearranged MLL, and
t(5;14)(q31;q32)/IL3-IGH. Hyperdiploidy (chromosome numbers in excess of 50)
and hypodiploidy (fewer than 45 chromosomes) are also frequently observed in
B-ALL. In contrast, T-cell leukaemias do not have any defining cytogenetic
abnormalities for the purposes of classification (WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissue, 2008).
Down’s Syndrome (DS, or Trisomy 21) is associated with a higher incidence of both
ALL and AML (Maloney 2011) with most of the standard chromosome
translocations represented in DS patients. The overall mortality rate in DS-associate
leukaemia is higher; this is likely due to the different frequencies of favourable and
unfavourable chromosome translocations in DS patients. For example, TEL/AML1+
leukaemia is less frequently observed in DS-associated ALL (Forestier et al 2008;
Maloney et al 2010).
~~~
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The first part of this chapter starts with an introduction to haematopoiesis and B cell
development and function, followed by an overview of two cell processes critical in
cancer: proliferation and apoptosis.
1.2 Haematopoiesis
Haematopoiesis, the generation of all blood cells from haematopoietic stem cells
(HSCs), is one of the most studied tissue development systems in biology. Indeed,
HSCs are the archetypal stem cell; Till, McCulloch, and colleagues were the first to
prove that cells existed in the bone marrow that could give rise to multiple
differentiated cell types (Becker et al 1963) and that these cells were capable of self-
renewal (Siminovitch et al 1963), two defining characteristics of all stem cells. This
started a new field of stem cell research, to determine how the decisions were made
between self-renewal and differentiation (Iscove 2011).
Haematopoiesis is a vast subject, and it is neither possible nor necessary to
summarise the whole body of research in this introduction. Presented here is an
overview of the important features of haematopoiesis that are necessary background
for the chapters to follow.
Differentiated blood cell types are not generated directly from HSCs, instead they
arise via a series of intermediate progenitors. Figure 1.1 shows a current
understanding of the hierarchy of haematopoietic development, adapted from Reya
et al 2001. This model divides HSCs into three categories, based upon their ability to
self-renew; long-term self-renewing HSCs (LT-HSCs), short-term self-renewing
HSCs (ST-HSC), and multipotent progenitors with no self-renewal capacity. These
categories were determined by the speed at which transplanted cells could restore
haematopoiesis in mice subjected to lethal X-ray irradiation, and the duration for
which this could be sustained (Morrison & Weissman 1994; Morrison et al 1997;
Reya et al 2001).
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Figure 1.1 – Overview of haematopoietic development.
HSCs are divided into long-term and short-term HSCs (LT-HSC and ST-HSC, respectively), capable of self
renewal (indicated by circular arrow), and multipotent progenitors, not capable of self-renewal. These give rise to
Common Lymphoid Progenitors (CLP) and Common Myeloid Progenitors (CMP). CLPs give rise to B, T, and
NK cells. CMPs give rise to granulocyte/macrophage precursors (GMPs) and Megakaryocyte/Erythrocyte
Precursor (MEPs), which generate platelets and red blood cells through Megakaryocyte precursors (MkP) and
Erythrocyte precursors (ErP), respectively. Dendritic cells are believed to arise from both CLPs and GMPs.
Adapted from Reya et al 2001.
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1.2.1 Stages of haematopoietic development
Haematopoiesis in the mammalian embryo originates in the extra-embryonic yolk
sac (Dzierzak & Speck 2008). The emergence of the first haematopoietic cells,
primitive erythrocytes, coincides with the development of vasculature at embryonic
day 7.5 (E7.5). This lead to the discovery of what is believed to be a common
precursor to haematopoietic and endothelial tissues, called the haemangioblast (Choi
et al 1998; Fehling et al 2003), although there is still debate around the identity and
differentiation potential of the haemangioblast (Hirschi 2012).
Definitive haematopoietic stem cells (HSCs), capable of reconstituting irradiated
adult mice when transplanted, do not appear in the developing embryo until E10.5 in
the aorta-gonad-mesonephros (AGM) region (Muller et al 1994; Medvinsky &
Dzierzak 1996; de Bruijn et al 2000). HSCs emerge from the luminal surface of the
dorsal aorta (de Bruijn et al 2002; North et al 2002; Taoudi & Medvinsky 2007),
from endothelial cells which are collectively known as the ‘haemogenic
endothelium’ (Zovein et al 2008). The foetal liver is a major source of HSCs in the
developing embryo, but does not itself generate HSC de novo (Johnson & Moore
1975; Houssaint 1981); rather it is colonised by HSCs from the AGM and other
tissues to which the circulation has transported HSCs, e.g. the placenta and yolk sac
(Kumaravelu et al 2002; Gekas et al 2005).
Between the first haematopoietic cells in the yolk sac at E7.5 and the emergence of
the first definitive HSCs at E10.5, a series of multipotent haematopoietic cells are
also generated. After primitive erythropoiesis begins in the yolk sac and before blood
circulation commences at E8.5, multipotent myeloid progenitors are generated in the
yolk sac (Palis et al 1999). Similarly, before the onset of circulation,
lymphoid-myeloid precursors are generated in the para-aortic splanchnopleura, the
region which will become the AGM (Cumano et al 1996). Finally, a HSC population
capable of repopulating neonatal mice, but not adult mice, is generated
concomitantly in the yolk sac and the AGM region at E9 (Yoder et al 1997).
HSCs generated from the AGM region migrate to colonise the liver, and then the
spleen and thymus are colonised either directly from the AGM or from the liver
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(Bertrand et al 2006; Yokota et al 2006). However, it is likely that HSCs that
populate the bone marrow in adult mice are derived not from the HSCs emerging
from the embryonic AGM region, but from those in the yolk sac (Gothert et al 2005;
Samokhvalov et al 2007; Tanaka et al 2012). The bone marrow becomes the main
site of haematopoiesis as extra-medullary haematopoiesis in the liver, spleen, and
thymus subsides and ceases.
1.2.2 Cell surface markers of early haematopoietic development
The elucidation of early haematopoietic development has been facilitated by cell
surface markers that can be used to identify populations of cells by immunostaining.
The classical marker for endothelium is CD31, the cell-adhesion molecule
PECAM-1 (Platelet/Endothelial Cell Adhesion Molecule-1; Newman 1994), which
was used to identify that haematopoietic and endothelial cells arise from a common
precursor (Choi et al 1998; Fehling et al 2003; Zovein et al 2008).
The clear identification of human HSCs capable of long-term engraftment (so called
‘LT-HSC’; Kondo et al 2003) has been more complicated than the identification of
the mouse equivalent, due to the assays being used to functionally identify such
populations (Kondo et al 2003). HSCs are known to express CD34, but the majority
of CD34+ haematopoietic cells are committed progenitors (Hogge et al 1996).
CD34+ HSCs have been further characterised by the lack of expression of CD45RA
(Mayani et al 1993) and CD38 (Hao et al 1995; Bhatia et al 1997), amongst others
(Kondo et al 2003). A recent study has characterised human LT-HSCs further by
CD34+ CD38− CD45RA− Thy1+ CD49f + (Notta et al 2011a). In addition, CD43 has
been identified as the earliest exclusive marker of haematopoietic cells emerging
from differentiation of human embryonic stem cells, or hESCs (Vodyanik et al
2006).
1.2.3 Haematopoietic transcription factors
SCL (Stem Cell Leukaemia), also known as TAL1 or TCL5, is a basic
helix-loop-helix (bHLH) transcription factor (Massari & Murre 2000), and one of the
earliest-acting regulators of haematopoiesis (Lecuyer & Hoang 2004). SCL is
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essential for haematopoiesis in vivo (Shivdasani et al 1995), as SCL-/- ES cells do not
contribute to any haematopoietic lineage in chimeric mice (Porcher et al 1996; Robb
et al 1996). SCL appears to act at several stages of haematopoietic development:
SCL is essential for the production of primitive haematopoietic cells from
hemangioblasts in the yolk sac (Robb et al 1995), as well as definitive
haematopoiesis (Porcher et al 1996). In adult haematopoiesis, SCL expression is
highest in HSCs and progressively decreases in more committed cells in the
haematopoietic hierarchy (Elefanty et al 1998), but still remains high in cells
differentiating towards erythrocyte, megakaryocyte, and mast cell lineages (Lecuyer
& Hoang 2004).
EKLF, also known as KLF1, is a member of the Krüppel-Like Factor family of
transcriptional regulators (Siatecka & Bieker 2011). EKLF is essential for definitive
erythropoiesis in the foetal liver, but dispensable for primitive erythropoiesis in the
yolk sac (Nuez et al 1995), despite its expression throughout primitive
haematopoiesis (Southwood et al 1996). EKLF is not expressed in early
haematopoietic progenitors, but is expressed in common myeloid progenitors and
their megakaryocytic-erythroid progenitor progeny, and increases as cells commit to
erythrocyte lineage, whilst simultaneously inhibiting megakaryocytic differentiation.
(Frontelo et al 2007).
PU.1, also known as SPI-1, is a member of the ets family of transcription factors,
and is an important transcriptional regulator during definitive haematopoiesis
(Kastner & Chan 2008). PU.1 knockout mice die late in gestation and have defects in
multiple definitive haematopoietic lineages, including B- and T-lymphocytes,
monocytes, and granulocytes (Scott et al 1994). PU.1 is essential for the
maintenance of adult and foetal liver HSCs, and also for the differentiation of
committed myeloid progenitors (DeKoter et al 1998; Iwasaki et al 2005). PU.1 has
an important role in B cell development (Medina et al 2004), as B cell differentiation
and maturation is inhibited, but not blocked, in PU.1 deficient mice (Iwasaki et al
2005).
Two of the GATA family of transcription factors, GATA1 and GATA2, have major
roles in the regulation of haematopoiesis. GATA1 is an important regulator of
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various myeloid lineages (Crispino 2005): it is essential for erythropoiesis, as
GATA1 null mice embryos die at around E10.5 from anaemia, and are found to have
defective primitive red blood cell development (Fujiwara et al 1996). Definitive
erythroid development from GATA1-null ESCs is also blocked (Weiss et al 1994).
In erythropoiesis, GATA1 is known to interact with multiple other transcription
factors including PU.1 and EKLF (Cantor & Orkin 2002). Aside from its importance
in erythoid development, GATA1 has a role in megakaryocyte growth and platelet
genesis (Shivdasani et al 1997), eosinophil development (Crispino 2005), and mast
cell differentiation (Migliaccio et al 2003).
GATA2 also has an important role in haematopoiesis (Vicente et al 2012). GATA2
is required for the production, proliferation, and survival of definitive HSCs right
from their earliest emergences in the AGM region (Tsai et al 1994; Tsai & Orkin
1997; Ling et al 2004). In this role, GATA2 is known to interact with other
haematopoietic transcription factors FLI1 and SCL (Pimanda et al 2007). GATA2
also has an overlapping role with GATA1 in the regulation of erythroid and
megakaryocytic development (Ikonomi et al 2000; Grass et al 2003). Both GATA1
and GATA2 also exert effects on myeloid differentiation through the regulation of
expression of PU.1 (Chou et al 2009).
1.2.4 Assays used to investigate haematopoiesis
Research in haematopoiesis, including the origins of haematopoietic precursors, has
required a variety of standardised assays to test how haematopoietic development is
affected. Here an overview is given of a selection of these methods, what function
they perform, and examples of how they have been used to investigate
haematopoietic development.
Perhaps the ‘gold standard’ test for determining the haematopoietic potential of a
suspected stem cell is to transplant cells into an irradiated recipient mouse.
Definitive HSCs are defined by their ability to reconstitute full long-term
haematopoiesis in an irradiated recipient mouse and, by serial transplantation, that
the same population can be transplanted from the recipient mouse into another
irradiated mouse and reconstitute haematopoiesis once more, and so on. This can be
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used to determine, for example, the origin of definitive HSCs in the developing
embryo (e.g. Muller et al 1994), or the influence of certain genes on HSC
populations (e.g. Hock et al 2004). However, with adaptation it can be used for other
purposes. For example, it is assumed that only one HSC is necessarily to reconstitute
haematopoiesis in an irradiated recipient mouse, and thus by performing a serial
dilution of a suspected stem cell population before transplantation, one can
determine how many definitive HSCs exist in the starting population by calculating
backwards from the biggest dilution that allows full haematopoietic reconstitution.
This limiting dilution assay has been used to determine, for example, the effects of
Sonic Hedgehog (Shh) signalling on the numbers of HSCs in the bone marrow
(Bhardwaj et al 2001). Another adaptation is xenograft into immunodeficient mice,
such as the NOD-SCID mouse, to perform the same assays for human HSCs, either
derived from primary bone marrow aspirates or cord blood (e.g. Larochelle et al
1996; Broxmeyer et al 2011), or from hESCs (e.g. Wang et al 2005; Ledran et al
2008).
The colony forming unit (CFU) assay was first described by Till and McCulloch
(1961); irradiated mice that received injections of bone marrow were found to
develop nodules in their spleen. The number of these nodules varied linearly with the
numbers of cell injected, and these nodules contained a number of different
haematopoietic cell types. These colonies were later found to be clonal in origin, i.e.
derived from a single cell (Becker et al 1963). In vitro CFU assays today involve
growing suspected haematopoietic progenitors in a semi-solid media (most
commonly methylcellulose) with haematopoietic cytokines to promote
differentiation. The resulting colonies of haematopoietic cells can be enumerated and
different cell types identified to determine the frequency and haematopoietic
potential of the cells in the starting population. This technique has been used, for
example, to study how cells from different haematopoietic niches influence the
differentiation of hESCs (Ledran et al 2008).
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1.3 B cell development
To understand the progression of B cell ALL, it is important to give a brief overview
of the function of B cells, and human B cell development, both normal and
leukaemic.
1.3.1 Normal function of B cells
The primary role of B cells is to produce antibodies with affinity to foreign antigens.
These antibodies bind to foreign pathogens, marking them for destruction by
different cell types of the immune system, in a mechanism called the ‘humoral
immune response’ (Murphy et al 2008). Antibodies can be secreted by B cells as a
soluble protein, but can also be bound to the plasma membrane, where they form the
main component of a signalling complex called the B-cell receptor (BCR). Two
other essential components of the BCR are the invariable immunoglobulins Igα
(otherwise known as mb-1 or CD79A) and Igβ (CD79B), which provide most of the
cytoplasmic domains of the BCR (Borst et al 1996; Murphy et al 2008).
BCR signalling is enhanced by a co-receptor complex made up of the
transmembrane proteins CD19, CD21, and CD81 (Murphy et al 2008). CD19 is
expressed from early B cell development and is frequently used as a marker for
B lineage commitment as a result.
Diversity in antibody binding is generated by a variety of mechanisms, and is an
integral part of the development of B cells. The basic structure of an antibody
consists of two heavy chains and two light chains. Both heavy and light chains have
a “variable region” which come together to form the antigen binding surface, and an
invariable “constant region”, which forms the remaining antibody structure. The
variable regions are produced by the recombination of multiple gene segments at the
light and heavy chain loci. For heavy chains, this consists of roughly 65 ‘Variable’
(V) segments, 27 ‘Diversity’ (D) segments, and 6 ‘Joining’ (J) segments. Light
chains only have V and J segments; for the two light chain loci, called kappa and
lambda, there are 40 V and 5 J segments for kappa, and 30 V and 4 J segments for
lambda. (The numbers of segments are not the same for all people, and there are
multiple non-coding ‘pseudogenes’ in each loci which are not included in this
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number; Murphy et al 2008). Recombination of the segments is controlled by two
Recombination Activating Genes, RAG1 and RAG2 (Schatz & Ji 2011).
Additional diversity is conferred by the removal and insertion of nucleotides at the
joins between the V and J segments in light chains (and also partially in the sequence
of the D region in heavy chains). Nucleotides called N-nucleotides are added by the
gene Terminal deoxynucleotidyl Transferase (TdT; Komori et al 1993). Further
diversity in mature activated B cells can be gained through a process called ‘somatic
hypermutation’, which generates point mutations in the V gene segments. This
allows further editing to generate enhanced binding to antigen (Di Noia & Neuberger
2007).
1.3.2 The humoral immune response
Upon infection by a pathogen, B cells expressing a BCR specific for a particular
antigen will engulf the pathogen by phagocytosis. Once internalised, the pathogen is
degraded, and peptides from the pathogen are presented back onto on the surface of
the B cell by a MHC class II molecule. These peptides are recognised by
helper T cells (TH2 cells) specific for that peptide, which have been ‘armed’ by
professional antigen presenting cells such as dendritic cells and macrophages. This
causes the production of various cytokines by the helper T cell, which in turn causes
‘B cell activation’: the differentiation and proliferation of that B cell into a ‘plasma
cell’, producing antibodies specific for the antigen it recognised on the pathogen
(Parker 1993). How these antibodies are distributed throughout the body, and what
happens when these antibodies bind to the antigen, is defined by the isotype of the
antibody, which is controlled by the cocktail of cytokines produced by the helper
T cell (Murphy et al 2008).
When bound to pathogens, isotypes such as IgM and IgG can activate the immune
process of ‘complement’ and stimulate removal of the pathogen by phagocytes, such
as neutrophils and macrophages. Phagocytes can also be stimulated directly via
receptors which recognise the “constant regions” on the antibodies known as
Fc receptors (Ravetch & Clynes 1998). Similarly, small particles such as bacterial
toxins and cellular debris can be neutralised by most antibody isotypes, particularly
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IgG and IgA. These antigen-antibody immune complexes are carried on erythrocytes
in the blood by the activation of complement, and transported to the spleen or the
liver where they are cleared by macrophages (Murphy et al 2008).
IgG antibodies binding to Fc receptors on natural killer (NK) cells stimulate these
cells to kill the antibody-bound pathogen by a process called antibody-dependent
cell-mediated cytotoxicity (ADCC; Lanier et al 1988); NK cells release granules
containing perforin and granzymes, which kills the pathogen by creating pores in the
membrane, and activating internal apoptosis pathways, respectively. Finally,
antibodies of the IgE isotype bind to Fc recptors on mast cells, basophils, and
activated eosinophils, which release chemicals such as histamine, increasing blood
flow and making blood vessels more permeable, as a means to recruit more immune
cells to the site of infection (Sutton & Gould 1993).
1.3.3 Early B cell development in humans
B-lineage cells develop in multiple locations during embryonic development,
including the foetal liver, but from mid-gestation onwards, all B cells originate in the
bone marrow (LeBien 2000). From the haematopoietic stem cell (HSC) in the bone
marrow, B cell development goes through a Common Lymphoid Progenitor (CLP)
stage, which is capable of differentiating towards B cells or T cells, Natural Killer
Cells (NK), or Dendritic Cells (DCs; Galy et al 1995). CLPs then give rise to a cell
termed ‘Early-B’, which is the first B-lineage committed cell, before progressing
through ‘pro-B’, ‘pre-B’, and ‘immature B’ cell stages to make a functional naïve
B cell (LeBien 2000). In this regard, human B cell development is largely similar to
murine B cell development, though there are some differences and gaps in
understanding of human B lymphopoiesis (LeBien 2000; Hardy et al 2007; LeBien
& Tedder 2008).
CLPs are defined as CD34+CD45RA+CD10+CD19– cells, which give rise to B, T,
NK cells, and DCs, but lack myeloid and erythroid potential (Galy et al 1995). The
next stage of B cell development, ‘Early-B’ cells, is defined by the same cell surface
markers as CLPs, but has characteristics of B cell lineage rather than T, NK, or DC
lineage. As such, Early-B cells are negative for the pan-B marker CD19, but express
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RAG1 and RAG2 (Ryan et al 1997) and undergo DJ-recombination of the heavy
chain immunoglobulin (Bertrand et al 1997; Davi et al 1997). Early-B cells also
express Pax5 (Ryan et al 1997), as well as cytoplasmic Igα (Dworzak et al 1998) and
VpreB (Wang et al 1998b), components of the pre-B Cell Receptor (pre-BCR)
complex.
Pro-B cells are defined as expressing the cell surface markers CD34 and CD19, and
high levels of CD10 (Loken et al 1987). These cells also express cytoplasmic TdT
(Loken et al 1987), continue to express cytoplasmic VpreB (Wang et al 1998b), and
the majority have undergone VDJ recombination (Bertrand et al 1997; Davi et al
1997).
The next stage of development, the pre-B cell, can be further subdivided into two
stages. Pre-BI cells are large proliferating cells, and have lost some expression of
TdT and all expression of the RAG genes. Pre-BI cells also express on their cell
surface the mu-heavy chain (µHC), which had undergone VDJ recombination during
the preceding stages (Loken et al 1987; Ghia et al 1996) and will later form the
heavy chain of IgM. In addition, VpreB and the other components of the pre-BCR,
λ5, Igα and Igβ, are also expressed on the surface of pre-BI cells, forming the
pre-BCR complex (Benschop & Cambier 1999). The combination of VpreB and λ5
are known as the ‘surrogate light chain’ or ψLC, which, as the name suggests, take
the role of the light chain immunoglobulin before rearrangements of the VJ gene
segments take place. Pre-BI cells progress to form smaller, non-proliferating cells
referred to as Pre-BII cells. These cells cease to express extracellular pre-BCR, but
express once more the RAG genes and TdT, as VJ recombination of the light chain
immunoglobulins takes place primarily at the kappa-light chain (κLC) locus (Ghia et
al 1996). Therefore, the formation of the pre-BCR can be seen as an important
checkpoint in the development of B cells, as it marks the transition from pro-B to
pre-B cell, and allows the cell to progress to recombination of the light chain genes.
Once rearrangements of the VJ gene segments has ceased, the cell expresses
complete IgM on the surface and the cell is designated an immature B cell. In the
bone marrow, immature B cells are tested for autoreactivity; immature B cells that
react to auto-antigens are eliminated in the bone marrow, those that do not are
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allowed to mature and leave the bone marrow. Alternative splicing generates
delta-heavy chains (δHC) and so the mature B cells express both IgM and IgD on
their surface (Murphy et al 2008).
1.3.4 Control of B cell development
B cell development is controlled by a variety of mechanisms. Cell intrinsic
mechanisms consist of the checkpoints of V(D)J recombination as described above,
and the actions of networks of transcription factors, which stimulate the expression
of the others sequentially. These intrinsic mechanisms are also controlled by
extrinsic mechanisms of cytokines produced by the bone marrow stroma cells, on
which haematopoietic development takes place. In addition to the production of
certain chemokines necessary for B cell development, stroma cells also express cell
adhesion molecules which developing B cells can attach to, presumably to enhance
and enable the effects of soluble and membrane bound ligands described below.
In murine lymphoid development, the expression of the transcription factors PU.1
and Ikaros in multipotent haematopoietic progenitors promotes the expression of
FLT3, the receptor for a ligand expressed on bone marrow stromal cells called
FLT3-ligand. In CLPs, signalling through FLT3 acts together with PU.1 to induce
the expression of the IL-7 receptor (IL-7R) signalling, which induces the expression
of E2A. The production of the transcription factor Early B-cell Factor (EBF) is
stimulated by PU.1, E2A, and IL-7R, which commits the lymphoid cell to B-lineage
differentiation. Finally EBF promotes the expression of the pan-B marker Pax5,
which directs the expression of key components of the BCR signalling complex,
such as CD19, Igα, and BLNK (Singh et al 2005; Murphy et al 2008). Human B cell
development is similar, however, the role of IL-7 signalling is not clear, as it is
known that IL-7 is not essential for human B cell development (LeBien 2000).
1.3.5 B cell activation in secondary lymphoid tissues
As described above in section 1.3.2, B cells presenting peptides from a pathogen are
activated by the co-stimulation of a helper T cell. However, it is clear that the
chances of a B cell presenting peptides from a pathogen encountering a T cell that
recognises those peptides in the blood stream are very slim. Instead, the chances of
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such an encounter are increased by bringing B cells and T cells together in lymphoid
organs such as the lymph nodes. The binding of antigen to B cells, and the
recognition of peptides by T cells and subsequent differentiation to helper T cells,
activates the expression of specific cell adhesion molecules. This ‘traps’ both primed
helper T cells and antigen-bearing B cells within particular regions of the lymph
node, thus greatly increasing the chances of a B cell encountering the appropriate
helper T cell (Garside et al 1998).
Once a B cell is activated, it proceeds to differentiate into antibody-producing
plasma cells. Some B cells form a ‘primary focus’, where B cell differentiation
proceeds quickly; such primary foci form in the red pulp of the spleen or in the
medullary cords where lymph drains from the lymph node. Alternatively, some
B cells continue to proliferate and form a ‘germinal centre’, which could be
described as an ‘island’ of dividing B cells in a ‘sea’ of resting B cells (Murphy et al
2008). In germinal centres, B cells undergo somatic hypermutation to further edit the
variable regions of their antibodies, the aim being to improve the affinity of the
antibody for the antigen should the pathogen not be cleared from the body promptly.
Germinal centre (GC) B cells will differentiate to form plasma cells, as well as
memory B cells which confer long-term protection against future infections by the
pathogen (MacLennan 1994).
1.3.6 B cell development in ALL
The lymphoblasts that are present in the bone marrow of patients with TEL/AML1+
leukaemia frequently exhibit a pro-B (CD34+CD19+CD10+) phenotype with aberrant
expression of some myeloid antigens (Golub et al 1995; Borowitz et al 1998; De
Zen et al 2000), and the gene expression profile of TEL/AML1+ lymphoblasts is
similar to those seen in normal pro-B cells (Andersson et al 2010). This indicates an
impairment in B cell differentiation at the transition from pro-B to pre-B cells, which
is frequently (Tsuzuki et al 2004; Fischer et al 2005), but not always (Andreasson et
al 2001; Morrow et al 2004; Schindler et al 2009) recapitulated in transgenic mouse
models.
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Mouse models involving xenografts of human cells, either from leukaemia patients
themselves or from normal haematopoietic progenitors exogenously expressing
TEL/AML1, present an opportunity to study characteristics of B cell development in
the context of TEL/AML1+ leukaemia. These have indicated that TEL/AML1
confers increased self-renewal properties on a CD34+CD38–CD19+ population,
which is not observed in normal bone marrow, but whose closest normal equivalent
is pro-B cells (Castor et al 2005; Hong et al 2008).
Some of the symptoms of leukaemia are associated with a decrease in myeloid
haematopoiesis, though it is not clear from investigating patient bone marrow alone
whether this abnormal haematopoiesis is due to effects of TEL/AML1 on HSCs, or
whether it is a result of the ‘crowding out’ of normal cells in the bone marrow by
leukaemic blasts. Transgenic mouse models give indications of the effects of
TEL/AML1 in mammalian haematopoiesis. Bone marrow transduced with
TEL/AML1 has normal myeloid development (Morrow et al 2004; Tsuzuki et al
2004; Fischer et al 2005), even increasing myeloid progenitor self-renewal (Tsuzuki
et al 2004; Fischer et al 2005). However, it has also been shown that TEL/AML1
increases self-renewal in HSCs, and possibly decreases differentiation towards
lineage-specific progenitors (Fischer et al 2005; Schindler et al 2009).
A summary of the main gene expression changes during selected stages of B cell
development is shown in Figure 1.2 below:
Figure 1.2 – Diagram of B cell development.
Outline of differentiation from common lymphoid progenitor (CLP) to pro-B and pre-B cells, via the Early B cell. Expression
of CD markers (34 = CD34, etc.) and pre-B cell receptor components µHC and ψLC are shown on the outside of each cell, and
expression of transcript for Rag1/2, Tdt, mb1, Pax5, and VpreB are shown on the inside of each cell. Below the B-lineage cells,
the recombination status of the heavy chain VDJ genes is shown. Dotted line indicates the stage at which B cell differentiation
appears to be blocked in TEL/AML1+ leukaemia patients and mouse models.
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1.3.7 B cell development and other B cell malignancies
As with the resemblance of B-cell ALL to normal pro-B cells, many of the various
B cell malignancies also appear to be the counterparts of normal B cell
developmental stages. This can be manifested in their V(D)J rearrangements,
morphology, surface phenotype, and tumour site (Shaffer et al 2002; Murphy et al
2008). For example, Follicular Lymphomas tend to resemble germinal centre B cells:
located in lymph nodes, expressing the GC B cell marker CD10, and are frequently
infiltrated by follicular dendritic cells and T cells. A malignancy called Diffuse
Large B Cell Lymphoma has a heterogeneous phenotype, but can be divided into two
forms which resemble GC B cells (with somatic hypermutation) or activated
peripheral B cells (without somatic hypermutation; Alizadeh et al 2000). A similar
situation is found in Chronic Lymphocytic Leukaemia (CLL) where both gene
expression profiling (Klein et al 2001; Rosenwald et al 2001) and mutation status of
V gene segments (Hamblin et al 1999; Gurrieri et al 2002) have distinguished two
subtypes of the disease, resembling normal memory B cells and activated peripheral
B cells (Shaffer et al 2002).
1.4 Proliferation
Cancer is defined by the uncontrolled proliferation of cells, both by means of
self-sufficiency in growth-promoting signals, and insensitivity to growth-inhibitory
signals (Hanahan & Weinberg 2000). To describe how proliferation is affected in
leukaemia, a brief introduction to the cell cycle and how it is controlled is given
below.
1.4.1 The cell cycle
As a means to ensure that the processes of cell division (including DNA replication,
chromosome condensation, and separation of chromosomes into daughter cells) are
carried in the correct sequence and in a controlled fashion, these processes are
divided into phases of the cell cycle. DNA Synthesis, which takes place during
S-phase, and Mitosis, occurring during M-phase, are separated by two ‘Gap’ or
G-phases, so that the cell cycle proceeds sequentially through G1, S, G2, and
M-phase. G1-phase can be seen as an opportunity for a cell to pause to assess
CHAPTER 1: INTRODUCTION
31
whether conditions (both external and internal) are favourable before committing to
the effort of cell division. In the case that conditions are not favourable, cells can
enter an optional resting phase known as ‘G0’, in which the cell can remain for
extended periods of time before restarting proliferation. Some differentiated cell
types, for example neurones and skeletal muscle cells, remain in G0 permanently and
will not divide again before they die (Alberts et al 2002).
Progression through the cell cycle, and thus the proliferation of cells, is controlled at
several checkpoints. As mentioned above, G1-phase is where the cell checks that the
environment is favourable for the cell to divide. Favourable external conditions for
cell division will include a ready supply of nutrients. In addition, transition through
the G1-checkpoint into S-phase can be stimulated by growth factors and mitogens.
Factors which might inhibit cell division include damage to DNA; the consequence
of DNA damage is for the cell to attempt to repair the damage, or to commit suicide
by apoptosis. The protein p53 is an important component in controlling this process.
The transition from G2-phase into M-phase, also known as the G2-checkpoint, occurs
in a similar fashion, by sensing DNA damage in the newly replicated DNA, and
either repairing the damage or triggering apoptosis in the cell. Finally, the metaphase
checkpoint can only be passed once, after the condensed chromosomes have aligned
in the cell and microtubule spindles have attached to each chromosome. This allows
the equal separation of sister chromatids, preventing an uneven distribution of
chromosomes in the daughter cells (Alberts et al 2002).
1.4.2 Internal control of the cell cycle
The molecular control of the progression of the cell cycle has several layers, the
foundation of which is the complexes formed by the cyclins and the
cyclin-dependent kinases (Cdks). The activity of these cyclin-Cdk complexes
increases and decreases cyclically, and the periods of activity for each complex, and
thus their names, roughly correspond to one phase of the cell cycle; the G1-Cdk
complex starts the progression of the cell cycle, the G1/S-Cdk complex commits the
cell to DNA replication, the S-Cdk complex promotes DNA replication, and the
M-Cdk complex promotes the events of mitosis (Morgan 1997; Alberts et al 2002).
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As suggested by the name, cyclin-dependent kinases are not active until bound by
cyclins. The full activation of the Cdk-cyclin complexes then requires
phosphorylation by protein complexes known as Cdk-activating kinases (CAKs); in
humans, this is performed by the kinase Cdk7 and its partners cyclin H and Mat1
(Morgan 1997). Further phosphorylation can also inhibit the activity of Cdk-cyclin
complexes, a process particularly important in controlling M-Cdk complex at the
onset of mitosis; phosphorylation by proteins related to the yeast kinase Wee1
inhibits Cdk-complexes, which can be reversed by phosphatases of the Cdc25
family. The formation and activity of Cdk-cyclin complexes can also be inhibited by
the binding of proteins called Cdk-inhibitor proteins (CKIs), which is a significant
regulatory mechanism during G1 and S-phase. In humans, well characterised
examples of such CKIs are p21-Cip1 (also known as CDKN1A), p27-Kip1
(CDKN1B), p16-Ink4A (CDKN2A), p15-Ink4B (CDKN2B), and p18-Ink4C
(CDKN2C; Morgan 1997; Pavletich 1999). Many of these genes that inhibit
progression of the cell cycle are known secondary mutations in leukaemias including
TEL/AML1+ acute lymphoblastic leukaemia, as described in section 1.9.2 below.
Destruction of cyclins during critical phases of the cell cycle is triggered by the
attachment of ubiquitin molecules to specific residues on the protein. Two protein
complexes that catalyse this reaction, known as ubiquitin-ligases, are important in
this control mechanism. The SCF complex targets cyclins and CKIs that control
S-phase initiation. The Anaphase-Promoting Complex (APC) ubiquitinates cyclins
involved in the regulation of mitosis. These ubiquitin ligases are controlled by
different mechanisms; ubiquitination by SCF is controlled by the phosphorylation
state of the target cyclins, whereas APC is controlled by the addition of subunits to
the complex, notably Cdc20 (Alberts et al 2002).
1.4.3 External control of the cell cycle
Cells can also receive cues from the environment to stimulate growth. This is
particularly important in complex multi-cellular organisms, where cell numbers need
to be controlled for the proper development of organs, limbs, and tissues, and when
cells need to be replaced after other cells die. As cell volume is intrinsically linked to
cell division, external factors can either promote proliferation by growth factors,
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which promote an increase in cell volume, or mitogens, which promote progression
in the cell cycle. Many factors can act as both growth factors and mitogens.
One well-known example of a mitogen signalling pathway that controls the cell
cycle is the MAP kinase pathway. This signalling cascade is triggered by the binding
of a growth factor (for example, EGF) to its receptor (e.g. EGFR), causing the
exchange of GDP with GTP in the GTPase protein Ras. This starts a cascade of
protein phosphorylation (made possible by GTPase), eventually leading to the
phosphorylation of MAPK, which in turn leads to the activation of a protein called
Myc. Myc is a transcription factor which stimulates the production of several cell
cycle genes, such as cyclin D, subunits of SCF, and a protein called E2F which
promotes transition into S-phase.
An example of growth factor signalling pathways which increase cell volume is the
activation of a PI3-kinase (PI3K), which phosphorylates inositol phospholipids in the
plasma membrane. These then act as docking sites for kinases with Pleckstrin
Homology (PH) domains which are then activated by phosphorylation, triggering a
phosphorylation cascade. An example of a protein phosphorylated in this pathway is
S6 kinase, which phosphorylates the ribosomal protein S6, eventually leading to an
increased production of ribosomes and thus an increase in protein synthesis (Stocker
& Hafen 2000; Alberts et al 2002).
Other signalling molecules inhibit growth; for example, the TGF-β family of
signalling proteins, which signal through cell surface receptors to alter the activity of
transcription factors of the SMAD family, can in certain situations be inhibitors of
cell cycle progression. TGF-β promotes the expression of p15-Ink4B and p21-Cip1,
CKIs which block the activity of Cdk-cyclin complexes and thus prevent the
phosphorylation (and inactivation) of the protein Retinoblastoma (Rb), an inhibitor
of G1 to S-phase transition (Datto et al 1997; Alberts et al 2002).
1.4.4 Dysregulation of proliferation in ALL
As described later in section 1.9.2, many genes frequently mutated in acute
lymphoblastic leukaemia are cell-intrinsic regulators of the cell cycle (for example,
CDKN2A; Takeuchi et al 1995). In addition to genes whose products dampen cell
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cycle progression, many mutations in ALL act to alter the response to external
factors – increasing sensitivity to growth factors and mitogens, and decreasing
sensitivity to growth inhibitory signals – and leukaemic cells become dependent on
these signalling pathways. For example, TEL/AML1 is known to reduce the growth
inhibitory effects of TGF-β signalling (Ford et al 2009). Mutations that
constitutively activate Ras signalling, and thus promote survival and proliferation
through the MAP kinase pathway, are found in many human cancers and at a rate of
about 15% in ALL (Perentesis et al 2004). Finally, PI3K signalling is required for
proliferation and survival in TEL/AML1+ leukaemia cells (Fuka et al 2011a) and
upregulation of the erythropoietin receptor, which acts via PI3K signalling, is
frequent (Ross et al 2003; Fine et al 2004). Taken together, the examples above
suggest that leukaemic cells become insensitive to both intrinsic and extrinsic growth
inhibitory signals, and more sensitive to proliferation promoting signals, resulting in
an increased cell growth.
1.5 Apoptosis
Apoptosis, the process of ‘programmed cell death’, is a critical mechanism
throughout embryo development and tissue homeostasis, and is not simply the
opposing force to proliferation. For example, during development, apoptosis is
critical for the shaping of the limbs and for the correct innervation of muscles, and in
normal immune development apoptosis eliminates self-reactive lymphocytes that
would otherwise cause autoimmune disorders. To describe the role of apoptosis in
leukaemia, a concise introduction to apoptosis is presented below.
1.5.1 The mechanisms of apoptosis
The mechanism of cell death is a controlled cascade of proteases called caspases,
which have a cysteine in their catalytic site and cleave other proteins at specific
aspartic acid residues. They are formed from an inactive procaspase, which is
cleaved by other caspases. To start the cascade off, specific procaspases called
‘initiator procaspases’ are brought together by adaptor proteins, resulting in a
complex of procaspases that mutually cleave each other. Once the initiator caspases
are active, they cleave other caspase molecules, resulting in an amplifying chain
reaction of caspase activation. Different caspases cleave cellular components, such
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as nuclear lamins, resulting in the disassembly of the nucleus, and DNAse precursors
which, when activated by cleavage, destroy the DNA in the cell. The cell dismantles
itself and is quickly taken up and digested by phagocytes such as macrophages
(Alberts et al 2002).
There are two routes by which the initiator caspases are brought together by adaptor
proteins: extrinsic and intrinsic routes. The extrinsic route involves the activation of
cell surface proteins called death receptors, an example of which is the protein Fas.
Binding of Fas ligand to Fas results in the trimerisation of Fas, which recruits
adaptor proteins such as FADD (Fas-Associated protein with Death Domain). FADD
then promotes the self-cleavage of procaspase-8, which then activates caspases
leading to apoptosis (Alberts et al 2002). Fas is a member of the Tumour Necrosis
Factor Receptor (TNFR) superfamily of death receptors (Wallach et al 1999).
Extrinsic death signalling is a common route for cytotoxic T lymphocytes to clear
infected cells and control lymphocyte numbers (Murphy et al 2008).
Cells can also activate apoptosis via the intrinsic pathway. This is understood to be
triggered by the release of cytochrome c from the mitochondria, which binds to the
adaptor protein APAF1 (Apoptotic protease activating factor 1), leading to the
activation of procaspase-9 (Green & Reed 1998). The intrinsic apoptosis activation
pathway is controlled by the various members of the Bcl-2 family of mitochondrial
proteins (Chao & Korsmeyer 1998). Bcl-2 and Bcl-XL both inhibit the release of
cytochrome c, whereas family members like Bax and Bak promote its release from
mitochondria. In addition, these core Bcl-2 family members are regulated by other
family members; Bad binds to inhibit the anti-apoptosis family members, and
pro-apoptotic members Bax and Bak are activated by Bid amongst others. It is
believed that the balance between Bcl-2 and Bax activity is a key determinant of the
sensitivity of cells to apoptotic signals (Chao & Korsmeyer 1998; Alberts et al
2002). Another apoptosis regulator family is the IAP (Inhibitor of Apoptosis)
proteins, which act primarily by binding to procaspases, preventing their cleavage
and subsequent activation (Deveraux & Reed 1999; Alberts et al 2002; Salvesen &
Duckett 2002).
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The activity of the Bcl-2 family members is controlled in part by the cell cycle
regulator p53, either transcriptionally by inducing the expression of pro-apoptotic
Bax, or by directly binding and inhibiting anti-apoptotic Bcl-2 family members
(Hemann & Lowe 2006). This therefore links the control of the cell cycle to
apoptosis, and providing one mechanism by which, for example, DNA damage that
cannot be repaired triggers cell death (Alberts et al 2002). The anti-apoptotic effects
of IAP proteins can be induced by growth factor or mitogen signalling, for example,
NFκB signalling (Salvesen & Duckett 2002) and PI3K signalling (Datta et al 1999).
1.5.2 Importance of apoptosis in lymphocyte development
Apoptosis is a major regulator of B cell development (see section 1.3.3), which in
turn is regulated in part by binding of auto-antigens to the pre-BCR and binding of
foreign antigens to the BCR (Niiro & Clark 2002). Bcl-2 expression can rescue
immature B cells at various stages of early development when they would otherwise
be eliminated, such as if a non-functional pre-BCR is produced (Marsden & Strasser
2003). In addition, whilst deletion of autoreactive B cells does not require Fas
signalling it can be inhibited by Bcl-2 or Bcl-XL; in transgenic mice, autoreactive
B cells that overexpress Bcl-2 are not eliminated (Cory 1995; Marsden & Strasser
2003). Fas signalling might instead mediate the control of B cell numbers by
cytotoxic T cells (Watanabe-Fukunaga et al 1992; Takahashi et al 1994; Marsden &
Strasser 2003). In this regard, activation of B cells by BCR signalling confers
resistance to Fas-mediated cell death induced by T cells (Rothstein et al 1995). Bcl-2
and Bcl-XL are essential for maintaining a pool of B cells in adults; mice deficient in
Bcl-XL show a significant reduction in mature B cells, whereas Bcl-2 deficient mice,
after initially showing normal post-natal B cell differentiation, quickly lose adult
B cells to apoptosis (Chao & Korsmeyer 1998).
1.5.3 Methods for studying apoptosis
DNA fragmentation during the late stages of apoptosis can be visualised by DNA
staining dyes such as DAPI, Propidium Iodide (PI), or 7-Aminoactinomycin D
(7-AAD). More accurate identification of nuclei undergoing DNA fragmentation is
permitted by an assay called a TUNEL (TdT dUTP nick end labelling) assay, to
identify the ‘nicks’ in the DNA made in this process by the addition of labelled
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terminal nucleotides by the enzyme Terminal deoxynucleotidyl transferases (TdT).
Additionally, DNA dyes can be used to label cells that have increased permeability
during the late stages of apoptosis, since live cells are not normally labelled by DNA
dyes without fixation; this can be exploited in fluorescent labelling for flow
cytometry.
Changes in the cell membrane can be used to indicate the earliest stages of apoptosis.
During apoptosis, the membrane phospholipid phosphatidylserine is translocated
from the cytosolic face to the exterior face of the plasma membrane, by an unknown
mechanism. Annexin-V is a protein that has high affinity for phosphatidylserine, and
so fluorescently labelled Annexin-V can be applied to identify cells undergoing the
early stages of apoptosis using, for example, flow cytometry. Other assays which can
also be used to measure apoptosis include, for example, the direct assessment of
activated caspase activity in cell lysates by cleaving recombinant proteins which
release fluorescent molecules.
1.5.4 Evasion of apoptosis in ALL
The PI3K signalling pathway is important in the survival of lymphoblasts in ALL
(Levy et al 2009). TEL/AML1 promotes survival of leukaemia cells via the PI3K
signalling pathway (Fuka et al 2011a), possibly through the upregulation of the
erythropoietin receptor EPOR (Inthal et al 2008; Torrano et al 2011). In addition,
TEL/AML1 is known to induce the upregulation of pro-survival factors HSP90
(which stabilises PI3K and proteins in its signalling pathway) and survivin (a
member of the IAP family; Diakos et al 2007). Activation of anti-apoptotic Bcl-2
does not appear to be sufficient for ALL, however; less than 15% of mice that
overexpress Bcl-2 have lymphoid malignancies, mostly lymphomas and mature
B cell leukaemias (Cory 1995; Marsden & Strasser 2003). Conversely, mutations in
the pro-apoptotic Bcl-2 family member Bax are frequently found in ALL cell lines
(Meijerink et al 1998). The above evidence suggests that lymphoblast survival in
ALL is mediated by increased insensitivity to pro-apoptotic signals.
~~~
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The second part of this chapter looks specifically at TEL/AML1 leukaemia, starting
with an introduction to TEL and AML1 individually, and finishing with the
experimental study of acute lymphoblastic leukaemia.
1.6 TEL (ETV6)
Information about TEL, its role in haematopoiesis, and its involvement in
leukaemias and other cancers, is presented in depth in the introduction to Chapter 4.
The TEL gene, located at 12p13 and also known as ETV6, was discovered in the
context of Chronic Myelomonocytic Leukaemia (CMML; Golub et al 1994). TEL is
a member of the ets family of transcription factors, which are identified by the DNA-
binding region ets (Wasylyk et al 1993), and also shares with many of its family
members a helix-loop-helix polymerisation domain known as pointed or sterile alpha
motif (SAM) domain, which allows TEL to form homo- and heterodimers (Kim et al
2001). TEL is a transcriptional repressor, acting via two main mechanisms;
recruiting histone deacetylases (HDACs) via the binding of corepressors N-CoR
(Guidez et al 2000), SMRT and mSin3A (Chakrabarti & Nucifora 1999), or via an
HDAC-independent mechanism of chromatin condensation involving the binding of
L3MBTL via the pointed domain (Boccuni et al 2003). TEL itself is regulated by
phosphorylation via the MAPK/ERK pathway (Arai et al 2002; Maki et al 2004).
Little is known about the targets of transcriptional regulation by TEL.
TEL is ubiquitously expressed in the mouse embryo (Wang et al 1997; Wang et al
1998a), and ETV6–/– mice are embryonic lethal from defects in yolk sac angiogenesis
(Wang et al 1997). TEL is not intrinsically required for embryonic or adult
haematopoiesis, but rather acts as a selective regulator of haematopoietic stem cell
(HSC) survival by controlling the colonisation of the bone marrow in the adult
mouse (Wang et al 1998a; Hock et al 2004).
1.7 AML1 (RUNX1)
1.7.1 Discovery of AML1
The AML1 gene, located at 21q22.3, was first identified in the context of Acute
Myeloid Leukaemia. Breakpoints for the chromosome translocation t(8;21)(q22;q22)
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were found to cluster within a specific region on a NotI-digested clone from
chromosome 21. The surrounding cDNA clones were sequenced to identify a unique
gene with no homology to any other gene at the time, and was named AML1 after the
association of the t(8;12) translocation with acute myeloid leukaemia (Miyoshi et al
1991). Soon after, it was discovered that the AML1 gene had homology to a region in
the Drosophila gene runt (Daga et al 1992) which had DNA binding properties
(Ogawa et al 1993). AML1 and its two related genes AML2 and AML3 (Levanon et al
1994) were later renamed RUNX1, RUNX2, and RUNX3, short for ‘runt-related
transcription factor’ (van Wijnen et al 2004). The proteins from these genes are also
called Core Binding Factor alpha (CBFα) genes, as they form heterodimeric
complexes with CBFβ (with the AML1/RUNX1 gene coding for CBFα2 protein) to
regulate gene expression (Speck et al 1999).
1.7.2 AML1 structure
The DNA binding activity of AML1 is conferred by a domain homologous to the
Drosophila gene runt (Daga et al 1992), and has consequently been named ‘runt
homology domain’ (RHD), shared by all of the AML/RUNX gene family (Levanon et
al 1994). The second major domain of AML1, not shared by its family members, is
the ‘transactivation domain’ (Kanno et al 1998). This is required for binding to
variety of cofactors for both activation and repressors functions (Ito 1999).
AML1 is known to bind to a consensus sequence originally found in the enhancer
region of the gene SL3-3 (Amtoft et al 1997), the core of which is PyGPyGGTPy
(where ‘Py’ is a pyrimidine nucleotide, i.e. C or T), for example TTTGCGGTTA/T
(Thornell et al 1991). DNA binding by AML1 is greatly enhanced by the binding of
the CBFβ subunit, coded for by the CBFB gene (Kanno et al 1998). CBFβ does not
bind to DNA, but does bind to AML1 via the runt homology domain (Meyers et al
1993), increasing the activity of AML1-mediated transcription (Ogawa et al 1993;
Zhang et al 1996).
The AML1 protein has a series of self-inhibitory regions which regulate its DNA
binding (Ito 1999). A region N-terminal to RHD has a modest inhibitory effect on
DNA binding (Gu et al 2000), but the main source of auto-inhibition comes from the
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regions C-terminal to RHD (Kanno et al 1998), by masking the DNA-binding
surface of AML1 i.e. the RHD. This auto-inhibition must be removed before
heterodimerisation of AML1 and CBFβ can occur; one protein believed to be able to
induce unmasking of the DNA binding surface and subsequent promote
heterodimerisation is the ets family member ETS-1 (Ito 1999). Other proteins that
can fulfil this function are yet to be determined, but must exist since CBF acts in
tissues that do not express ETS-1.
1.7.3 AML1 activity
The CBF complex can act as both an activator and a repressor of gene expression,
through its association with either histone acetyltransferases (HATs) or deacetylases
(HDACs; Zelent et al 2004). AML1 recruits the adapter proteins p300 and
CREB-Binding Protein (CBP) via the transactivation domain (Kitabayashi et al
1998), which have intrinsic HAT activity (Ogryzko et al 1996) and recruit the HAT
protein P/CAF (Yang et al 1996). The decondensation of chromatin permits gene
expression; genes known to be regulated by AML1 / CBF activity include the T-cell
receptors TCRα and TCRβ (Ito 1999), TCRδ (Hernandez-Munain & Krangel 1994),
IL-3 (Uchida et al 1997) and PU.1 (Okada et al 1998).
There are two potential routes by which AML1 recruits HDACs to repress gene
expression. Firstly, via the C-terminal VWRPY motif, AML1 may recruit
Groucho-family corepressors (Aronson et al 1997; Levanon et al 1998), which may
act through HDACs (Chen et al 1999). Secondly, AML1 interacts with mSin3A
(Fenrick et al 1999), an interaction which is regulated by phosphorylation (Imai et al
2004).
AML1 and CBFβ, when dimerised, are known to interact with other transcription
factors, including c-Myb (Hernandez-Munain & Krangel 1995), C/EBP (Zhang et al
1996), MITF (Ogihara et al 1999), and SMAD proteins (Hanai et al 1999). It is
believed that the binding of Core Binding Factors to other proteins creates gene
expression complexes which enable specificity of expression in tissues and during
developmental stages; one such example is the expression of TCRα (Ito 1999).
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1.7.4 AML1 function
The role of AML1 and Core Binding Factor in haematopoiesis has been reviewed
extensively, e.g. de Bruijn & Speck 2004. Provided here is an overview of the main
functions of AML1 in embryonic and adult haematopoiesis.
AML1-/- mice are embryonic lethal at around E12.5 due to extensive haemorrhaging
in the CNS (Okuda et al 1996; Wang et al 1996b). Primitive yolk sac erythropoiesis
is unaffected in these mutants, but mice fail to initiate definitive haematopoiesis
from any site, and AML1-/- ES cells fail to contribute to haematopoiesis in chimeric
mice (Okuda et al 1996; Wang et al 1996b). The expression of only a specific set of
haematopoiesis-related genes is absent in AML1-/-, which include PU.1, Vav,
flk-2/flt-3, M-CSF receptor, G-CSF receptor and c-Myb (Okada et al 1998).
However, despite the critical role that AML1 plays in foetal haematopoiesis, the loss
of AML1 appears to have a subtler effect in adult haematopoiesis, as shown by
conditional mouse mutants in which Runx1 could be excised under the control of
Cre-loxP system. Normal haematopoietic development was maintained in adult mice
despite loss of Runx1, but a reduction in all white blood cells (particularly B- and
T-lymphocytes) and platelets was observed (Ichikawa et al 2004; Growney et al
2005). The Common Lymphoid Progenitor (CLP) population was unaffected with
loss of Runx1, indicating that it is the commitment to B- and T-lineage that is
affected in these mice (Ichikawa et al 2004). The HSC compartment in these mice
was increased but was otherwise functional. Interestingly, loss of Runx1 in adult
mice leads to mild myeloid expansion in the bone marrow and spleen, mirroring the
myeloproliferative disorders in patients with homozygous loss of RUNX1 (Growney
et al 2005).
1.7.5 AML1 fusion proteins in leukaemias
The importance of AML1 in haematopoiesis and leukaemia can be recognised by its
frequent involvement in fusion proteins resulting from chromosome translocations.
The t(8;21)(q22;q22) translocation, giving rise to the AML1-ETO fusion protein,
appears in about 18% of AML patients (Rowley 1973; Perry et al 2002). The rare
t(3;21) translocation fuses AML1 to any of a number of genes in the 3q26 region,
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including EVI1, MDS1, and EAP, and is often observed in AML, myelodysplasia
syndrome, and in the ‘blast crisis’ phase of CML (Nucifora et al 1993; Nucifora &
Rowley 1995; Perry et al 2002). Finally, the t(12;21) translocation was identified as
a recurrent genetic abnormality in ALL (Romana et al 1994) and was soon
discovered to fuse most of the AML1 protein with the N-terminus of the newly
discovered TEL protein (Romana et al 1995a). These fusions act to inhibit the
transcriptional activation activities of AML1 (Perry et al 2002).
1.8 TEL/AML1 and ALL
1.8.1 Discovery of TEL/AML1
The t(12;21) translocation was identified as a frequent feature of ALL by Romana
and colleagues (1994), where three out of eight B-cell ALL patients were shown by
Fluorescence In Situ Hybridisation (FISH) to harbour the t(12;21) translocation in
cells from their bone marrow. Shortly after the identification of TEL as the partner of
PDGFRβ in the CMML-associated translocation t(5;12)(q33;p13) (Golub et al
1994), it was discovered that in the t(12;21)(p13;q22) translocation, TEL was fused
to AML1 (Golub et al 1995; Romana et al 1995a). The TEL/AML1 fusion protein
was found to be frequently associated with childhood ALL (Romana et al 1995b), a
surprising discovery considering these genes had independently been identified in
the context of myeloid leukaemias (Miyoshi et al 1991; Golub et al 1994).
1.8.2 Structure of TEL/AML1
The fusion of TEL and AML1 commonly occurs between exons 5 and 6 of TEL and
exons 1 and 2 of AML1; i.e. in intron 5 of TEL and intron 1 of AML1 (Wiemels &
Greaves 1999). The TEL moiety of TEL/AML1 conserves the pointed domain,
required for hetero- and homo-dimerisation (Kim et al 2001) and the central
repression domain, to which HDACs are recruited (Wang & Hiebert 2001), but loses
the DNA-binding ets domain (Golub et al 1994). Almost the entire of the AML1 is
conserved, including both the DNA-binding runt homology domain (RHD; Levanon
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et al 1994) and the transactivation domain which can recruit both HATs and HDACS
(Kanno et al 1998).
1.8.3 Molecular biology of TEL/AML1
Whereas AML1 acts as both an activator and repressor of gene expression,
TEL/AML1 constitutively represses AML1 targets, as discovered using reporter
gene constructs of AML1 targets (Hiebert et al 1996; Fears et al 1997). One
mechanism of this action is the by the recruitment of HDACs by the interaction of a
complex containing N-CoR, SMRT, and mSin3A with TEL/AML1 (Fenrick et al
1999; Guidez et al 2000), which are recruited by domains present in both the TEL
and AML1 moieties (Chakrabarti & Nucifora 1999; Fenrick et al 1999; Guidez et al
2000). CBFβ is required for the binding of AML1 to its targets via RHD (Zhang et al
1996), and similarly it is required for functional TEL/AML1 activity (Roudaia et al
2009).
The pointed dimerisation domain of TEL appears to be important in the gene
repression activity of TEL/AML1, as its deletion removes most (but not all) of the
inhibition of reporter gene activation (Hiebert et al 1996; Fears et al 1997). This is
likely to be due to the stabilisation of interactions between TEL/AML1 dimers and
their corepressors, rather than any intrinsic properties of the pointed domain itself, as
the replacement of the pointed domain with a different oligomerisation domain
preserves the gene repression activities (Lopez et al 1999).
TEL and TEL/AML1 can form heterodimers in vitro (McLean et al 1996) through
their pointed domains. TEL does not appear to have any effect on the gene
repression activity of TEL/AML1 on AML1 targets (Hiebert et al 1996), but
TEL/AML1 can have a dominant-negative effect over TEL, inhibiting both its gene
repression activity and its ability to repress transformed-NIH3T3 cell growth (Gunji
et al 2004). Since the loss of TEL is a common secondary mutation in TEL/AML1+
leukaemia (Cave et al 1995), this dominant-negative effect of TEL/AML1 over TEL
is significant as it indicates a possible mechanism of leukaemogenesis through the
loss of heterozygosity of TEL. The role of TEL deletions in leukaemia will be
discussed in Chapter 4 (section 4.1.7).
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In addition to a negative effect on basal levels of expression of AML1 targets,
TEL/AML1 has a dominant-negative effect over AML1-mediated transcriptional
activation (Hiebert et al 1996) and the AML1-induced proliferation of NIH3T3 cells
(Gunji et al 2004). In vivo, TEL/AML1 dominant-negative effects on both TEL and
AML1 does not appear to copy the phenotype of knockouts of either of these genes
(Schindler et al 2009), indicating that the negative effects of TEL/AML1 on its
wild-type components is subtle, a contrast to observations in AML1/ETO-expressing
mice, for example (Yergeau et al 1997).
1.8.4 Prenatal origins of the TEL/AML1 fusion
It is known that the TEL/AML1 fusion occurs prenatally; the breakpoint of
TEL/AML1 in newly-diagnosed patients can be retrospectively matched by PCR
with DNA samples from their dried blood spot cards taken at birth (Wiemels et al
1999a) which are normally used to diagnose phenylketonuria. In addition, such
breakpoints are found to be identical in monochorionic twins (those that share a
placenta) diagnosed with leukaemia (Wiemels et al 1999b); the only feasible
explanation for this being the migration of a TEL/AML1+ cell from the bone marrow
of one twin, through the shared placenta, to the other twin (Greaves et al 2003).
It has been previously reported that TEL/AML1 has been found in 1% of cord blood
samples (Mori et al 2002), which is 100-fold more frequent than the incidence of
TEL/AML1+ leukaemia, implying that only 1 in 100 newborns positive for
TEL/AML1 will go on to develop ALL. However, the findings of Mori and
colleagues has been disputed by a recent paper (Lausten-Thomsen et al 2011), which
claims the frequency of the TEL/AML1 translocation event is closer to 0.01%, thus
implying that most if not all of TEL/AML1+ newborns will go on to develop ALL.
After the publication of the paper from Lausten-Thomsen and colleagues, another
group revealed in correspondence evidence apparently confirming the original report
by Mori and colleagues, that the TEL/AML1 transcript could be detected in
approximately 1% of neonatal cord-blood samples (Zuna et al 2011). An
examination of the methods used by the papers from Mori and Lausten-Thomsen and
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possible explanations for their discrepancy followed (Greaves et al 2011;
Schmiegelow et al 2011).
All three papers performed PCR for TEL/AML1 transcript on cDNA prepared from
cord blood samples and found 1% of cord-blood samples from healthy neonates were
TEL/AML1+. However, the frequency of TEL/AML1+ cells in the cord blood
samples (as measured by the relative expression of TEL/AML1 in the samples)
differed, with Mori estimating between 10–3 and 10–4 cells, and Lausten-Thomsen
estimating less than 10–5.
After this initial PCR screen, the three papers attempted to confirm the results using
different methods. Lausten-Thomsen and colleagues, having used fresh cord blood
samples for the first screen, re-performed the PCR on their TEL/AML1+ samples by
thawing out frozen samples and flow sorting for CD19+ cells. However, all of the
repeated samples were found to be negative for TEL/AML1; since they expected to
see an increase in the level of TEL/AML1 transcript in the CD19+ sorted
populations, they concluded that these samples were indeed negative. They attributed
the identification of TEL/AML1+ samples in their first screen as low level
contamination (Lausten-Thomsen et al 2011).
Mori and Zuna and their respective colleagues confirmed their TEL/AML1+ samples
by FISH after cell sorting for B cell markers CD19 and CD10 for the presence of
TEL/AML1 fusions. Mori and colleagues positively confirmed the presence of
TEL/AML1 fusions in the two TEL/AML1+ samples they investigated by FISH
(Mori et al 2002), and Zuna and colleagues confirmed TEL/AML1 in the one sample
they analysed (Zuna et al 2011).
Ultimately, the discrepancy between the results of Mori’s and Lausten-Thomsen’s
experiments has not yet been resolved, and it is likely there is a technical
explanation, rather than biological explanation (such as the nationalities of the
populations analysed). Both groups called for further, large scale investigations from
other scientists (Greaves et al 2011; Schmiegelow et al 2011).
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1.8.5 Progression of TEL/AML1+ leukaemia
It is clear that two very different models of the progression TEL/AML1+ leukaemia
emerge if the frequency of the translocation that generates the fusion gene is 1% or
0.01%, given that the incidence of TEL/AML1+ leukaemia in children is 1 in 10,000
(0.01%). If the latter is true, then the presence of TEL/AML1 is sufficient to cause
leukaemia; if the former is true, then TEL/AML1 is not sufficient for leukaemia, and
‘secondary hits’ are required to progress to overt leukaemia.
Beyond the translocation frequencies presented by Mori and colleagues, there are
several lines of evidence that support the ‘two-hit’ hypothesis, one of which is the
study of leukaemia in twins. If a TEL/AML1+ cell was all that was needed to cause
leukaemia, and if both twins of identical genetic makeup had the same transformed
clone (as it is known is possible via trans-placental transfer; Wiemels et al 1999b),
then one would expect that both twins develop leukaemia, and at roughly the same
time. However, from the few (albeit small) studies that have been performed on the
subject, it is known that this is not the case; despite shared TEL/AML1+ clones,
concordance of childhood leukaemia in twins is low, and there is often a delay from
the prenatal translocation and the presentation of overt leukaemia in both individual
twins and singletons (Greaves et al 2003).
Commonly mutated, deleted, and abnormally regulated genes in TEL/AML1+
patients have been identified through the analysis of patient material, which has
recently entered a new era with the use of high-throughput and large scale screens.
As such, screens for gene expression changes (Golub et al 1999; Fine et al 2004;
Andersson et al 2005a; Andersson et al 2005b; Gandemer et al 2007; Andersson et
al 2010), single nucleotide polymorphisms (SNPs) and copy number alterations
(CNAs; Mullighan et al 2007; Kawamata et al 2008; Bateman et al 2010; Kuster et
al 2011; Notta et al 2011b), chromosomal structural changes (Attarbaschi et al 2004;
Mullighan et al 2007), and epigenetically regulated genes (Starkova et al 2007) in
TEL/AML1+ leukaemia patient samples have identified genes and pathways
commonly disrupted in TEL/AML1+ leukaemia, and thus suggest a ‘two-hit’ model
of leukaemogenesis.
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Mutations likely to drive leukaemia progression are always discordant in twins
(Bateman et al 2010), and thus probably occur post-natally. One such common
mutation, deletions in the short arm of chromosome 12 where ETV6 is located, could
not be ‘backtracked’ to birth when comparing samples from patients and their
matched neonatal blood spot cards (Wiemels et al 2008).
A ‘two-hit’ model of disease progression in leukaemia has also been suggested in
animal models. Most mouse models expressing TEL/AML1 on its own have failed to
recapitulate overt B lineage ALL. Endogenous expression of TEL/AML1 under the
control of immunoglobulin heavy chain enhancer/promoter, EµVHP failed to cause
haematological malignancies (Andreasson et al 2001; Ford et al 2009). Exogenous
expression of TEL/AML1, by the viral transduction of haematopoietic precursors
from bone marrow or foetal liver, failed to induce leukaemia (Morrow et al 2004;
Tsuzuki et al 2004; Fischer et al 2005), but instead caused abnormalities in B cell
development, either causing increased self-renewal of B cell precursors (Morrow et
al 2004; Morrow et al 2007) or impairment of transition from pro-B to pre-B cells
(Tsuzuki et al 2004; Fischer et al 2005). The result is the accumulation of persistent
early B cell progenitors, which is believed to represent a ‘pre-leukaemic state’ that
predisposes individuals for further transformation and ultimately overt leukaemia.
1.8.6 Infection in the aetiology of ALL
An interesting area of study has been the role that early childhood infections might
play in the progression of ALL (Greaves 2006). This theory was originally
speculated on the basis of three observations: firstly, the peak incidence of ALL, in
children aged two to five, coincided strongly with that of common childhood
infections such as measles; secondly, the presentation of ALL was usually associated
with previous history or coincidence of respiratory infections; and thirdly, that that
certain haematological malignancies could be caused by specific viral infections
(such as adult T-cell leukemia/lymphoma by Human T-cell Lymphotropic Virus-1
[HTLV1] and Burkitt’s lymphoma by Epstein-Barr Virus [EBV]; Greaves 2006).
Epidemiological studies lead to the proposal of two possible mechanisms of an
immunological aspect of ALL. Firstly, the ‘population mixing’ hypothesis (Kinlen
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1988) arose from studies of clusters of ALL cases in remote towns (including those
of British towns with nuclear power plants such as Sellafield), and proposed that a
large influx of migrants exposes the endogenous community to previously
unencountered infections, such as a (symptomatically mild) virus. Secondly, the
‘delayed exposure’ hypothesis (Greaves 1988) arose from the observations of
increased incidence in more affluent (and therefore more ‘hygienic’) societies and
countries, and proposed that a delay in the exposure to common childhood infections
might inadvertently lead to an inappropriate proliferative response to such an
infection.
Kinlen’s ‘population mixing’ hypothesis has been supported by a series of events in
which populations mixed in a specific place at a specific time, the majority of which
results in a transient increase in the incidence of childhood leukaemia (McNally &
Eden 2004). There is an array of evidence to support Greaves’ ‘delayed exposure’
hypothesis; for example children who attend day-care or a nursery in their first years
of life (an indicator of increased exposure to infections) have a reduced risk of
leukaemia (Ma et al 2002; Gilham et al 2005). Similar hypotheses to Greaves’ have
been put forward to explain the increased incidence of immunological diseases such
as allergies (Wills-Karp et al 2001) and Type-I diabetes (McKinney et al 2000) in
affluent societies; indeed the distributions of these diseases correlate with that of
ALL (Stene & Nafstad 2001; Feltbower et al 2004).
It is worth noting that both of the theories are consistent with a ‘two-hit’ model of
leukaemogenesis, and that such an infectious influence isn’t a necessary component
of the natural history of ALL, but might contribute to its observed characteristics. In
this respect, Greaves (2006) proposes something akin to a ‘three-hit’ model; a
pre-natal fusion event, an expansion of the transformed clone as a result of an
infection, followed by subsequent genetic mutations in the transformed clone pool.
1.8.7 Clonal evolution
Clonal evolution of cancer is a concept parallel to that of Darwinian evolution of
species, and is the result of the study of multi-step carcinogenesis (Greaves & Maley
2012). As a concept it incorporates many features typical of cancers, such how
CHAPTER 1: INTRODUCTION
49
mutations accumulated over time (i.e. during the lifetime of an individual) can lead
to cancerous growth, the genetic diversity found in tumours, and maintain the
potential for relapse after treatment.
Many random genetic changes in cells might be harmful for the cell, in which case
the cell will die. However, genetic changes that confer an advantage to a cell are
passed onto its daughter cells, and thus provide the opportunity for further mutations.
Here, ‘advantages’ for the cell include the abilities to proliferate and survive, and
thus resulting in populations of cells that rapidly proliferate and are resistant to
apoptosis, i.e. cancer. Mutations occur concurrently in different cells, and so there
may be several clones at any one point which have the ability to form a cancer, thus
representing a tree of divergence of clones, rather than a step-wise linear
progression. Typically however, only a minority of these will come to form the main
bulk of the tumour, as they dominate over their competitor clones.
The concept of clonal evolution has been applied to acute lymphoblastic leukaemia,
including the TEL/AML1+ subtype. In the case of monochorionic twins, the
concordance rate for childhood ALL is typically 10-15% (Greaves et al 2003). There
are published examples of such twins, discordant for TEL/AML1+ ALL, where the
‘healthy’ twin also harbours the pre-leukaemic clone (for example, Hong et al 2008).
Mutations present in the twin with leukaemia were not present in the pre-leukaemic
clone in the ‘healthy’ twin (Hong et al 2008). In addition, there are examples of
identical monochorionic twins concordant for TEL/AML1+ (e.g. Bateman et al 2010)
which are discordant for the mutations responsible for their leukaemia. These
examples not only indicate a requirement for further mutations beyond the t(12;21)
translocation event, but also the diversity of mutations that give rise to leukaemia,
even in the genetically identical backgrounds found in the twins with a shared
pre-leukaemic clone, support a branching, divergent model of leukaemia
progression.
The importance of this divergence has been illustrated in relapsed leukaemia
(Mullighan et al 2008). Access to samples of bone marrow from both the initial
diagnosis and relapse of leukaemia allowed the comparison of the genetic
differences between the clones present. By analysing the copy number alterations
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(CNAs) present in the dominant clones, Mullighan and colleagues were able to map
out the origins of the relapse clone with respect to the clone from the initial diagnosis
of ALL. In 6% of cases, there were no common CNAs in the diagnostic or relapse
clone, indicating the relapse might be a secondary, unrelated leukaemia. In 42% of
cases, CNAs present in the initial diagnosis clone were all present in the relapse
clone, indicating that these cases of relapsed leukaemia represented clonal evolution
from the original leukaemia. However, in the majority of the cases (52%), the
relapsed clone shared only a few of the CNAs present in the initial diagnosis clone,
indicating that the relapse clones were derived from ancestral clones to the initial
diagnosis clone, which remained in the bone marrow whilst the initial diagnosis
clone dominated during the overt primary leukaemia.
The ‘clonal architecture’ of TEL/AML1+ (Anderson et al 2011) and BCR-ABL1+
(Notta et al 2011b) ALL has also been plotted out using similar techniques to track
different clones within one bone marrow sample. An important finding of both of
these studies that the interaction and competition between the different clones is
dynamic; once bulk bone marrow is transplanted into immunodeficient mice,
individual clones would continue to evolve, leading to previously minor clones that
over time become the dominant clone. These findings are significant when
considering the treatment of relapse; relapsed leukaemias are likely to be divergent
from the primary leukaemias, and so therapies targeted at the initial diagnosis clone
may not be effective for the treatment of the relapse. Indeed, in one study analysing
CNAs in matched relapse and diagnosis samples from TEL/AML1+ patients, many
of the CNAs unique to relapse samples were in genes involved in glucocorticoid
signalling and so provide a potential mechanisms for acquired drug resistance at
relapse (Kuster et al 2011).
Study of clonal evolution in leukaemias has also allowed the identification genes
mutated at a higher frequency than expected, which are presumed to confer a
selective advantage to clones, and so are called ‘driver’ mutations. Other genes
which have a neutral effect on leukaemic clones are known as ‘passenger’ mutations,
since they will frequently be passed along with ‘driver’ mutations, but are not as
frequent nor believed to confer any advantage (Haber & Settleman 2007). In a study
of CNAs present in TEL/AML1+ leukaemia in identical twins (Bateman et al 2010),
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it was estimated that 5.1 CNAs were present in each case, 3.2 ‘driver’ mutations
(range 2-7) and 1.9 ‘passenger’ mutations (range 1-4). Ultimately the distinction
between ‘driver’ and ‘passenger’ mutations requires functional studies (Bateman et
al 2010).
1.9 Common secondary mutations in acute lymphoblastic leukaemia
The identification of genetic alterations in ALL has allowed for the elucidation of
common pathways of leukaemogenesis, as well as the investigation of mutations
specific to certain leukaemia subtypes and patient groups. Karyotyping allows for the
gross genetic changes such as translocations, deletions and amplifications, and
aneuploidy to be identified quickly and cheaply, and is still the method by which
many chromosome translocations that define subtypes of leukaemia are diagnosed.
Fluorescence In Situ Hybridisation (FISH) can be used to confirm certain fusion
genes resulting from translocations, and also to identify deleted alleles of specific
genes. However, karyotype analysis is subjective and can only identify large changes
in chromosome structure, far bigger than any single gene. FISH is labour intensive,
and by definition requires a probe for a specific gene with a known sequence,
precluding it from genome-wide studies.
Microarray platforms provide the opportunity for unbiased and detailed screens for
genetic alterations (Mullighan & Downing 2009). Comparative genomic
hybridisation (CGH) array screens use large fragments (up to ~200kb) of the human
DNA, cloned into bacterial artificial chromosome (BAC) vectors, allowing coverage
of most of the entire genome. Single Nucleotide Polymorphism (SNP) arrays use
much shorter (20-100 bp), and were originally designed to identify known single
nucleotide changes in the genome that are associated with susceptibility to certain
diseases. However, by virtue of the probes being able to identify both maternal and
paternal alleles, they can also be used to identify the copy number of genes, and as
such deletions or amplifications of regions of chromosomes, known as copy number
alterations, or CNAs. This ability of SNP arrays to detect CNAs added with the high
resolution and the small amounts of DNA required have resulted in their widespread
use to identify genetic alterations in acute lymphoblastic leukaemia.
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1.9.1 ETV6
Deletions in 12p, and specifically deletions at ETV6 locus, have been identified as a
common feature of ALL (Irving et al 2005; Kuiper et al 2007; Mullighan et al 2007;
Strefford et al 2007; Kawamata et al 2008; Bungaro et al 2009), in particular
TEL/AML1+ leukaemia (Raimondi et al 1986; Raynaud et al 1996; Cave et al 1997;
Attarbaschi et al 2004; Kawamata et al 2008). The role of ETV6 deletion in the
context of TEL/AML1+ leukaemia will be discussed in Chapter 4 (section 4.1.7).
1.9.2 Cell Cycle control genes
Recurrent mutations in a variety of proteins involved in cell cycle control have been
identified in the context of ALL, for example CDKN1B, CDKN2A, CDKN2B, and
RB1 (Irving et al 2005; Kuiper et al 2007; Mullighan et al 2007; Strefford et al
2007; Kawamata et al 2008; Bungaro et al 2009; Bateman et al 2010; Notta et al
2011b). CDKN2A, found on chromosome 9p21 and also known as P16INK4, is a
cyclin-dependent kinase inhibitor, an important regulator of cell cycle progression,
as discussed above in section 1.4.2. It is also a known tumour suppressor gene,
frequently mutated in various cancers (Smith-Sorensen & Hovig 1996). Deletions of
CDKN2A are frequent in both B- and T-lineage ALL (Takeuchi et al 1995), though
less frequent in TEL/AML1+ leukaemia (Sulong et al 2009), and genetic alterations
within 9p are associated with relapse and poor prognosis in ALL (Heerema et al
1999; Hann et al 2001; Calero Moreno et al 2002; Mullighan et al 2008). The
deletion of the CDKN2A locus in mice, in combination with exogenous expression of
TEL/AML1, gives rise to frequent leukaemias (Bernardin et al 2002), and the
deletion of CDKN2A in RAG knock-out mice induces B-ALL (Hauer et al 2011).
1.9.3 B cell development genes
Another group of genes frequently mutated or deleted in B-ALL are genes involved
in B cell development (Kuiper et al 2007; Mullighan et al 2007). PAX5 is a
transcription factor which induces B cell specification in lymphoid progenitors by
repressing alternative lineage pathways (Nutt et al 1999). Loss of functional PAX5 is
observed through a variety of mechanisms, including mono-allelic deletions, exon
deletions, small translocations, point mutations, and mutations in the PAX5 promoter
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(Mullighan et al 2007). Genes that are regulated by PAX5 are enriched in gene
expression patterns in leukaemic cells from B-ALL patients without a common
cytogenetic abnormality, indicating that the loss of PAX5 is of significant functional
consequence in these leukaemic cells (Mullighan et al 2007). Mutations in two
proteins that directly regulate PAX5 expression, EBF and E2A, are also often
identified in ALL (Kuiper et al 2007; Mullighan et al 2007).
1.9.4 Other genes associated with TEL/AML1+ leukaemia
Throughout this thesis, a selection of the many genes involved in leukaemia was
studied, in addition to some of those listed above. These genes, namely PIK3C3,
TNFRSF7, SMAD1, ANGPTL4, EPOR, and IKZF2, are described below, in terms
of their function and their relationship to TEL/AML1+ leukaemia.
PIK3C3, also known as VPS34, belongs to a family of Phosphoinositide 3-kinases;
PIK3C3 phosphorylates membrane-bound phosphotidylinositol which activates a
signalling pathway (introduced in section 1.4.3) that regulates a variety of membrane
transport functions such as endocytosis and biosynthetic trafficking (Simonsen et al
2001). PIK3C3 has been identified by three separate gene expression microarrays as
a gene upregulated in TEL/AML1+ leukaemia (Yeoh et al 2002; Andersson et al
2005b; Gandemer et al 2007). Upregulation of PIK3C3 was also observed in CML
patients (Li et al 2002), indicating that PIK3C3 upregulation may represent a
common pathway of haematological malignancies. PIK3C3 promotes survival of
T cell; a lack of PIK3C3 in T lymphocytes results in increased cell death and
reduced IL-7Rα (McLeod et al 2011). Mutations in another PI3K family member,
PIK3CA (p110α), which lead to its increased activity, have been frequently observed
in a variety of cancers (Karakas et al 2006).
TNFRSF7, also known as CD27, is a marker of memory B cells in humans
(Agematsu et al 2000). TNFRSF7 and its ligand, CD70, is found on both T and B
lymphocytes, and their interaction is believed to be important in the activation of
both lymphocytes in the germinal centre (Borst et al 2005). High expression of
TNFRSF7 has been associated previously with TEL/AML1+ leukaemia (Yeoh et al
2002; Fine et al 2004; Gandemer et al 2007). Similarly, high levels of TNFRSF7
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have been detected by flow cytometry on leukaemic B lymphoblasts (Nilsson et al
2005; Troeger et al 2008). In addition, TNFRSF7 in both membrane-bound and
soluble forms has been associated with Chronic Lymphoid Leukaemia and Non-
Hodgkin’s Lymphoma (van Oers et al 1993; Ranheim et al 1995). The function of
TNFRSF7 is not clear; however, it is believed to transduce pro-apoptotic signals
through Siva-1 (Prasad et al 1997; Yoon et al 1999; Xue et al 2002), but can also
activate both canonical and non-canonical NF-κB pathways (Ramakrishnan et al
2004), which are known to activate anti-apoptotic pathways (Borst et al 2005).
SMAD1 is a member of a family of signal transducers that act downstream from the
TGF-β family of ligands, and have a variety of roles in proliferation and
differentiation in many organs (Blank & Karlsson 2011). In haematopoiesis, the role
of SMAD1 and its family members is believed to be highly context specific, and so
the results from in vitro and in vivo data can sometimes be conflicting. In mice, a
pulse of expression of SMAD1 during early development increases the numbers of
haemangioblasts (Zafonte et al 2007), but SMAD1 appears to be redundant in adult
haematopoiesis (Singbrant et al 2010). In zebrafish, SMAD1 deficiency leads to
enhanced erythropoiesis but a lack of mature macrophages (McReynolds et al 2007).
In human B cell lymphoma, SMAD1 overexpression and activation decreases
proliferation (Munoz et al 2004). However, the role of SMAD1 in acute
lymphoblastic leukaemia is not known.
Angiopoietin-like 4 (ANGPTL4), along with its family member ANGPTL2, was
associated with leukaemia with TEL/AML1+ leukaemia compared to normal
haematopoietic populations (Andersson et al 2005b). In addition to their role of
influencing angiogenesis, angiopoietin-like proteins are known to promote expansion
of HSCs (Zhang et al 2006), and have been implicated in acute myeloid leukaemia.
The EPOR gene codes for the receptor for erythropoietin (EPO), a cytokine which
promotes the production of erythrocytes (red blood cells). In two independent gene
expression microarray studies, EPOR has been found to be consistently highly
expressed in TEL/AML1+ ALL compared to other subtypes (Ross et al 2003; Fine et
al 2004). In addition, a mutation in the promoter of EPOR which leads to its
upregulation has been identified as a mutation that contributes to leukaemogenesis in
CHAPTER 1: INTRODUCTION
55
a recently published mouse model of TEL/AML1+ leukaemia (van der Weyden et al
2011), and two reports have shown that EPO signalling through EPOR promotes
proliferation and survival in TEL/AML1+ leukaemia (Inthal et al 2008; Torrano et al
2011).
IKAROS, encoded by the gene IKZF1, acts as a transcription factor via chromatin
remodelling, and is involved in lymphoid lineage commitment, B cell development
in particular (Georgopoulos 2002). A null mutation of Ikaros leads to the complete
absence of both foetal and adult B cells and foetal T cells (Wang et al 1996a) and a
reduction in the HSC pool (Nichogiannopoulou et al 1999). Deletions and
dysregulation of IKZF1 are commonly observed in B- and T-lineage leukaemia, and
are associated with poor prognosis and increased risk of relapse (Mullighan et al
2008; Mullighan et al 2009; Payne & Dovat 2011). Since abnormal B cell
development is a hallmark of TEL/AML1+ leukaemia, the frequent deletion of genes
associated with B lymphopoiesis provides a potential mechanism by which B cell
progenitors can persist, allowing for further mutations to be acquired for progression
towards overt leukaemia. In Chapter 4, the Ikaros family member IKZF2 (also
known as ‘Helios’) is studied in relation the impact of gene expression of the loss of
TEL. Deletion of IKZF2 has been identified as a recurrent mutation in relapsed B-
and T- lineage ALL (Mullighan et al 2008), and overexpression of certain isoforms
of IKZF2 has been associated with T-cell ALL (Nakase et al 2002) and adult T cell
leukaemia/lymphoma (Fujii et al 2003).
1.10 Experimental study of leukaemia
As more is revealed about the nature of TEL/AML1+ leukaemia, researchers will
continue to use model systems as tools to address questions about fundamental
aspects of the disease. Such model systems can be divided into three categories:
in vivo models using transgenic animals, models using patient-derived material either
ex vivo or in a xenograft animal model, and studies using cell lines in vitro. I will
discuss the use of model systems in the study of TEL/AML1+ leukaemia in more
detail in the introduction to Chapter 3, but here I will give an overview of each of
these.
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1.10.1 In vivo models
Firstly, in vivo mouse models, either by studying transgenic animals (Schindler et al
2009) or recipients of TEL/AML1-transduced bone marrow (Tsuzuki et al 2004),
which have been used to investigate the development and clonal evolution of
TEL/AML1+ HSCs. Using these models, it has been found that TEL/AML1
increases quiescence in HSCs (Bernardin et al 2002; Schindler et al 2009), but also
self-renewal in downstream multipotent precursors and B lymphoid precursors
(Morrow et al 2004; Fischer et al 2005), and that this activity requires domains
present in both the TEL and AML1 moieties of the fusion protein (Morrow et al
2007). In addition, these transgenic mice have demonstrated the necessity of
secondary mutations to provoke overt leukaemia (Schindler et al 2009; van der
Weyden et al 2011), a finding also confirmed in a zebrafish model of TEL/AML1
(Sabaawy et al 2006).
1.10.2 Xenograft models
Secondly, models using leukaemia patient-derived material (le Viseur et al 2008) or
TEL/AML1-transduced cord-blood samples (Hong et al 2008), either as a xenograft
or ex vivo, have been described. These have further revealed the self-renewal
capacity of committed progenitors (le Viseur et al 2008), and identified a serially
transplantable pluripotent cell population, akin to a ‘leukaemic stem cell’ (Hong et al
2008) which responds abnormally to TGF-β (Ford et al 2009).
1.10.3 Cell lines
Thirdly, patient-derived cell lines and in vitro studies have been used to investigate
molecular and cellular aspects of leukaemia. For example, using cell lines,
TEL/AML1 was found to interfere with the activities of both TEL and AML1 (Gunji
et al 2004), and bone marrow stromal cells were found to regulate chemotherapy
resistance via TGF-β signalling (Dosen-Dahl et al 2008). RNAi silencing of
TEL/AML1 in cell lines has revealed it is not necessary for survival of these cells
(Zaliova et al 2011), but maintains a malignant gene expression program that differs
to normal B cell precursors (Fuka et al 2011b).
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One of the most widely used cell lines for studying TEL/AML1+ leukaemia is the
REH cell line. The REH cell line was derived from the peripheral blood of a 15-year-
old in acute lymphoblastic leukaemia relapse (Rosenfeld et al 1977), making it the
first cell line representative of a B cell precursor leukaemia (Matsuo & Drexler
1998). It was later discovered to harbour TEL/AML1 (Uphoff et al 1997), shortly
after the discovery of the fusion gene in 1995 (Golub et al ; Romana et al ). It was
also shown that the REH cell line lacked the remaining untranslocated TEL allele; in
this case by a second translocation t(5;12)(q31;p13) resulting in the deletion of TEL
(Uphoff et al 1997). The use of the REH cell line in the study of TEL/AML1+
leukaemia is further discussed in section 4.1.10.
1.11 Gene delivery methods
The experimental study of the role of a particular gene, including the work presented
in the examples above and the current work presented in this thesis, often requires
the transfer of genes into cells by gene vectors. Summarised below are the two main
types of vectors used for gene delivery into mammalian cells; plasmid vectors and
viral vectors. In the introduction to Chapter 3 (section 3.1.9), the methods of
transgene expression in hESCs are further explored.
1.11.1 Plasmid vectors
DNA plasmid transfection is commonly used to transiently express proteins in cells
as it is relatively simple to construct a DNA plasmid, and there is not the same limit
on the size of the genetic material that can be delivered, unlike viral vectors (see
below). The stable expression of the transgene requires the integration of the plasmid
in the host genome, as plasmids are not commonly transferred to daughter cells when
cells divide, and so are ‘diluted out’ over time. However, both the transfection
efficiency and the efficiency of stable integration of plasmids is low, and certainly
much lower than that of viral vectors such as lentiviruses (Washbourne & McAllister
2002).
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The delivery of DNA plasmids across the plasma membrane into cells can be
performed by a variety of methods, loosely defined in two categories: chemical and
non-chemical methods. Chemical methods tend to induce endocytosis of DNA by
enhancing the ability of DNA to bind to the plasma membrane, a process that
generally does not occur normally because of the charged nature of DNA. For
example, calcium phosphate precipitation (Graham & van der Eb 1973) allows for
the binding of DNA to the plasma membrane. Alternatively, DNA plasmids can be
delivered into the cell in liposomes, small lipid-membrane vesicles that bind to the
plasma membrane and are taken into the cell by endocytosis. Non-chemical methods
involve the ‘forced entry’ of DNA into cell. In the case of plant cells, DNA can be
fired into the cell attached to tungsten particles in a method known as biolistics, but
the most commonly used method in animal cells is electroporation. The precise
mechanism of action for electroporation is unknown, but it is believed that firing a
pulse of electricity through the cell causes large pores to open in the plasma
membrane, through which charged particles like DNA can pass (Neumann et al
1982).
1.11.2 Viral vectors
The use of viral vectors for the expression of exogenous genes appears to be an
obvious choice – viruses have evolved to deliver genetic material into cells and
express it at high levels. As such, the advantage of using viral vector for gene
delivery is the high transduction efficiency of many different types of tissues. Viral
vectors used for laboratory research are frequently engineered for safety and thus
lack genes required for replication. However, the advantages of viral vectors are also
balanced by several disadvantages, namely the production of the high titres of
viruses required is time consuming and labour intensive, and the size of the gene
insert used is limited by the capacity of the virus.
Adenoviruses are DNA viruses that have a double-stranded DNA genome. They are
non-integrating viruses, and so are often only used for transient transduction of cell
lines. The cloning capacity of the virus is about 5-14kb, but the production of
adenoviruses is time-consuming at about four to six weeks (Ross & Parks 2009). As
such, adenoviruses are not often used in laboratory research, but closely related
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viruses, so-called adeno-associated viruses (AAVs), are showing promise as gene
delivery vectors for gene therapy, as unlike adenoviruses, AAVs do not elicit a
significant immune response in humans (Flotte & Carter 1995).
Retroviruses are a family of RNA viruses which integrate their genes into host
genomes using the enzyme reverse transcriptase to convert their genome into
single-stranded DNA. The cloning capacity of retroviruses is about 10kb (Trono
2000), but retroviruses are mostly only able to infect dividing cells, and tend to insert
randomly into the genome, which can lead to unintended consequences in host gene
expression. Lentiviruses are a genus of the retrovirus family, but have the advantage
over most retroviruses in that they are able to transduce both dividing and
non-dividing cells. The integration of lentiviruses into the genome occurs at less
random locations (Cattoglio et al 2007), and coupled with their high transduction
efficiency and long-term stable expression, lentiviruses are a commonly used viral
vector in laboratory gene expression experiments.
1.12 Conclusion and Aims
Acute Lymphoblastic Leukaemia (ALL) is the rapid proliferation of immature
lymphoblasts in the bone marrow, and is the most common cancer in children. The
t(12;21) translocation, generating the TEL/AML1 fusion protein, is the most
frequently identified initiating genetic lesion in childhood ALL, and is most likely to
occur prenatally, but further postnatal mutations are necessary for the progression to
overt leukaemia.
The transcription factors TEL and AML1 (coded for by the genes ETV6 and RUNX1,
respectively) are key players in normal and malignant haematopoiesis. TEL/AML1
appears to interfere with the normal activities of both wild-type TEL and AML1, but
little is known about the genes which are regulated by either, and how their aberrant
regulation leads to the ‘pre-leukaemic state’ of a persistent clone that is predisposed
to further mutations. In addition, it has not been directly proved in which
haematopoietic progenitor cell the translocation needs to occur to generate this
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leukaemia initiating cell, although it is assumed to be early multipotent cells such a
HSCs (Schindler et al 2009).
A diagram showing a model of initiation and progression of TEL/AML1+ leukaemia
is shown in Figure 1.3. As depicted in Figure 1.3A, HSCs present in the developing
embryo are subject to the chromosome translocation t(12;21), which generates HSCs
of increase self-renewal (as described in Schindler et al 2009). These multipotent
HSCs are capable of differentiation along any lineage, but in the event of
commitment to B cell development, they can generate the a ‘pre-leukaemic clone’
(Hong et al 2008) with similar phenotype to pro-B cells, that have self-renewal
properties and a reduced capacity to differentiate into pre-B cells and further along
the B lymphocyte lineage. The main feature of this model is that TEL/AML1 on its
own is not sufficient for leukaemia. In the first chapter of this thesis, the
development of a model of TEL/AML1+ leukaemia is described, which provides
additional evidence to support this model.
From the TEL/AML1+ pre-leukaemic clone, overt leukaemia develops resulting in
lymphoblast population with TEL deficiency (Figure 1.3B), commonly manifested
either by the genetic deletion of the remaining TEL allele or a down-regulation of
TEL, as is observed in approximately 75% and 25% of TEL/AML1+ patients,
respectively (Cave et al 1997; Patel et al 2003). A third hypothetical possibility is
the loss of TEL function through the loss of downstream mediators of TEL activity,
or activation of opposing mechanisms, through either mutation or dysregulation.
What role this TEL deficiency plays in progression from pre-leukaemia to overt
TEL/AML1+ leukaemia is depicted as three possible models in Figure 1.3B. The loss
of TEL could be sufficient for progression into overt leukaemia (1), though this does
not take into other frequent mutations which may be significant (as described in
section 1.9) or the influence of infection (described in section 1.8.6). Another
possibility (2) is that TEL deficiency is a necessary requirement of the pre-leukaemic
clone, but is not sufficient for progression to overt leukaemia, which requires other
mutations or environmental factors (shown as a question mark). Finally, it is possible
that overt leukaemia can be triggered without the loss of TEL (3), but instead that
TEL deficiency confers an advantage to a leukaemic clone, such that it quickly
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becomes the dominant clone in the population. In the second chapter of this thesis,
these three possibilities for the role of TEL in the context of TEL/AML1+ will be
examined by over-expressing TEL in the REH leukaemia cell line. This aims to
illuminate the role TEL plays, both on a transcriptional and functional level, and thus
what is lost during TEL/AML1+ leukaemia progression.
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Figure 1.3 – Models for the progression of TEL/AML1+ leukaemia.
(A) TEL/AML1 increases self-renewal in transformed HSCs and can generate a persistent self-renewing
‘pre-leukaemic clone’ akin to a pro-B cell lineage, which has reduced ability to differentiate further along the
B lymphocyte lineage. (B) The progression of this TEL/AML1+ pre-leukaemic clone ends with TEL deficiency,
either through a genetic loss or a functional loss. This suggests one of three possible models for progression of
TEL/AML1+ leukaemia: (1) TEL deficiency is both necessary and sufficient for progression; (2) TEL deficiency
is necessary but not sufficient; (3) TEL deficiency is not necessary for progression to leukaemia, but confers a
selective advantage to a leukaemic clone such that it eventually becomes the dominant clone. See text for further
discussion of these models.
A
B
(1)
(2)
(3)
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Chapter 2: Materials and Methods
2.1 hESC culture
2.1.1 Culture of human embryonic stem cells (hESCs)
The human embryonic stem cell (hESC) line H9 was obtained from Peter Andrews
(Centre for Stem Cell Biology, University of Sheffield) with permission from
WiCell Research Institute (University of Wisconsin). hESCs were cultured on
irradiated mouse embryonic fibroblasts (iMEFs; MEFs obtained from UK Stem Cell
Bank) seeded onto gelatinised 6-well plates. hESC culture media was made using
Knockout Dublecco’s Modified Eagle Medium (KO-DMEM, Gibco), supplement
with 20% Knockout Serum Replacement (KO-SR), 2mM L-glutamine, 100µM Non-
Essential Amino Acids (NEAA, Gibco), 100µM β-mercaptoethanol (Gibco), 4ng/ml
human basic fibroblast growth factor (hbFGF), and 1× Penicillin-Streptomycin
(PenStrep, Invitrogen). Media was replaced every day, 2ml per well.
Stably transfected hES cell lines (‘T/A D1’, ‘T/A D2’, ‘T/A F1’, ‘T/A F2’, ‘GFP1’,
‘GFP2’, ‘ΔRHD5’, and ‘ΔRHD6’) were maintained as above, except for the use of
drug-resistant DR4 iMEFs (Tucker et al 1997; DR4 MEFs kindly provided by Peter
Andrews at University of Sheffield), and the media was supplemented with 1µg/ml
puromycin.
2.1.2 Preparation of mouse embryonic fibroblasts (MEFs)
To prepare frozen aliquots of low passage MEFs, E13.5 day mouse embryos were
homogenised using a scalpel and incubated with Trypsin-EDTA at 37ºC for
10-20 mins in a centrifuge tube. MEF Media (DMEM supplemented with 10%
Foetal Bovine Serum [FBS], 2mM L-glutamine, and 1× PenStrep) was added to the
tube, large chunks left to settle and then the supernatant transferred to one T75 flask
per embryo used, which was incubated at 37ºC until confluent. Cells were then
detached using Trypsin-EDTA, then frozen in one aliquot per flask, in freezing
media (FBS with 20% DMSO).
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2.1.3 Preparation of frozen aliquots of inactivated MEFs (iMEF)
To prepare frozen aliquots of iMEFs, a frozen aliquot of low passage MEFs (as
prepared above) was thawed and cultured in a T75 until confluent. These cells were
then passaged into several T175 flasks (commonly from one T75 to eight T175
flasks), and cultured until confluent. The cells were then harvested using Trypsin-
EDTA, and then resuspended in a small volume (~10ml) of MEF media in a 50ml
centrifuge tube. MEFs were inactivated by X-ray irradiation (40Gy), and then
counted. These iMEFs were centrifuged and resuspended in freezing media at a
concentration of 2 million cells per ml. Aliquots of 2 million cells are then frozen.
2.1.4 Preparation of iMEF plates for hESC culture
To prepare plates of iMEFs on which to culture hESCs, 6-well plates (Corning) were
gelatinised by diluting bovine Gelatin solution (Sigma-Aldrich) 1:20 in pre-warmed
Phosphate Buffered Saline (PBS; PAA), dispensing 2 ml per well, and incubating at
room temperature for at least 20 minutes. Frozen aliquots of 2 million iMEFs (as
prepared above) were thawed and resuspended in 10ml of MEF media. These were
centrifuged and resuspended in 12ml media, before dispensing into the gelatinised
6-well plate (after removing the gelatine solution) and incubating at 37ºC overnight.
2.1.5 Passaging hESCs
To split, cells were washed with PBS, and incubated with 1mg/ml Collagenase IV
(Gibco) in KO-DMEM for 20-30mins. Cells were harvested from the plate by
pipetting, centrifuged for 5 minutes at 200g, washed once with 2mls hESC media
and centrifuged, and seeded into a freshly prepared gelatinised iMEF plate at a split
ratio of between 1:6 and 1:10.
2.2 Transfection of hESC
Transfection of hESCs was performed using the NEON electroporation system
(Invitrogen). H9 hESCs were dissociated into single cells using 0.05%
Trypsin-EDTA, and resuspended at a concentration of 1×107 cells/ml, in
Resuspension buffer R. 10µl of cells (i.e. 1×105 cells) was mixed with 0.5µg DNA,
and was electroporated using the NEON transfection system, with 2 pulses of 1050V
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with a pulse width of 30ms. Cells were then dispensed into gelatinised 6-well plates
seeded with DR4 iMEFs, containing pre-warmed hESC media supplemented with
10µM Y-27632, a selective inhibitor of ROCK (Watanabe et al 2007). Media was
supplemented with 1µg/ml puromycin from two days after transfection, Y-27632
was supplemented to media until colonies with more than ten cells were visible.
2.3 Western Blot
Cell extracts were prepared using radioimmunoprecipitation assay buffer (RIPA
buffer, Sigma Aldrich) following manufacturer’s instructions. Protein samples from
hESC lines to detect TEL/AML1 were resolved on a 12.5% SDS-polyacrylamide
gel. Protein was transferred to a polyvinylidene fluoride membrane (Immobilon-P,
Millipore), and blocked in PBS with 5% (w/v) milk powder for one hour. Primary
antibodies were diluted in PBS with 5% milk and 0.1% Triton; 1 in 2000 for anti-HA
tag, and incubated overnight at 4ºC (more information and manufacturers for
antibodies used can be found in Table 2.1). Membranes were washed three times
with PBS-Triton for five minutes, and then incubated with a Horseradish Peroxidase-
conjugated secondary antibody at a dilution of 1 in 5000, in PBS with 5% milk.
Membranes were washed as before and proteins detected using the
chemiluminescent reagent ECL (GE Healthcare) and photographic film (Amersham
Hyperfilm, GE Healthcare).
2.4 Imaging of hESCs using immunocytochemistry
hESC lines were grown on chamber slides onto which DR4 iMEFs had previously
been seeded. After three or four days of culture, cells were fixed using 4%
Paraformaldehyde (PFA) for 15 minutes, washed with PBS for 5 minutes, and
permeabilised using PBS supplemented with 0.5% Triton X-100 and 3% goat serum
(hereafter referred as PBS-Triton-Serum) for 30 minutes. The anti-HA tag primary
antibody was diluted 1 in 500 in PBS-Triton-Serum and incubated for 1 hour. Cells
were washed three times with PBS-Triton for 5 minutes, and fluorescently-
conjugated primary and secondary antibodies applied (Goat anti-rabbit Alexa647 and
anti-GFP-Alexa488, diluted 1 in 500 in PBS-Triton-Serum) for 45 minutes. The cells
were washed three times for 5 minutes with PBS-Triton, with the first wash
containing DAPI at a dilution of 1 in 2000. Cells were post-fixed with 4% PFA for 5
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minutes, before being washed three times again with PBS-Triton. Finally,
PBS-Triton was removed and replaced with PBS to prevent cells from drying out.
Fluorescently labelled cells were imaged using a Multiphoton Zeiss LSM 780 NLO,
and images processed using Volocity software (PerkinElmer).
2.5 Preparation of samples for karyotyping
hESCs in exponential growth were incubated with colcemid solution (KaryoMAX,
Gibco), diluted to 2µg/ml in PBS, for four hours at 37ºC. Cells were detached from
the culture dish by Trypsin-EDTA and aspirated to form a single cell suspension,
which was transferred to a 15ml centrifuge tube, to which 6mls of prewarmed
hypotonic KCl solution (37.5mM in dH2O) was added, and incubated for 5 minutes
at 37ºC. The tubes were centrifuged at 100g for 8 minutes to pellet the cells, before
being fixed using a fixative (3:1 methanol:glacial acetic acid); the pellet was
resuspended in the fixative and centrifuged three times. After the final centrifuge
step, the samples ready for karyotyping were resuspended in the fixative and stored
at -20ºC. Karyotyping was kindly performed by Duncan Baker (Sheffield Children’s
Hospital). All cell lines were found to be karyotypically normal female (46, XX).
2.6 Haematopoietic differentiation of hESC
2.6.1 Differentiation culture
hESCs were differentiated towards haematopoietic lineage following the OP9
co-culture method as described in Vodyanik & Slukvin 2007. To summarise, on
day 0, hESCs were seeded onto overgrown OP9 cultures in 10cm dishes, in small
aggregates at a concentration equivalent to 106 cells per plate. Media used for
differentiation was Minimum Essential Medium Alpha-modification (α-MEM,
Gibco), supplemented with 10% Foetal Bovine Serum (FBS, HyClone), 100µM
monothioglycerol (MTG, Sigma-Aldrich), 50µM Ascorbic Acid (Sigma-Aldrich)
and 1× PenStrep. On day 1, medium was replaced with 20ml differentiation medium,
and on days 4 and 6, medium was half-changed, with 10ml fresh medium.
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2.6.2 Harvesting of differentiated hESCs
On day 8, the cells from the differentiation cultures were harvested by 20 minutes
incubation with Collagenase IV solution followed by 30 minutes in Trypsin-EDTA
solution. Cells were washed three times with ‘Washing Buffer’: Phosphate Buffered
Saline (PBS) without calcium or magnesium (PAA Laboratories), supplemented
with 5% FBS and 2mM EDTA. On the third wash, cells were passed through a
70-µm Cell Strainer (BD Biosciences) to remove any clumps, and then cells were
counted by trypan blue exclusion, either manually by microscope or automatically
using the Vi-CELL XR cell counter (Beckman Coulter).
2.6.3 Analysis of differentiation by flow cytometry
For flow cytometric analysis, the cell concentration was adjusted to 5 × 106 cells /ml
and 100µl of cells (i.e. 5 × 105 cells) were stained in 100µl staining volume for at
least 30 minutes using combinations of the following monoclonal antibodies:
CD31-PE, CD31-Alexa488, CD43-FITC, CD43-PE, and TRA-1-85-APC (more
information and manufacturers for antibodies used can be found in Table 2.1). For
dead cell discrimination, cells were stained with 7-Amino-actinomycin D (7-AAD).
Cells were analysed using the CyAn-ADP flow cytometer (Beckman Coulter), and
subsequent analysis was carried out using the Summit (Beckman Coulter) and
FlowJo (TreeStar) software programs.
2.6.4 Sorting of CD43+ cells by MACS and FACS
For MACS enrichment prior to sorting by FACS, harvested cells were subjected to
two MACS enrichments: dead cell depletion and enrichment on CD43.
First, for the dead cell depletion, cells were washed once with PBS (with added
magnesium, in the form of hydrous magnesium chloride at a final concentration of
0.1g/L) and then MACS Binding Buffer (Miltenyi Biotec). Cells were resuspended
in 100µl Dead Cell Removal Microbeads per 107 cells (Miltenyi Biotec) and
incubated at room temperature for 15 minutes. The mixture of cells and beads was
then passed through a LS positive selection column in a MACS separator, which was
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then washed four times with Binding Buffer. All the flow through was collected as
the live cell fraction.
Second, for the enrichment for CD43+ cells, the protocol described by Vodyanik &
Slukvin was adapted. Briefly, cells were centrifuged, and the pellet was resuspended
in an equal volume (i.e. if the pellet volume was 0.2ml, the pellet was resuspended in
0.2ml) – this is called the staining volume. The anti-CD43-PE antibody was added at
a 10th of this total volume (i.e. 40µl, in the above case), and the mixture was
incubated at 4ºC for 20 minutes. Cells were washed using Washing Buffer (PBS,
5% FBS, and 2mM EDTA), resuspended in the same staining volume as before, and
Anti-PE Microbeads added at a 10th of the volume. This mixture was incubated for
20 minutes at 4ºC. Cells were washed using Washing Buffer, and the cells were
passed through a LS positive selection column in a MACS separator. The column
was washed three times with Washing Buffer, removed from the MACS separator,
and then the cells adhering to the column were eluted in Washing Buffer.
For sorting of CD43+ cells directly by FACS, harvested cells were stained with
TRA-1-85-APC, CD43-PE, and 7-AAD, and cells were sorted using the MoFlo cell
sorter (Beckman Coulter) on the basis of lack of 7-AAD staining, expression of
TRA-1-85, and expression of CD43.
2.7 Haematopoietic Precursor Colony Forming Assay
To assess the haematopoietic capacity of differentiated hESCs, sorted CD43+ were
resuspended in 0.3ml differentiation media (αMEM, 10% FBS, 100µM MTG, 50µM
Ascorbic Acid, and 1× PenStrep), and added to a pre-aliquotted tube containing 3ml
of methylcellulose-based medium (MethoCult H4435, STEMCELL Technologies).
The tube was vortexed to mix and incubated in a 37ºC water bath for 10 minutes to
allow bubbles to dissipate. Using a blunt-end needle (STEMCELL Technologies)
and a 1ml syringe (BD Biosciences), cells in MethoCult were dispensed into three
35mm low adherence dishes (BD Biosciences), which were placed inside a square
petridish (Nalgene Nunc) with an open 35mm filled dish with dH2O. After two
weeks, the dishes were checked for colonies containing differentiated cells.
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2.8 Differentiation of hESC-derived haematopoietic precursors
towards B lymphoid lineage
Sorted CD43+ haematopoietic precursors from hESC differentiation were
differentiated towards B lymphoid lineage as described in Vodyanik et al 2006. To
summarise, sorted CD43+ cells were seeded onto Mitomycin-C-inactivated MS-5
stromal cell monolayers, at a density of 103 cells per well of 6-well plates (MS-5
cells kindly provided by Claudine Schiff, Centre d’Immunologie de Marseille
Luminy, Université de la Méditerranée). Differentiation media consisted of αMEM
supplemented with 10% FBS, 100µM MTG, 50ng/ml Stem Cell Factor (SCF),
50ng/ml Fms-related tyrosine kinase 3 ligand (Flt-3L), 20ng/ml Interleukin-7 (IL-7),
and 5ng/ml Interleukin-3 (IL-3; all cytokines from Peprotech). Media was
half-changed every 4 days, with media without IL-3. All cells were harvested on the
fourth week of culture (both adherent and non-adherent), and analysed by qPCR.
2.9 REH cell culture
The REH cell line was obtained from the American Type Culture Collection
(ATCC). Cells were cultured in RPMI-1640 (Gibco) supplemented with 10% FBS
and 2mM L-glutamine. Cells were passaged by centrifugation at 300g for 5 minutes
and were commonly split at a 1:10 ratio. Stably transfected REH cells (REH:TEL
and REH:pCIneo) were maintain in media supplemented with 600µg/ml G418 and
1× PenStrep.
2.10 Transfection of REH cells with DNA plasmids
Transfection of REH cells was performed using the NEON electroporation system
(Invitrogen). REH cells were resuspended at a concentration of 1×107 cells/ml, in
Resuspension buffer R. 10µl of cells (i.e. 1×105 cells) was mixed with 0.5µg DNA,
and was electroporated using the NEON transfection system, with 2 pulses of 1050V
with a pulse width of 30ms. Cells were then dispensed into 6-well plates containing
pre-warmed REH media. Two days after transfection, the media was replaced,
supplemented with 600µg/ml G418.
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2.11 Transduction of REH cells with viral vectors
Transduction of REH cells was performed by spinoculation; 106 REH cells were
resuspended in 500µl of media without FBS, and mixed with 500µl of viral
supernatant (either MSCV-TEL-IRES-eGFP or MSCV-eGFP, cited in Morrow et al
2007 and kindly provided by Owen Williams, Institute of Child Health, University
College London) and Polybrene (Hexadimethrine bromide, at a final concentration
of 5µg/ml, Sigma-Aldrich), and centrifuge at 800g for 45 minutes at room
temperature. Cells were resuspended in the supernatant, and plated out into a 6-well
plate. 1ml of media without FBS was added, and incubated at 37ºC. 24 hours later,
media was replaced with media containing FBS. Cells expressing GFP were sorted
by FACS 48 hours after the initial transduction.
2.12 Gene expression profiling by qPCR
RNA extract, cDNA synthesis, and qPCR for all cells followed the same protocol.
Cells were lysed by resuspending in 350µl RLT buffer (Qiagen), and RNA was
extracted using the RNAeasy Spin Column Kit (Qiagen), following manufacturer’s
instructions. RNA concentration was assessed using NANOdrop (Thermo
Scientific). cDNA was synthesised using the EZ-First Strand Kit (Biological
Industries), using between 0.5µg and 1µg of RNA, following manufacturer’s
instructions. cDNA was either used immediately or stored at -20ºC for future use.
Real-time quantitative PCR was performed with the SYBR Green PCR kit using the
ABI Prism 7300 system (Applied Biosystems) following manufacturer’s
instructions. Expression of target genes was normalised to GAPDH and expressed as
a fold change in expression using the change in cycle threshold (ΔΔcT) method.
Primer sequences for target genes are listed in Table 2.2.
2.13 Microarray
The integrity of the RNA samples was assessed using Agilent 2100 Bioanalyzer, and
were all deemed to be of good quality. RNA was subjected to a further RNA quality
control test; Figure 4.1C shows the fragments of amplified (complimentary) RNA
for loading onto the chip are of similar sizes between samples and within the
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necessary range (200-1000 nucleotides). Raw data from the microarray was
normalised so that median values and spread of data for both replicates in each group
were the same (Figure 4.1D). The microarray platform used was Agilent Human
Gene Expression 4×44k Microarray. The same RNA as used in the microarray was
used again to validate the expression of a selection of genes (Table 4.3) by qPCR
(Figure 4.3, Figure 4.8, and Figure 4.9).
2.14 EdU uptake assay
Proliferation of REH cells was assessed by directly measuring DNA synthesis using
the ‘Click-iT EdU Flow Cytometry Assay Kit’ (Invitrogen). Briefly, the nucleoside
thymidine analog EdU was added to cells in media at a final concentration of 10µM.
After incubating for one hour, cells were washed, fixed with 4% PFA, and
permeabilised with PBS-Triton (0.15% v/v), before reacting the EdU with a
fluorescently-labelled azide (either azide-Alexa488 or azide-Alexa647, depending on
the application) using the reagents included in the kit. EdU uptake was assessed by
flow cytometry.
2.15 Cell cycle analysis
REH cells transduced with either GFP or TEL-GFP oncoretrovirus were seeded into
culture for 96 hours. At 24 hour time points, samples were taken, and washed in PBS
by centrifugation. Cells were then fixed with 4% PFA, before being permeabilised
with PBS-Triton. The cells were finally stained with DAPI (1 in 2000 dilution in
PBS-Triton), washed in PBS, and analysed by flow cytometry.
2.16 Apoptosis assay
REH cells transduced with either GFP or TEL-GFP oncoretrovirus were seeded into
culture for 72 hours with or without staurosporine (STS; 1µM). At 24 hour time
points, samples were taken, washed once in PBS, and washed again in “Annexin-V
binding buffer” (10mM HEPES, 140mM NaCl, and 2.5mM CaCl2 in water), by
centrifugation. The cells were resuspended in 100µl binding buffer, to which 5µl
Alexa647-conjugated anti-Annexin-V antibody and 5µl of pre-diluted DAPI (1% v/v
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in binding buffer) was added. Cells were incubated at room temperature in the dark
for 15 minutes, before 400µl binding buffer was added, and the cells were analysed
by flow cytometry.
2.17 Statistical analysis
All statistical analyses were performed using GraphPad Prism 5 software. To
perform statistical analysis on the data from the differentiation of hESC (Figure 3.8),
I first assessed whether the data fitted a normal distribution using the in-built
D’Agostino-Pearson omnibus normality test (D'Agostino & Pearson 1973). None of
the data sets passed the test for normality, due to the small sample sizes used.
I therefore analysed data using non-parametric statistical tests, specifically the
Mann-Whitney test for comparing two groups (the non-parametric counterpart to
Student’s t-test), and Kruskal-Wallis test for comparing three or more groups (the
non-parametric counterpart to One-way ANOVA). Statistic significance was set to
p values less than 0.05.
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2.18 Antibody Table
Specificity Label Clone Isotype Manufacturer Host Use
Annexin-V Alexa647 n/a n/a Molecular Probes Goat FC
Anti-CD31 PE WM59 IgG1, κ BD Pharmingen Mouse FC
Anti-CD31 Alexa488 M89D3 IgG2a, κ BD Pharmingen Mouse FC
Anti-CD43 PE/FITC 1G10 IgG1, κ BD Pharmingen Mouse FC
Anti-GFP Alexa488 - IgG Molecular Probes Rabbit ICC
Anti-HA tag Purified n/a
(polyclonal)
IgG AbCam Rabbit WB,
ICC
Anti-SSEA-1 APC MC-480 IgM R&D Systems Mouse FC
Anti-SSEA-4 PE MC-813-70 IgG3 Millipore Mouse FC
Anti-TRA-1-60 FITC TRA-1-60 IgM Millipore Mouse FC
Anti-TRA-1-85 APC TRA-1-85 IgG1 R&D Systems Mouse FC
Anti-Rabbit
IgG secondary
HRP n/a
(polyclonal)
IgG AbCam Goat WB
Table 2.1 – List of antibodies used in this thesis
Abbreviations- PE: R-Phycoerythrin; FITC: Fluorescein isothiocyanate; APC: allophycocyanin;
HRP: Horseradish Peroxidase; FC: Flow Cytometry; ICC: Immunocytochemistry; WB: Western Blot.
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2.19 Primer list
Gene Target Forward Primer (5’  3’) Reverse Primer (5’  3’)
ANGPTL4 GGCCAAGCCTGCCCGAAGAA CGGTGCAGGCGGCTGACATT
BCL-2 GTACCTGAACCGGCACCTGCAC AGCCTCCCATTGCCCCAGGAG
CD10 TGCACAGGTGTGGTGTGGAACC TGCGGCAGTGAAAGGCTTCTGA
CD19 GCCGGTCGCCAGGACAATGG AGGGAGGTTGCTTCCCGGCT
CD34* TGGACCGCGCTTTGCT CCCTGGGTAGGTAACTCTGGG
CD43 GCCCCAGTGCTGCGTCCTTA GCTGTTGTGCTCCCCAGAGCG
CDKN1B AAGAGGCGAGCCAGCGCAAG GGCCGCGGGGGTCTGTAGTA
CDKN2A AGACCCAACCTGGGGCGACT CGAGTGCTCGGAGGAGGTGC
CLIC5 GGCGACAGCTAACGGGGACG CGCTGAGAGAAAGGACAGTTGCCG
EKLF* CGGACACACAGGATGACTTC GGCTGGTCCTCAGACTTCAC
EPOR TGGACCCCCTCATCCTGACGC AACTCGCTCTCTGGGCTCGGG
GAPDH AAGGTGAAGGTCGGAGTCAA AATGAAGGGGTCATTGATGG
GATA1* GGGATCACACTGAGCTTGC ACCCCTGATTCTGGTGTGG
GATA2* GCGTCTCCAGCCTCATCTT GGAAGAGTCCGCTGCTGTAG
HPRT § GTTGGATACAGGCCAGACTTTGTTG GTTGGATACAGGCCAGACTTTGTTG
IKZF2 GCACAAACACACGTTAGGCACAG ACCCCTCAAAGAGGAGGTGACAA
MB1 CCGCACAATAGCAGCAACAA CCACGTGTAGTTGCCATGGA
NANOG GCCCTGATTCTTCCACCAGTCCC TGACCGGGACCTTGTCTTCCTT
NETO ATCCCCCTGACCGGGAATGC TTTGCACTCCCAAGACGGTTCAA
OCT4 GCCACATCGCCCAGCAGCTT GCCCTTCTGGCGCCGGTTAC
p53 § GGGACAGCCAAGTCTGTTATGTGC CTGTCTTCCAGATACTCGGGATAC
PAX5 CGTTTAGTTTCAGCTCAGTGATCAG CGCTCACAGGTCGGAATAATTC
PIK3C3† GCCTTGGAACTTCTGGGAAAA CAACAGCATAACGCCTCACAG
PU.1* CACAGCGAGTTCGAGAGCTT GATGGGTACTGGAGGCACAT
RAG1 TTTGCCGGGTCTGCATTC TCAGTAGGGAAGCATGGATATCG
SCL* ATGAGATGGAGATTACTGATG GCCCCGTTCACATTCTGCT
SMAD1 GGCGGAGAAAGGAGAGGCCGAG GTCCGTGTGGGAGCACGAGTGG
TDT TTGCCCTGTTGGGATGGA CATAGCGCCGGAGGTCTCT
TTBK CGGGCGAGTGGAGCTACCTG ACTGGCCTGTCGGTCAGCGT
TEL‡ TCCCAACGGACTGGCTCGACT TAGTGGCGCAGGGCTCTGGA
TEL/AML1‡ CATCATGGTCTCTGTCTCCCCGCC TGGCATCGTGGACGTCTCTAGAAGG
TNFRSF7† AGGGACAAGGAGTGCACCG AAGGTAAGTGGGTGGGCTGAG
VpreB ACTGAAGACAGCAGAGGCAC GCTCCACCCTCTTCCATGAC
Table 2.2 – List of primer s used in this thesis
* Primers from Zambidis et al 2005
† Primers from Gandemer et al 2007
§ specific for mouse gene, all others specific for human genes
‡ Primers for TEL amplify across exon 7-8 of TEL, TEL/AML1 is across the breakpoint of TEL/AML1.
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Chapter 3: The effects of TEL/AML1 on haematopoietic
development of human embryonic stem cells
3.1 Introduction
There are critical aspects of TEL/AML1+ acute lymphoblastic leukaemia which are
yet to be elucidated. For example, it is commonly assumed that the original
translocation event occurs in the haematopoietic stem cell (HSCs), though that has
not been proven (le Viseur et al 2008). In addition, the frequency of the translocation
generating TEL/AML1 in the normal, non-leukaemic, population is subject to debate
(Mori et al 2002; Brown 2011; Lausten-Thomsen et al 2011). Also, the interaction
between different leukaemic sub-clones in a single patient, and their ‘evolution’ of
over the course of the disease (Anderson et al 2011; Notta et al 2011b), complicates
the interpretation of any study using whole bone marrow, and therapeutic
approaches.
As more is revealed about the nature of TEL/AML1+ leukaemia, researchers will
continue to use model systems as tools to address questions about fundamental
aspects of the disease. Such model systems can be divided into three categories:
in vivo models using transgenic animals, xenograft models using ex vivo
patient-derived material, and studies using cell lines in vitro.
3.1.1 In vivo models
Firstly, in vivo mouse models, either studying transgenic animals (Schindler et al
2009) or recipients of TEL/AML1-transduced bone marrow (Tsuzuki et al 2004),
have been used to investigate the development and clonal evolution of TEL/AML1+
HSCs. A common feature is that TEL/AML1 on its own is not sufficient to cause
leukaemia in most of the mouse models, consistent with predictions made from the
analysis of leukaemia in monozygotic twins (Wiemels et al 1999b). Neither
endogenous expression (Andreasson et al 2001; Ford et al 2009) nor exogenous
expression of TEL/AML1 (Morrow et al 2004; Tsuzuki et al 2004; Fischer et al
2005; Lyons et al 2010) caused overt leukaemia.
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Expression of TEL/AML1 in vivo increased quiescence in HSCs (Schindler et al
2009), and caused abnormalities in B cell development, either causing increased self-
renewal of B cell precursors (Morrow et al 2004; Morrow et al 2007; Lyons et al
2010) or impairment of transition from pro-B to pre-B cells (Tsuzuki et al 2004;
Fischer et al 2005). The result is the accumulation of persistent early B cell
progenitors, which is believed to represent a ‘pre-leukaemic state’ that predisposes
individuals for further transformation and ultimately overt leukaemia.
Other groups have focussed on the cooperation between TEL/AML1 and common
secondary mutations. Bernardin and colleagues (2002) transduced bone marrow with
TEL/AML1 and transplanted into syngeneic mice, and only 2 of 9 mice developed
leukaemia (one T-cell ALL, one B-cell ALL). Bone marrow from mice lacking
p16-INK4a and p19-ARF genes (a common mutation in childhood ALL; Takeuchi et
al 1995) transduced with TEL/AML1 gave rise to leukaemia in 6 of 8 recipient mice,
but none could be diagnosed as B-lineage. TEL/AML1+ transgenic mice described
by Schindler and co-workers (2009) have a predisposition for haematological
malignancies when exposed to chemical mutagens (though mostly T cell lymphomas
and leukaemias). Finally, a mouse model developed by van der Weyden and
colleagues (2011) expressed TEL/AML1 under the control of the endogenous Etv6
locus. Using this in combination with a ‘Sleeping Beauty’ transposase, they
performed an insertional mutagenesis screen to identify genes that when mutated
contribute towards leukaemia. 20% of the mice developed B lineage leukaemia, and
the screen gave an insight into cooperating mutations, both known and novel.
3.1.2 Xenograft models
Secondly, models using xenografts of patient-derived cells or cord blood
haematopoietic progenitors transduced with TEL/AML1 have been used to imitate
human disease features. There is an increased morbidity in SCID mice receiving
material from patients who suffered relapse shortly after discontinuing treatment
than those whose leukaemia relapsed later or did not relapse at all (Kamel-Reid et al
1991), a feature that could even be used to predict which patients would relapse
(Uckun et al 1995). Leukaemic cell invasion in NOD/SCID mice was commonly
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observed in the spleen, but only rarely into other organs, mimicking the human
disease (Nijmeijer et al 2001).
Subsequently, and following work from John Dick and contemporaries working in
Acute Myeloid Leukaemia (Lapidot et al 1994; Bonnet & Dick 1997) the most
common use of xenografts has been focussed on the identification of the cell which
gives rise to the leukaemia, referred to as the ‘leukaemic stem cell’, or LSC.
Cobaleda and colleagues identified from patients with the ‘Philadelphia
Chromosome’ subtype of ALL (‘Ph+ ALL’) a population of CD34+CD38– cells
which propagated leukaemia in SCID mice, also shown to be the engrafting
population from AML (Bonnet & Dick 1997) as well as normal bone marrow
(Cobaleda et al 2000). In TEL/AML1+ ALL it was found that CD34+CD38–CD19+
cells, a B lineage population not seen in normal bone marrow, were able to
self-renew in vitro and in vivo giving rise to TEL/AML1+ cells, whereas their CD19–
counterparts gave rise to TEL/AML1– cells of various lineages (Castor et al 2005).
This population could be observed in the peripheral blood of the healthy twin of a
TEL/AML1+ leukaemia patient (but not in that of an unrelated normal age-matched
control), and that, by VDJ rearrangement sequencing, they are likely to derive from
the same monoclonal population in both twins, indicating a pre-natal transfer from
one twin to the other (Hong et al 2008). In addition, the transduction of cord-blood
with TEL/AML1 generated the CD34+CD38–CD19+ population, which could
transfer a ‘pre-leukaemic’ state in serially transplanted mice. The concept of LSCs
has clinical relevance; it was found that bone marrow from ‘poor outcome’ ALL
patients lead to high engraftment in NOD/SCID/IL2Rγ-/- (NSG) mice, indicating
high numbers of LSCs (Morisot et al 2010).
However, there has been some ambiguity about the identity of the LSC. Kong and
colleagues (2008) showed that both CD34+CD38–CD19+ and CD34+CD38+CD19+
cells could initiate ALL in newborn NSG mice, whereas le Viseur and co-workers
(2008) showed that cells comprising of either CD34+CD19–, CD34+CD19+, or
CD34–CD19+ were able to re-establish all leukaemic cell phenotypes when
transplanted into NOD/SCID mice. Various technical explanations have been put
forward for these discrepancies, including sub-100% purity of flow-sorted
populations, the genetic backgrounds and ages of mice used for xenografts (Shultz et
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al 2007), and low levels of clearance of antibody-stained cells (Taussig et al 2008).
However, it has been suggested that the immunophenotypically defined populations
are more similar functionally than previously thought and that they fluctuate between
different states (le Viseur et al 2008).
3.1.3 Models using cell lines
Thirdly, patient-derived cell lines and in vitro studies have been used to investigate
molecular and cellular aspects of leukaemia. One of the caveats of this approach is
that cell lines may acquire genetic changes to adapt to growth factor-independent
proliferation ex vivo. Nevertheless, gene expression analysis of leukaemia cell lines
and primary leukaemia samples has shown that cell lines harbouring similar genetic
lesions cluster together, as well as with patients who also carry that lesion
(Andersson et al 2005a), indicating that the transcriptional profile in primary
leukaemia samples remains intact in cell lines despite extended ex vivo culture, and
so are a valuable tool for studying leukaemia.
Using leukaemia patient-derived cell lines, common chromosomal changes (Uphoff
et al 1997), other genomic changes (Tsuzuki et al 2007), and how TEL/AML1 is
processed in the cell (Chakrabarti et al 2000) have been identified and confirmed in
primary patient samples. In particular, the molecular biology of TEL/AML1 and its
transcriptional effects have been studied using cell lines. It was discovered that the
fusion of TEL to AML1 and its isoforms represses AML1 targets (Hiebert et al
1996), that TEL/AML1 can only have its suppressive effects on AML1 targets when
dimerised (Fears et al 1997), and that it also has an effect on wildtype TEL (Gunji et
al 2004).The role of the domains of TEL and AML1 in the DNA binding of the
fused TEL/AML1 has also been studied using TEL/AML1 mutants transduced into
cell lines (Morrow et al 2007).
The use of cell lines has also helped identify pathways that contribute to the survival
and pathogenesis of leukaemic cells. For example, the role of TCL-1 has been
identified and investigated using cell lines (Andreasson et al 2001; Fears et al 2002),
as well as the circumvention of the mitotic checkpoint (Krapf et al 2010) and the
anti-apoptosis networks that leukaemia cells exploit (Accordi et al 2007; Diakos et al
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2007; Fuka et al 2011a). The protection from chemotherapeutic drugs that bone
marrow stroma confers has been elucidated in leukaemia cell lines (Dosen-Dahl et al
2008). Cell lines have also been used to assess the effects of common mutations, for
example, by the overexpression of TEL (Tsuzuki et al 2007) or the RNAi-mediated
silencing of TEL/AML1 itself (Fuka et al 2011b; Zaliova et al 2011). The role of
microRNA (miRNAs) in leukaemia, a relatively new direction in cancer research,
has also been investigated using cell lines (Gefen et al 2009; Diakos et al 2010).
3.1.4 The prospect for a hESC-based model
Whilst important discoveries have been made with these models, each of these
approaches has its disadvantages. Haematopoietic development in animal models
does share many characteristics with that in humans, but there are subtle differences
that limit the application of results from transgenic animal models to human disease
(for a review of mouse models of leukaemia, see Bernardi et al 2002). For similar
reasons, the xenograft of human haematopoietic precursors into mice is dependent on
the mouse strain being used, some of which may skew haematopoietic development
toward certain lineages (Shultz et al 2007; McDermott et al 2010). However,
primary human material, whether in the form of bone marrow samples or cord blood
samples, is difficult to obtain, and the inherent genetic variability between donors
may conceal subtle but significant differences. Cell lines avoid this problem, but
there are still concerns about the adaptations made by these cells to survive in growth
factor free conditions (Matsuo & Drexler 1998), either as a result of their malignant
transformation, or by exogenous factors such as Epstein-Barr virus (Gerber et al
1969). In addition, cell lines at best only provide a ‘snapshot’ of a particular human
cell type and cannot provide information about its developmental origins.
The use of human embryonic stem cells (hESCs) as a source of haematopoietic
precursors for a model of TEL/AML1+ leukaemia would complement the above
models, but could also address some of their shortfalls. Working with a human
system enables a more direct comparison to the disease than might be possible with
mouse models, allowing, for example, gene expression changes to be compared with
array data from patients. The use of hESCs – pluripotent cell lines that can be
efficiently and genetically manipulated, expanded, and differentiated in vitro –
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provides a potentially limitless source of syngeneic human haematopoietic
precursors, capable of differentiating to mature blood cell types, and avoids the
difficulties of culturing human HSCs ex vivo.
3.1.5 Use of ES cells in models of leukaemia and other diseases
There have been examples of the use of mouse ESCs (mESCs) to study leukaemias.
The effects of BCR-ABL fusion gene (associated with Chronic Myeloid Leukaemia,
or CML) upon the differentiation capacity of mESCs has been investigated, and has
been shown to inhibit haematopoietic differentiation via activation of STAT3
(Coppo et al 2003), increasing the numbers of multipotent and myeloid-committed
haematopoietic progenitors whilst decreasing erythroid progenitors (Era & Witte
2000), consistent with observations in patients in the chronic phase of CML.
Haematopoietic progenitors derived from BCR-ABL-transduced mESCs cause
leukaemia upon injection into mice which recapitulated specific aspects of CML,
such as IL-3 production (Peters et al 2001).
Recently a hESC model of MLL/AF4+ leukaemia has been described (Bueno et al
2012). In infant pro-B ALL, MLL/AF4 (generated by the t(4;11) translocation) is
associated with a short latency and a poor prognosis. hESCs expressing MLL/AF4
(transduced with lentiviral vector) show an increased ability to generate
haemato-endothelial precursors, but that differentiation from these cells is skewed
towards endothelium and away from haematopoiesis. The significance of these
results is not known, although bone marrow mesenchymal stem cells carrying
MLL/AF4 have been reported in infant MLL/AF4+ B-ALL, suggesting a
pre-haematopoietic cell of origin for this leukaemia (Menendez et al 2009).
In addition, there have been several examples of the use of hESCs for modelling
other diseases. Pre-implantation genetic diagnosis of blastocysts has allowed the
identification of embryos carrying mutations for congenital diseases, which has
permitted the derivation of hESCs (Mateizel et al 2006) and their use to model
diseases such as Fragile-X syndrome (Eiges et al 2007), Turner’s syndrome (Urbach
& Benvenisty 2009), and Huntington’s disease (Niclis et al 2009). Homologous
recombination in hESCs has also been used to model disorders such as Lesch-Nyhan
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disease (Urbach et al 2004), Paroxysmal nocturnal haemoglobinuria (Zou et al
2009), and Ataxia-telangiectasia (Song et al 2010).
These studies into the use of mESCs and hESCs to study leukaemia and other
diseases demonstrate the potential of a hESC-based model which can be utilised at
multiple levels of leukaemia research.
3.1.6 Embryonic stem cells
Embryonic stem cells (ESCs) were first described in 1981 by two groups attempting
to culture the pluripotent cells in mouse pre-implantation blastocysts (Evans &
Kaufman 1981; Martin 1981). These cells are able to form teratocarcinomas
containing all three germ layers when injected into mice, a property previously
described in cells from germ cell tumours, termed embryonic carcinoma cells, or
ECCs (Kleinsmith & Pierce 1964). mESCs are also able to contribute to the embryo
when injected into mouse blastocysts.
The derivation of embryonic stem cells from human blastocysts (hESCs) was
demonstrated in 1998 by Thomson and colleagues, and shared the same
characteristics as mESCs, namely derived from the pre-implantation blastocysts,
indefinite pluripotent culture in vitro, and potential to form cells from all three germ
layers (Thomson et al 1998). As of December 2011 there were over 1,000 described
hESC lines, but three of the cell lines described in Thomson’s paper, H1, H7, and
H9, are still the most widely used today (Levine 2011).
3.1.7 Definition of hESCs by pluripotency markers
Embryonic stem cells are defined by two main characteristics – their capability for
indefinite self-renewal, and their pluripotency, usually demonstrated by their ability
to form teratomas containing tissues of all three germ layers when implanted into
immunodeficient mice (Thomson et al 1998). The expression of certain genes and
cell surface molecules has also been used as markers to define hESCs.
The transcription factor OCT4, coded for by the gene POU5F1, is a critical regulator
of pluripotency. OCT4 protein is present in the mammalian oocyte, and is expressed
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at low levels from the 4-cell stage of the fertilised zygote, before being upregulated
from the 8-cell stage (Pesce et al 1998). In the blastocyst, whilst the expression of
OCT4 remains high in the inner cell mass, its expression is lost upon differentiation
to form the trophoblast, which go to form the extra-embryonic tissues (Nichols et al
1998). Consistent with this, Oct4–/– embryos develop up to blastocysts stage, but fail
to form an embryo as the inner cell mass loses its pluripotency and differentiates
towards the trophoblast lineages (Nichols et al 1998).
NANOG is another transcription factor required for the maintenance of pluripotency
in hESCs. The loss of Nanog in mESCs caused a loss of pluripotency and
differentiation to trophoblast lineages (Mitsui et al 2003), similar to the effects of the
loss of OCT4. It has since been discovered that pluripotency is maintained by the
cooperation of OCT4, NANOG, and another transcription factor SOX2, by inhibiting
the expression of transcription factors involved in lineage specification, and
stimulating the expression of other transcription factors involved in pluripotency
(Boyer et al 2005). In addition, these transcription factors co-operate to stimulate
their own expression, and in so doing form a self-regulatory ‘feed-forward’ loop
(Boyer et al 2005).
The cell surface antigens Stage-Specific Embryonic Antigen-4 (SSEA-4) and
SSEA-1 are glycolipids used to distinguish between pluripotent and differentiating
cells. Production of SSEA-4 is high in undifferentiated pluripotent cells, such as the
embryonic carcinoma cell lines 2102Ep, but as pluripotent cells differentiate,
production of SSEA-4 ceases and SSEA-1 production increases (Kannagi et al
1983). TRA-1-60 is another antigen expressed on the cell surface of pluripotent cells
(Draper et al 2002), and has been identified as a glycosaminoglycans (Badcock et al
1999), which might be attached to the proteoglycan podocalyxin (Schopperle &
DeWolf 2007). The functions of these cell surface antigens are not known.
3.1.8 Haematopoietic differentiation of hESCs
Haematopoietic differentiation from hESCs was first described by Kaufman and
colleagues (Kaufman et al 2001), using a co-culture methods with murine bone
marrow stromal cells. Haematopoiesis from hESCs goes through waves of primitive
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and definitive stages (Zambidis et al 2005), mimicking the development of blood
lineages during embryonic development. To date, hESC have been differentiated to
functional cells comprising of almost the full range of adult haematopoietic cell
types, including megakaryocytes and platelets (Lu et al 2011), enucleated red blood
cells (Lu et al 2008), mast cells (Kovarova et al 2010), neutrophils (Yokoyama et al
2009), eosinophils (Choi et al 2009), monocytes and macrophages (Klimchenko et al
2011), dendritic cells (Slukvin et al 2006), T cells (Timmermans et al 2009), and NK
cells (Woll et al 2005, Vodyanik et al 2006). Differentiation towards B cells has
been demonstrated up to pre-B cell stage with multiple genomic D-JH
rearrangements (Vodyanik et al 2006; Carpenter et al 2011), but as of yet no VH-DH
rearrangements, and no secretion of antibodies typical of mature plasma cells.
Basophilic granulocytes have been produced (e.g. Ma et al 2007), but no functional
assays have been performed on such cells.
There are two main methods of haematopoietic differentiation of ES cells: embryoid
bodies and stromal co-cultures. Differentiation of ES cells by embryoid bodies, small
spheroid aggregates of ES cells, follows closely early embryonic development
(Keller 1995; Leahy et al 1999). The resultant spontaneous lineage specification in
human embryoid body cultures can be directed towards haematopoietic
differentiation using a cocktail of haematopoietic cytokines, for example Stem Cell
Factor (SCF), Flt-3 Ligand (Flt-3L), Interleukins 3 and 6 (IL-3 and IL-6),
Granulocyte Colony-Stimulating Factor (G-CSF), and Bone Morphogenic Protein-4
(BMP-4; Chadwick et al 2003).
Haematopoietic differentiation by co-culture is dependent upon the contact between
ES cells and stromal cell lines derived from sites of haematopoiesis (Wilson &
Trumpp 2006). The OP9 cell line, derived from the bone marrow of op/op mice
deficient in Macrophage Colony-Stimulating Factor (M-CSF) was first used to
differentiate mESCs (Nakano 1995), and later for hESCs (Vodyanik et al 2005). S17
cells, generated from a long-term bone marrow cultured to enrich for myeloid cells
(Collins & Dorshkind 1987), are another popular cell line used to differentiated
hESCs (Kaufman et al 2001; Qiu et al 2005). Cell lines derived from the first site of
definitive haematopoiesis in the mouse embryo, the aorta-gonad-mesonephros
(AGM) region, have also been used to induce haematopoietic differentiation in
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hESCs (Ledran et al 2008). One advantage of the co-culture systems is that they do
not require supplementary cytokines.
3.1.9 Methods of transgene expression in hESCs
The recent derivation of iPSCs from cord blood (Giorgetti et al 2009; Haase et al
2009; Ye et al 2009) and peripheral blood (Chou et al 2011) will undoubtedly lead to
models of haematological malignancies using iPSCs derived from leukaemia patients
in the future (see section 3.1.10). In the meantime, hESCs could fulfil this role by the
exogenous expression of TEL/AML1 (Lensch & Daley 2006; Bueno et al 2007). The
methods by which this could be achieved fall in to three broad categories:
constitutive exogenous promoters, inducible promoter systems, and the use of
endogenous promoters.
Constitutive and stable expression of GFP has been achieved using the
phosphoglycerate kinase 1 (PGK) promoter, cytomegalovirus (CMV) promoter,
human elongation factor 1 alpha (hEF1α) promoter, and chicken β-actin promoter
(Eiges et al 2001; Kim et al 2005). A chimeric promoter pCAG, containing elements
of human CMV, chicken β-actin, rabbit β-globin, and the virus polyoma mutant
enhancer sequence PyF101, was found to sustain high levels of expression in hESCs
over extended culture periods (Liew et al 2007). Other promoters have been
quantitatively compared using lentiviral vectors and show varying levels of
expression stability both in undifferentiated culture and upon differentiation
(Norrman et al 2010).
There is concern that the overexpression of any transgene can aberrantly affect cells
(including hESCs), presumably by the overloading of protein metabolism pathways,
in a phenomenon called ‘transgene toxicity’ (Vallier et al 2007; Zafarana et al 2009).
One solution to this problem is to express the gene under an inducible system. One
of the first instances of inducible expression in hESCs used a variant of a
Tetracycline-inducible system (Gossen et al 1995) to express GFP and
phosphatidylinositol glycan A (PIG-A; Zhou et al 2007). Later work showed that
inducible GFP expression could be maintained even upon directed differentiation in
vitro and in teratomas formed in vivo (Xia et al 2008).
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In this chapter, the inducible system I first used to express TEL/AML1 in hESCs is
called Tet-ON, and is based upon the tetracycline system (Gossen et al 1995), further
developed by Clontech. The expression of the gene-of-interest is controlled by the
binding of a constitutively-expressed recombinant tetracycline-dependent
transactivator (rtTA) to the tetracycline response element (TRE), which lies
upstream of a minimum CMV promoter. This binding only occurs in the presence of
doxycycline (a tetracycline derivative), so the expression of the gene-of-interest can
be “switched on” by administering doxycycline. The advantages of using an
inducible expression system, in particular a chemically inducible system like the
Tet-ON system, are three-fold: (1) the timing of expression can be controlled; (2) the
level of expression can be controlled by varying the concentration of doxycycline;
and (3) expression is controlled by a non-cytotoxic drug which would not have an
effect on non-transgenic cell lines, such as those used for co-culture differentiation
methods.
The use of endogenous promoters to appropriate the cell’s own gene expression
machinery has been demonstrated in hESCs. This work has mostly been described in
the context of the creation of ‘reporter genes’, where genes for fluorescent proteins
are expressed concurrently with a gene of interest, either indirectly under the control
of a promoter for the gene, or directly, by the disruption of one allele of this gene
with the fluorescent protein gene. For example, the expression of a GFP driven by
the Rex1 promoter in a extra-genomic plasmid vector (Eiges et al 2001) and the
disruption of the POU5F1 (Oct4) locus by homologous recombination (Zwaka &
Thomson 2003; Hockemeyer et al 2009) have been described to act as ‘pluripotency
reporter genes’, whereas the homologous recombination of a fluorescent protein
gene into the loci of Mixl1 (Davis et al 2008), Pitx3 (Hockemeyer et al 2009), Fezf2
(Ruby & Zheng 2009), and Olig2 (Ruby & Zheng 2009), all markers of
differentiation towards specific lineages, have also been demonstrated. In addition,
homologous recombination of transgenes has been achieved into loci such as the
human equivalent of the mouse ROSA26 gene (Irion et al 2007) and AAVS1
(Hockemeyer et al 2009), both of which contain genes ubiquitously and strongly
expressed in most cell types, and have been previously useful in the generation of
transgenic mice. Finally, homologous recombination has been used to disrupt genes
by insertional mutagenesis to demonstrate the use of hESCs to model diseases; for
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example, the X-chromosome HPRT gene to model Lesch-Nyhan disease (Zwaka &
Thomson 2003; Urbach et al 2004), X-chromosome PIG-A gene to model
paroxysmal nocturnal hemoglobinuria (Zou et al 2009), and bialleic disruptions of
p53 and ATM, recapitulating various cancers and Ataxia-telangiectasia respectively
(Song et al 2010).
3.1.10 Modelling human diseases with induced pluripotent stem cells
Differentiated somatic cells can be reprogrammed by transduction of transcription
factors active in embryonic stem cells (ESCs) to form cells resembling ESCs, called
‘induced pluripotent stem cells’, or iPSCs. This was demonstrated first in fibroblasts
taken from mice, where it was shown that the minimal set of genes required for
reprogramming, called ‘reprogramming factors’, comprised of Klf4, Sox2, c-Myc,
and Oct4 (Takahashi & Yamanaka 2006). These iPSCs would form teratomas when
injected subcutaneously into mice, and when injected into blastocysts would
contribute to embryonic development, two key tests of pluripotency. Soon after it
was shown that it was possible to generate iPSCs from human fibroblasts using the
same four factors (Takahashi et al 2007).
The impact of the technology to generate iPSCs goes beyond the study of
pluripotency or an alternative source of hESCs-like cells. The potential to use human
iPSCs for disease modelling and even drug screening was instantly recognised
(Zaehres & Scholer 2007). In theory, one could take fibroblasts from a diseased
patient to generate iPSCs, which could then be used to provide an unlimited source
of differentiated cells of any lineage to study their disease. This may be particularly
useful for diseases which do not have a suitable animal model or appropriate cell line
to study the disease (Saha & Jaenisch 2009). In addition, with respect to disease
modelling, iPSCs have an advantage over the alternative of genetically-modified
hESCs in that any disease-causing mutations do not necessarily have to be fully
identified before they can be modelled by iPSCs; all that is required is a patient
which to take cells from to be reprogrammed. However, there are challenges with
modelling human diseases with iPSCs, which fall roughly into three groups; firstly,
the reprogramming of human cells; secondly, the culture and differentiation of
CHAPTER 3: TEL/AML1 IN HAEMATOPOIETIC DEVELOPMENT
87
iPSCs; and thirdly, how amenably a specific disease is to being modelled in this
way.
The main concern with the method originally used to deliver the ‘reprogramming
factors’ into differentiated cell types, retroviral or lentiviral transduction, is that the
vectors will insert randomly into the genome and the genes will remain highly
expressed after reprogramming, which could affect the differentiation towards the
desired cell types, and/or any disease phenotypes from arising (Saha & Jaenisch
2009; Stadtfeld & Hochedlinger 2010; Grskovic et al 2011). To combat this, a
number of methods to generate ‘reprogramming factor-free’ iPSCs have been
developed. Integrating vectors can be removed by using either transposon vectors
such as piggyBac (Kaji et al 2009) or Cre-recombinase mediated excision (Soldner
et al 2009), but in the former the excision is inefficient and laborious, and the latter
still leaves behind viral promoters (Saha & Jaenisch 2009). Non-integrating vectors,
such as episomal vectors (Yu et al 2009), adenoviral vectors (Stadtfeld et al 2008),
or transient plasmid transfection (Okita et al 2008) have been used, though the
efficiency of transduction using these methods, and the possibility of fragments of
vector integrating, have been a concern. ‘DNA-free’ methods, such as the use of the
reprogramming factor proteins (Kim et al 2009), synthetic mRNA (Warren et al
2010), or miRNAs (Miyoshi et al 2011) have also been demonstrated, but
reprogramming with these methods remains low efficiency.
The theoretical possibility of deriving any cell types by the differentiation of human
ESCs or iPSCs in vitro is, in practise, much more difficult. Although various cell
lineages have been derived from these human pluripotent stem cells, assessed by
morphology and expression genetic and phenotypic markers, there have been only a
few examples of functional studies in differentiated cell types from hiPSCs; for
example with neural crest cell types (Lee et al 2009) and haematopoietic progenitors
(Raya et al 2009). There are additional problems if one wanted to use an iPSC- or
hESC-based disease model for drug screening, in that the large scale culture of
iPSCs in bioreactors is still a significantly more complicated process than normal
cell lines [ref]. In addition, the differentiation protocols required to differentiate
hESCs and iPSCs can take weeks, going through intermediate stages and producing
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a variety of different lineage which may not be the desired end product (Saha &
Jaenisch 2009; Grskovic et al 2011).
Ultimately, although the modelling of any human disease using iPSCs is an attractive
prospect, in reality some diseases will be less amenable to modelling in this way than
others. Diseases most likely to be modelled successfully will be cell-autonomous (so
that the phenotype of the disease will appear in the cells with little influence from
other cell types or the environment) and should manifest the phenotype rapidly with
high penetrance, so that the phenotype becomes apparent in a reasonable time-frame
for cells in culture (Grskovic et al 2011). Unfortunately, many diseases do not have
these traits; they are diseases that impact on multiple interacting cell types as well as
environmental factors (such as diabetes), or diseases which have a long latency
where symptoms manifest themselves over many years (such as Alzheimer’s
disease). It may be possible to replace some environmental influences and interacting
cell types, and accelerate disease progression with factors such as oxidative stress,
but the relevance of the model may then be called into question (Saha & Jaenisch
2009).
Researchers have already begun modelling a wide variety of diseases using iPSCs; a
list of these models can be found in Grskovic et al 2011. As a couple of illustrative
examples, I will give an overview of the iPSC models of Hutchinson-Gilford
progeria syndrome and familial Parkinson’s disease.
Hutchinson-Gilford progeria syndrome (HGPS) is a disease caused by a mutation in
the Lamin A (LMNA) gene, which is characterised by early onset of ageing, with
patients often dying in their teens from heart attack or stroke. Researchers studying
the disease derived iPSCs from HGPS patients (Zhang et al 2011) and differentiated
the cells towards the variety of mesenchymal cell lineages that are affected in the
disease, including vascular smooth muscle cells (VSMCs). The cells affected all
showed signs of DNA damage and nuclear abnormalities. The VSMCs from these
patients responded poorly to both hypoxic stress and electrical stimulation
attempting to mimic the pulse of blood circulation, compared to controls. This work
was confirmed by other researchers studying iPSCs derived from HGPS patients
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(Liu et al 2011); smooth muscle cells showed nuclear abnormalities and an
accelerated senescence, an indicator of vascular ageing.
Models of familial Parkinson’s disease using iPSCs have also been described, and
represent a rarer group of iPSC-based models of diseases which commonly manifest
themselves in adults. One example used iPSCs from a patient with a mutation in the
gene encoding leucine-rich repeat kinase-2 (LRRK2), the most common mutation
associated with Parkinson’s disease (Nguyen et al 2011). Dopaminergic neurones
derived from these iPSCs showed increased susceptibility to oxidative stress and
inducers of apoptosis, which is consistent with current understanding of the early
development of Parkinson’s disease. Since familial Parkinson’s disease has much in
common with the sporadic disease, it is hoped that this iPSC model and others like it
could be used to study the underlying biology of both.
So what are the prospects for acute lymphoblastic leukaemia models using iPSCs?
ALL meets some of the preferred criteria for modelling with iPSCs; it is a relatively
early onset disease (in children) that manifests itself rapidly (rapid progression
leading to death if left untreated) with a clear phenotype in a particular cell type (in
the form of lymphoblasts). Researchers have a choice of starting material to generate
iPSCs for haematological disease modelling, since efficient reprogramming has been
demonstrated from differentiated blood cells (e.g. Loh et al 2010) stem cells from
mobilised peripheral blood (Loh et al 2009), cord blood (Haase et al 2009), bone
marrow from both healthy donors and chronic myeloid leukaemia patients (Hu et al
2011), and even lymphoid cell lines (Choi et al 2011). In addition, methods for the
differentiation of both hESCs (Vodyanik et al 2006) and iPSCs (Carpenter et al
2011) toward B-lymphoid lineages (as well as T cells e.g. Timmermans et al 2009)
have already been established.
However, one potential obstacle to the modelling of ALL using a iPSC model are
that leukaemia as a haematological malignancy is not solely cell autonomous, as
there is evidence that leukaemia is as dependent on the interaction of the bone
microenvironment as normal haematopoiesis (e.g. Colmone et al 2008; Doan &
Chute 2012). In addition, it may be difficult to model the effects of infection in the
development of leukaemia as suggested by Greaves and contemporaries (described
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in the Introduction in section 1.8.6). Nevertheless, the opportunity to study
leukaemias using iPSCs derived from leukaemic blasts is attractive, and one that I
believe will be exploited in the near future. Such iPSCs could be used, for example,
to study the effects of mutations present in the blasts on their survival and
proliferation by the ‘correction’ of mutations using non-mutated transgenes.
3.1.11 Aims
The work presented in this chapter describes the development of a model of
TEL/AML1+ leukaemia, where transgenic hESCs expressing TEL/AML1 were
differentiated to generate haematopoietic progenitors. As controls for the effects of
TEL/AML1, I used hESCs expressing either GFP or a non-DNA binding mutant
TEL/AML1, which has a 39 amino acid deletion in the runt homology domain
(RHD) of the AML1 moiety of TEL/AML1 (the TEL/AML1-ΔRHD mutant ;
Morrow et al 2007). These transgenic hESCs were then differentiated towards
haematopoietic lineage and assessed for the expression of haematopoietic
transcription factors. The haematopoietic precursors produced during differentiation
were further directed B lymphocyte lineage to reproduce a leukaemic phenotype
in vitro. I assessed this by the expression of markers of early B cell differentiation,
and also tested for a selection of genes associated with TEL/AML1+ leukaemia.
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3.2 Results
3.2.1 Inducible expression system
To express TEL/AML1 in hESCs, I initially intended to make use of the
tetracycline-inducible expression system ‘Tet-ON’ (Gossen et al 1995; developed by
Clontech). A summary of the inducible expression mechanism was described in
section 3.1.9, and is shown in Figure 3.1A.
Using the TRE-TEL/AML1 and pCMV-rtTA plasmid constructs (provided by Owen
Williams, Institute of Child Health, UCL), I first tested the inducible expression
system by transfecting the TRE-TEL/AML1 plasmid into a MEF cell line which
contained the Tet-ON machinery to express a mutated form of p53 (Jiang et al 2001;
provided by Jo Milner, University of York); when doxycycline is administered, the
activated rtTA would bind not only to the TRE driving the expression of the mutant
p53 transcript, but also that driving TEL/AML1 expression. TEL/AML1 transcript
could then be detected by RNA extraction and cDNA synthesis, followed by PCR.
When doxycycline was administered to the transfected ‘Tet-ON MEFs’, a small
increase in the quantity of the PCR product for mutant p53 transcript was observed,
but no change in that for TEL/AML1 (Figure 3.1B). I subsequently discovered that
small quantities of the transfected TRE-TEL/AML1 plasmid remained in the RNA
extract despite performing an on-column DNA digest (Figure 3.1C). Any carryover
of the transfected plasmid DNA would end up acting as a template for the PCR.
To avoid any problems with significant TRE-TEL/AML1 plasmid carrying over into
the PCR reaction, it was decided to test the system ‘in reverse’ instead; that is, to
generate a stable cell line containing the TRE-TEL/AML1 (which has a neomycin
resistance gene as a selection marker), and transfect the pCMV-rtTA into the cell
line before administering doxycycline. However, despite several attempts, no
expression of TEL/AML1 could be detected in the transgenic HT1080 cells
transfected with the rtTA plasmid and treated with doxycycline (Figure 3.1D). It was
decided that a constitutive expression system would be developed instead.
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Figure 3.1 – Inducible expression system.
(A) Diagram showing mechanism of the Tet-ON inducible expression system. (B) RT-PCR showing no change
in quantity of PCR product for TEL/AML1 in the presence or absence of doxycycline, in the p53 mutant TET
cell line (C) RT-PCR showing presence of TRE-TEL/AML1 plasmid DNA in RNA extract, even after DNase
treatment. (D) Lack of inducible expression of TEL/AML1 in the presence of both rtTA and Doxycycline in the
‘reverse model’ (see text for details).
A
B
C
D
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3.2.2 Cloning of pCAG-TEL/AML1 plasmid
Constitutive expression of TEL/AML1 was controlled by the CAG promoter, a
CMV based promoter which does not lose expression in hESCs (Liew et al 2007).
I cloned the TEL/AML1 sequence into the pCAG-eGFP plasmid (provided by Peter
Andrews) after removing the eGFP sequence (Figure 3.2A). After several
unsuccessful attempts to make the plasmid using standard ‘restriction digest-ligation’
methods (not shown), the pCAG-TEL/AML1 construct was made by using the
InFusion cloning system (Clontech), outlined in Figure 3.2B. Primers were designed
to amplify the insert sequence that also contain a 15bp homology to the linearised
vector sequence either side of the insertion site (Figure 3.2C), and PCR conditions
optimised to give a single clean band by gel electrophoresis (Figure 3.2D). The
vector was then linearised using two restriction enzymes (AgeI and NotI, Promega),
excising GFP in the process (Figure 3.2E). Finally, the linearised vector and insert
are joined together using the InFusion cloning reagents, giving rise to plasmid
clones, from which clones comprising of both the vector and insert were selected
(Figure 3.2F).
3.2.3 Cloning of pCAG-TEL/AML1-ΔRHD plasmid
As a control for studying the effects of TEL/AML1 expression on haematopoiesis,
I used a non-DNA binding mutant TEL/AML1, which has a 39 amino acid deletion
in the runt homology domain (RHD) of the AML1 moiety of TEL/AML1 (Figure
3.3A, reproduced from Morrow et al 2007; construct provided by Owen Williams).
This TEL/AML1-ΔRHD sequence was inserted into the pCAG vector using a PCR-
based cloning method, as shown in Figure 3.3B. To summarise, primers were
designed to amplify the TEL/AML1-ΔRHD sequence and add restriction sites for
AgeI and NotI at the 5’ and 3’ ends, respectively, with an appropriate length ‘clamp
sequence’ (Figure 3.3C). The PCR reaction was optimised to produce a single clean
band corresponding to the size of the TEL/AML1-ΔRHD sequence, and this product
and the pCAG-eGFP vector were digested using AgeI and NotI restriction enzymes
(Figure 3.3D). Finally the linearised pCAG vector and the digested
TEL/AML1-ΔRHD PCR product were joined together by T4 Ligase (Promega),
from which clones comprising of both the vector and insert were selected (Figure
3.3E).
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Figure 3.2 – cloning of pCAG-TEL/AML1.
(A) Cloning strategy to construct the pCAG-TEL/AML1 plasmid. (B) Overview of the InFusion reaction. (C)
PCR primers used to amplify the TEL/AML1 insert for InFusion cloning, showing homology to pCAG vector
and TEL/AML1. (D) Optimisation of TEL/AML1 PCR amplification using the InFusion primers, to give single
clean band, indicated by the red box. (E) Digest of pCAG-eGFP, showing single digest with AgeI and NotI
enzymes, and double digest; note that the band representing double-digested vector has been cut out of the gel to
minimise mutagenesis by exposure to UV during imaging. (F) Gel showing the plasmid clones obtained after
InFusion ligation and transformation of bacteria. Clones #4 and #5 do not contain the TEL/AML1 insert, whereas
clones #1, #2, #3, and #6 do.
TEL/AML1
pCAG GFP IRES puroR
HA-tag
A
B
C
D
E
F
InFusion_FWD: CCCGGGATCCACCGGTGAATTCATGTCTGAGACTC
InFusion_REV: GCTTATCGAGCGGCCGCTTAAGCGTAATCTGGAACATC
Homology regions to pCAG vector
Homology regions to TEL/AML1 insert
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Figure 3.3 – Cloning of pCAG-TEL/AML1-ΔRHD.
(A) Diagrams showing deleted regions in Runt Homology Domain (ΔRHD) mutant; reproduced from Morrow et
al 2007. (B) Cloning strategy for pCAG-TEL/AML1-ΔRHD (C) PCR primers used to amplify the
TEL/AML1-ΔRHD sequence for cloning, with restriction sites and ‘clamp’ regions indicated. (D) left, digest of
pCAG-GFP vector; right, PCR product of TEL/AML1-ΔRHD. (E) Gel showing plasmids (uncut and cut with
AgeI and NotI) from eight bacteria colonies after ligation and transformation, red boxes indicating lanes
containing fragments of the correct size.
A
B TEL/AML1-ΔRHD
pCAG GFP IRES puroR
HA-tag
AgeI NotI
C Cloning_FWD: GACGTCACCGGTGAATTCATGTCTGAGACTCCTGCTCA
Cloning_REV: ACTAGTTCTAGAGCGGCCGCTTAAGCGTAATC
Homology with TEL/AML1-ΔRHD cDNA
Restriction sites (AgeI or NotI)
‘Clamp’ sequence
D
E
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3.2.4 Characterisation of TEL/AML1 expression in transgenic hESC lines
The human embryonic stem cell (hESC) line H9 was transfected with
pCAG-TEL/AML1, pCAG-TEL/AML-ΔRHD, or pCAG-GFP, as described in
Chapter 2. Eight monoclonal transgenic cell lines were generated; four expressing
TEL/AML1 (referred to hereafter as T/AD1, T/AD2, T/AF1, and T/AF2), two
expressing GFP (GFP1 and GFP2), and two expressing TEL/AML1-ΔRHD (ΔRHD5
and ΔRHD6). Expression levels of TEL/AML1 and TEL/AML1-ΔRHD were
assessed by qPCR (using primers amplifying across the breakpoint of TEL/AML1,
which is unaffected in the ΔRHD mutant; Figure 3.4A), and are shown in Figure
3.4B, comparing with TEL/AML1 expression in REH cells, a TEL/AML1+
leukaemia patient-derived cell line (Rosenfeld et al 1977). Expression levels of
TEL/AML1 and the ΔRHD mutant were high (from 3-fold to 43-fold that of
TEL/AML1 expression in REH cells), with no TEL/AML1 expression in the GFP+
cell lines. TEL/AML1 and TEL/AML1-ΔRHD protein levels were assessed by
western blot against the HA-tag found at the 3’ end of both the TEL/AML1 and
ΔRHD mutant sequences. Protein levels are compared with the H9 hESC line, and
were consistent with transcript levels shown by qPCR (Figure 3.4B).
To identify the location of the TEL/AML1 protein in the cell, immunocytochemistry
was performed on cultures in glass chamber slides (as described in Materials and
Methods), and images were acquired using confocal microscopy. TEL/AML1 was
present in TEL/AML1-expressing hESC colonies and not in the ‘feeder layer’ of
iMEFs (Figure 3.5A; T/AD1 cell line), and with higher magnification TEL/AML1
can be seen localising to the nucleus (Figure 3.5B; colocalisation with DAPI,
staining double-stranded DNA). TEL/AML1 was not observed in GFP-expressing
hESC lines (Figure 3.5C), which were confirmed as positive for GFP (Figure 3.5D).
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Figure 3.4 – Characterisation of TEL/AML1 expression in transgenic hESC lines.
(A) Diagram indicating features the cDNA sequences of TEL/AML1 and TEL/AML1-ΔRHD, running 5’ to 3’, 
left to right. Oligonucleotide primers to test for expression of TEL/AML1 or TEL/AML1-ΔRHD are shown in 
red, across the breakpoint of the TEL and AML1 moieties of these fusion genes. The HA tag, against which
antibodies are used for Western blot and immunocytochemistry (see Figure 3.5) is shown at the 3’ end as a solid
black bar (B) Expression of TEL/AML1 or TEL/AML1-ΔRHD by qPCR, compared to REH cells, and by
Western Blot against HA-tag, compared to H9 hESCs (mean of three technical replicates).
H9
B
Non-specific
TEL/AML1 &
TEL/AML1-ΔRHD
150
100
75
kDa
A
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Figure 3.5 – Confocal images of transgenic hESCs.
Red = HA-tag. Blue = DAPI, Green = GFP; white scale bar = 100µm, yellow scale bar = 50µm. (A) T/AD1,
showing several colonies, on DR4 iMEFs. (B) Close-up view of A, showing co-localisation of TEL/AML1 and
DAPI in the nucleus. (C) GFP1, showing absence of TEL/AML1 expression. (D) GFP1, showing GFP
expression.
A B
C D
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3.2.5 Characterisation of pluripotency markers in transgenic hESC lines
To show that the expression of transgenes does not affect the pluripotency of hESCs,
the expression of pluripotency markers Nanog (Figure 3.6A) and Oct4 (Figure 3.6B)
was assessed by qPCR. All transgenic hESC lines showed no decrease in expression
of either pluripotency marker, though the expression levels are higher than H9 in
seven of the eight transgenic cell lines, the significance of which is unknown.
However, the expression levels of Oct4 and Nanog appeared to correlate in each cell
line. This is consistent with Oct4 and Nanog (along with Sox2), forming parts of a
self-regulatory ‘circuitry’ for pluripotency, consisting of ‘feed-forward’ loops to
maintain high levels of all pluripotency genes (Boyer et al 2005).
Next, the expression of cell surface markers of pluripotency SSEA4 (Figure 3.6C)
and TRA-1-60 (Figure 3.6D), and marker of differentiation SSEA1 (Figure 3.6E)
were assessed by flow cytometry. All transgenic cell lines were shown to be positive
for SSEA4 and TRA-1-60, and negative for SSEA1. Finally, all hESC lines were
karyotyped to identify any karyotypic changes (Figure 3.7), but all were found to be
of normal female karyotype (46,XX).
3.2.6 Differentiation of transgenic hESC lines
Differentiation of hESC lines was performed using an established differentiation
protocol was used (Vodyanik & Slukvin 2007), outlined in Materials and Methods.
Figure 3.8A shows the differentiation of hESCs, starting with a discrete hESC
colony on OP9 cells on day 1, to a less distinct mesodermal colony on day 4,
expanding on day 6, and generating small round cells of ‘cobblestone’ appearance by
day 8, which represent haematopoietic precursors. Cells from these OP9 co-cultures
were harvested and analysed by flow cytometry for cell surface markers of haemato-
endothelial differentiation (Figure 3.8B). The endothelial marker CD31 was
regularly present in about 5-15% of hESC-derived (TRA-1-85+) cells, and
CD31+CD43+ cells made up to 1% of hESC-derived cells. Since haematopoietic
differentiation progresses through an endothelial (CD31+CD43-) precursor before
gaining the early haematopoietic marker CD43, it was decided that CD31 would be
useful as a surrogate marker of haematopoietic differentiation.
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Figure 3.6 – Characterisation of pluripotency markers in transgenic hESC markers.
(A-B) Expression of pluripotency genes Nanog (A) and Oct4 (B) in the transgenic hESC lines by qPCR,
compared to H9 hESCs. (C-E) Flow cytometry histograms showing expression of pluripotency markers SSEA-4
(C) and TRA-1-60 (D), and differentiation marker SSEA-1 (E), in the T/AD2 cell line, compared to H9 hESCs.
Histograms are representative of all transgenic hESC lines
Nanog Oct4A B
C
SSEA4-PE
H9 T/AD2
TRA-1-60-FITC
D
SSEA1-APC
E
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Figure 3.7 – Karyotypes of transgenic cell lines.
All transgenic hESC lines were found to be karyotypically normal (46, XX). Shown are the karyotypes for (A)
H9, (B) T/AD1, (C) T/AD2, (D) T/AF1, (E) T/AF2, (F) GFP1, (G) GFP2, (H) ΔRHD5, and (I) ΔRHD6.
A
D E
F G
H I
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Figure 3.8 – Differentiation of transgenic hESC lines towards haematopoietic lineages.
(A) Sequential bright-field images showing the differentiation of hESCs, starting from day 1 (after seeding)
ending at day 8 (when cells were harvested); Scale bar = 400µm. (B) Flow cytometry gating strategy for
assessment of differentiation. Following the arrows from left to right, Live-Dead stain (7-AAD), human-mouse
discrimination (human TRA-1-85 antibody), and CD31 vs. CD43. (C-F) Plot showing percentage CD31+ cells
derived from simultaneous differentiation trials with (C) T/AD1, T/AD2, GFP1, and GFP2, (D) T/AD1, T/AF1,
and T/AF2, (E) ΔRHD5 and ΔRHD6, and (F) all transgenic lines combined, with lines showing mean and
standard deviation. (G) plot showing percentage CD43+ cells in CD31+ to show consistent levels of
haematopoietic development from endothelium. Statistical analysis was performed using the non-parametric
Mann-Whitney and Kruskal-Wallis tests, as described in Material and Methods (section 2.17)
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Differentiation experiments took place in a series of ‘trials’, using different
combinations of transgenic cell lines each time. ‘Trial 1’ (Figure 3.8C),
differentiating the cell lines T/AD1, T/AD2, GFP1, and GFP2, showed a significant
difference in the differentiation capacity of T/AD1 and T/AD2, but no significant
difference between any of the TEL/AML1-expressing and GFP-expressing cell lines.
‘Trial 2’ (Figure 3.8D), differentiating T/AD1, T/AF1, and T/AF2, showed low
levels of expression for all cell lines, but no significant differences. Finally, ‘Trial 3’
(Figure 3.8E) showed no significant differences in the differentiation of the cell lines
ΔRHD5 and ΔRHD6.
Compiling the differentiation data together (Figure 3.8F), there is no general trend to
suggest that the overexpression of TEL/AML1 has a significant effect on the
haemato-endothelial differentiation of hESCs. There is a significant difference in the
level of differentiation between T/AF1 and GFP1, but since differentiation of T/AD1
during Trial 2 was low (which in Trial 1 gave rise to CD31+ cells at a rate of 10% on
average), it is possible that this significant difference is down to poor induction of
differentiation in Trial 2, as opposed to an intrinsic block of differentiation in T/AF1
and T/AF2.
The percentage CD43+ cells within the CD31+ population did not differ significantly
for the cell lines (Figure 3.8G), showing there was no block in differentiation from
endothelial (CD31+CD43–) to haemato-endothelial (CD31+CD43+) cells, apart from
in the T/AF2 hESC line. However, differentiation of T/AF2 was particularly low
(Figure 3.8D), so even small numbers of CD31+CD43+ cells would make up a large
percentage of the total CD31+ population.
3.2.7 Analysis of hESC-derived CD43+ cells
To further analyse haematopoietic precursors derived from the transgenic cell lines,
CD43+ cells were sorted from the bulk harvest by swapping the fluorescent colours
conjugated to the CD31 and CD43 antibodies (Figure 3.9A), using CD31-Alexa488
and CD43-PE instead of CD31-PE and CD43-FITC. This allowed for a much better
separation of the CD31+CD43+ population from the CD31+CD43– population, and
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also allowed for enrichment of the CD43+ population from the bulk harvested cells
by MACS, using anti-PE microbeads (Miltenyi Biotec).
Sorted CD43+ cells derived from the T/AD1 hESC were able to generate
differentiated haematopoietic colonies when incubated in semi-solid methylcellulose
medium. By the size and density of the colonies, it was concluded that they consisted
of monocytes and granulocytes (Figure 3.9B).
I investigated the expression of haematopoietic transcription factors in the
co-cultures, namely SCL, EKLF, PU.1, GATA1, and GATA2 (Zambidis et al 2005).
Genes were not found to be expressed in OP9 cells (Figure 3.9C) nor in hESCs, apart
from low levels of GATA2 (Figure 3.9D). Expression of these genes in the
differentiated transgenic hESCs was assessed using two approaches. Firstly, cDNA
was prepared from the ‘bulk harvest’ (i.e. all the cells in the dish, including OP9s
and undifferentiated hESCs) of differentiated T/AD1 and ΔRHD5 hESC lines
(Figure 3.9E). Secondly, cDNA was prepared from sorted CD43+ cells from day 8
and day 11 of co-culture of T/AD1 (Figure 3.9F). qPCR was performed on the
cDNA samples and Ct values were normalised to CD43 to take into account different
levels of haematopoietic differentiation in the co-cultures.
Comparing the T/AD1 and ΔRHD5 bulk cultures, no significant difference was
observed in the expression of any of the transcription factors (Figure 3.9E). In the
sorted CD43+ cells, expression of all transcription factors was reduced in cells taken
from day 11 of co-culture compared to day 8, apart from PU.1, which was highly
upregulated. PU.1 is a transcription factor associated with differentiation towards B
lymphocyte and macrophage lineages (DeKoter & Singh 2000), so this might
indicate a shift of the CD43+ cells from a ‘stem cell’ or ‘precursor’ identity towards a
more differentiated phenotype.
CHAPTER 3: TEL/AML1 IN HAEMATOPOIETIC DEVELOPMENT
105
Figure 3.9 – Analysis of differentiated transgenic hESC lines.
(A) Representative plot showing how the swapping of fluorophores on the antibodies enable clear discrimination
of CD31+CD43+ population (encircled in blue), which is the basis of MACS enrichment and FACS sorting. (B)
Representative images showing differentiated colonies derived from sorted CD43+ cells derived from T/AD1
hESCs cultured in methylcellulose based media for two weeks; Scale bar = 200µm. Colonies were made up of
granulocyte and monocyte lineage cells. (C) PCR products using early haematopoietic genes (SCL, EKLF, PU.1,
GATA1, GATA2) and CD43, showing no expression of these genes in OP9 cells (D-F) graphs showing the
transcript expression level by qPCR of early haematopoietic genes normalised to CD43 expression from (D)
undifferentiated hESC lines, (E) all cells harvested from co-cultures of T/AD1 or ΔRHD5 transgenic hESC lines
(‘Bulk Culture’), and (F) sorted CD43+ cells from day 8 or day 11 of co-cultures of T/AD1 (each bar represents
the mean of three technical replicates to measure one biological replicate per graph).
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3.2.8 B lymphopoiesis
I next examined the capacity of the transgenic cell lines to differentiate towards
B lymphocytes, by taking the sorted CD43+ cells from the OP9 co-cultures of
T/AD1, GFP1, and ΔRHD5, and co-culturing these with the bone marrow stromal
cell line MS-5, for four weeks, with additional cytokines (see Materials & Methods
and Vodyanik et al 2006). Figure 3.10A shows a basic schematic of the expression
of markers of B cell development (TdT, RAG1, PAX5, mb1, VpreB, CD19, CD10,
and CD34) from the haematopoietic stem cell (HSC), via the common lymphoid
progenitor (CLP), and through pro-B and pre-B cells (LeBien 2000; Sanz et al 2003;
Hystad et al 2007; Sanz et al 2010). The protein VpreB forms part of the ψ-light
chain (ψLC), which is a component of the pre-B cell receptor, expressed on the cell
surface of pre-B cells (Wang et al 1998b), and is also shown. The dotted line
indicates at which stage the impairment in B cell differentiation commonly occurs in
patients (Golub et al 1995), which is frequently (Tsuzuki et al 2004; Fischer et al
2005), but not always (Andreasson et al 2001; Morrow et al 2004; Schindler et al
2009) recapitulated in mouse models.
The numbers of CD43+ cells used in the MS-5 co-cultures were small (1,000 cells
per well of a six-well plate), and so it would have been difficult to sort these cells by
FACS. Therefore, I assessed the B lymphocyte differentiation in MS-5 co-cultures
by preparing cDNA samples from the entire culture (similar to the ‘bulk culture’
method used to analyses haematopoietic differentiation in Figure 3.9E) and
analysing gene expression by qPCR. B cell markers expressed in REH cells were not
expressed in MS-5 cells (Figure 3.10B), whereas the MS-5 co-cultures showed
expression of CD10 and CD19 transcript (Figure 3.10C), indicating that
differentiation towards B cell lineage in all co-cultures progressed at least as far as
pro-B cells. MS5 co-cultures from differentiated T/AD1 hESCs showed a
significantly increased level of CD34 compared to those from differentiated ΔRHD5
hESCs, possibly indicating a higher pro-B to pre-B ratio from TEL/AML1-
expressing hESCs. In addition, the expression of CD10 was significantly decreased
in MS5 co-cultures from differentiated GFP1 hESCs compared to those from
ΔRHD5 hESC, but the implication of this is not clear. Comparing B cell marker
expression within the MS-5 co-cultures of T/AD1-, GFP1-, and ΔRHD5-derived
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Figure 3.10 – B lymphopoiesis from transgenic hESCs.
(A) Outline of differentiation from common lymphoid progenitor (CLP) to pro-B and pre-B cells, via Early B
cell. Expression of CD markers (34 = CD34, etc.) and pre-B cell receptor components µHC and ψLC are shown
on the outside of each ‘cell’, and expression of transcript for Rag1/2, Tdt, mb1, Pax5, and VpreB are shown on
the inside of each ‘cell’. Below the B-lineage cells, the recombination status of the heavy chain VDJ genes is
shown. Dotted line indicates the stage at which B cell differentiation appears to be blocked in TEL/AML1+
leukaemia patients and mouse models. (B) Gel electrophoresis of qPCR products showing no expression of the
indicated genes in MS-5 cells. (C-D) Expression by qPCR of (C) CD19 and CD10 or (D) B cell markers in
MS-5 co-cultures of T/AD1-, GFP1-, and ΔRHD5-derived CD43+ cells, bars representing individual
experiments. Relative expression values are normalised against (C) REH and (D) one of the MS-5 co-cultures of
ΔRHD5-derived cells (each bar represents the mean of three technical replicates, p-values as calculated using
Mann-Whitney U test represented by asterixes: * p<0.05, *** p<0.01).
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CD43+ cells, there are no significant differences in expression between the different
cell lines, though there are slightly higher levels of expression of Pax5 and VpreB in
the T/AD1 MS-5 co-cultures than in those with GFP1 and ΔRHD5 (Figure 3.10D).
3.2.9 Leukaemia Associated genes
I also examined the expression of genes commonly associated with TEL/AML1+
acute lymphoblastic leukaemia that have been identified in gene expression
microarray screens of samples from ALL patients (Andersson et al 2005b;
Gandemer et al 2007). I hypothesised that any differences in the expression of these
genes would be best observed after B cell differentiation, since TEL/AML1+
leukaemia is exclusively a B lineage leukaemia (Uphoff et al 1997).
Andersson and colleagues generated a gene expression profile that distinguished
TEL/AML1+ leukaemia from other types of ALL. They then compared this profile to
the gene expression profile of normal haematopoietic cells, and identified expression
patterns for 67 genes that were unique to leukaemia cells (Andersson et al 2005b).
I compared this list to the TEL/AML1+ gene expression profile created by Gandemer
and colleagues (2007), and picked four genes (PIK3C3, TNFRSF7, SMAD1, and
ANGPTL4) for further analysis. PIK3C3 was identified by both microarray screens,
whilst family members of TNFRSF7 (identified by Gandemer’s study) were also
observed in Andersson’s study. SMAD1 was chosen for its involvement in the BMP
signalling pathway, known to regulate haematopoiesis and leukaemia (Bhatia et al
1999). Finally, ANGPTL4 was chosen as several of its related family members were
identified in Andersson’s study, which have been shown to support expansion of
HSCs (Zhang et al 2006) and implicated in myeloid leukaemia (Loges et al 2005).
Out of these genes, two – PIK3C3 and ANGPTL4 – were expressed in the transgenic
hESCs normally (Figure 3.11A), but not in MS-5 cells (Figure 3.11B). In the MS-5
co-cultures of CD43+ cells derived from the transgenic hESCs, TNFRSF7 and
SMAD1 were both significantly upregulated in the T/AD1 co-cultures compared to
the ΔRHD5 co-cultures. ANGPTL4 was significantly downregulated in co-cultures
using differentiated GFP1 hESCs compared to those from ΔRHD5 hESCs (Figure
3.11C).
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Figure 3.11 – Expression of genes associated with TEL/AML1+ leukaemia in transgenic hESCs.
(A) Expression by qPCR of leukaemia-associated genes in undifferentiated transgenic hESCs. (B) Gel
electrophoresis of qPCR products showing no expression of the indicated genes in MS-5 cells. (C) Expression by
qPCR of leukaemia-associated genes in MS-5 co-cultures of T/AD1-, GFP1-, and ΔRHD5-derived CD43+ cells,
bars representing individual experiments. Ct values are normalised to CD19, and relative expression values are
normalised one of the MS-5 co-cultures of ΔRHD5-derived cells. (each bar represents the mean of three technical
replicates, p-values as calculated using Mann-Whitney U test represented by asterixes: *** p<0.01).
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3.3 Discussion
The data presented in this chapter describes the creation of a model of TEL/AML1+
acute lymphoblastic leukaemia using hESCs as a source of human haematopoietic
progenitors. The stable expression of TEL/AML1 was not found to affect markers of
pluripotency in hESCs nor cause any karyotypic changes. Differentiation towards
haematopoiesis, performed using a co-culture method with OP9 cells, was not
affected by the presence of TEL/AML1. CD43+ hESC-derived haematopoietic
precursors expressed markers of haematopoiesis and were capable of differentiating
to mature blood cells. Directed differentiation of the haematopoietic precursors
towards B lineage lymphocytes, using a co-culture method with MS-5 cells, was able
to generate cells expressing markers of B cell development. The expression of
TEL/AML1 resulted in a slight increase in CD34 expression, and in the expression
of two of four genes investigated that have previously been associated with
TEL/AML1+ leukaemia.
3.3.1 Generating a model of leukaemia using hESCs
The hESC model of ALL presented here aims to complement previous models,
including mouse in vivo models (Tsuzuki et al 2004; Schindler et al 2009), xenograft
models (Hong et al 2008; le Viseur et al 2008), and models using cell lines (Diakos
et al 2007; Gefen et al 2009; Zaliova et al 2011). Whilst expanding HSCs from cord
blood, bone marrow, or mobilised peripheral blood, is still technically challenging
(Dahlberg et al 2011), hESCs can provide a theoretically limitless supply of human
haematopoietic precursors with which to study ALL.
The H9 hESC line was one of the original lines (along with H1 and H7) generated by
James Thomson in the first description of hESC (Thomson et al 1998). Previously,
I had used hESC lines developed at the University of Sheffield (SHEF1, SHEF3, and
SHEF4), but found in our lab that the efficiency of haematopoietic differentiation
from these cells was low; this was not necessarily surprising, since the capacity of
different hESC lines to differentiate towards various lineages is known to vary
significantly (Osafune et al 2008). I was granted access to H1, H7, and H9, and
found H1 and H9 to be the easiest of the three hESC lines to grow in cell culture.
These cell lines could be considered ‘gold standards’ with regards to haematopoietic
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differentiation, with the use of H1 in particular widely reported in the literature.
I chose the H9 cell line as the basis of our model as it was available to use first, and
was reported to have equivalent differentiation capacity as H1 (Vodyanik et al
2005).
I initially aimed to inducibly express TEL/AML1 for several reasons. Firstly, it
would allow the timing of TEL/AML1 expression to be controlled. This would avoid
any potential problems with inhibition of differentiation, previously observed whilst
expressing the acute myeloid leukaemia (AML)-associated fusion gene MLL/ENL in
hESCs (Mark Coles, unpublished observations), but also allow an investigation of at
which level of the haematopoietic developmental hierarchy TEL/AML1 has its
influence, which is still under debate (Schindler et al 2009). Secondly, it would
allow the control of the expression level of TEL/AML1, which would enable the
study of the effects of physiological levels of TEL/AML1, as opposed to superfluous
levels which may have unexpected effects. Unfortunately, I was not able to achieve
inducible expression of TEL/AML1 when testing in cell lines (Figure 3.1). This may
have been due to poor expression of or a mutation in the recombinant
tetracycline-responsive transactivator (rtTA), or similarly a mutation in the
tetracycline response element (TRE) to which rtTA binds.
It was decided to proceed instead with a constitutive expression system; however,
there were two main concerns with this method that needed to be addressed. Firstly,
a promoter needed to be selected that would consistently express TEL/AML1
without silencing, a problem often encountered with hESCs (Kim et al 2005). I opted
to use the pCAG vector, which has been demonstrated to drive stable expression in
hESCs, compared with other CMV derivatives (Liew et al 2007). Secondly, I wanted
to ensure that expression of a transgene, in this case a mutant transcription factor
associated with malignant haematopoiesis, would not cause the hESCs to
spontaneously differentiate, but would allow differentiation when induced. After
generating the pCAG-TEL/AML1 (Figure 3.2) and pCAG-TEL/AML1-ΔRHD
(Figure 3.3) plasmid constructs and transfecting these (along with pCAG-eGFP) into
H9 hESCs, I found the transgenic cell lines maintained their hESC morphology and
pluripotency markers (Figure 3.6). hESCs are prone to acquiring karyotypic changes
(Amps et al 2011) that are typically found in embryonic carcinoma cells, commonly
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affecting chromosomes 17 and 12, the latter the location of the ETV6 gene. To
confirm that the transgenic hESC lines had not undergone similar structural changes,
the cell lines were karyotyped, and were found to be normal (46, XX; Figure 3.7).
I was thus convinced that the overexpression of TEL/AML1 in hESCs was a valid
approach.
In absence of an inducible system which allowed the level of TEL/AML1 expression
to be controlled, several cell lines were generated to form a panel with varying
transgene expression. The resulting TEL/AML1 lines gave mRNA transcript levels
ranging between 3- and 43-fold more than that in the TEL/AML1+ cell line REH
(Rosenfeld et al 1977).
In summary, I believe that the expression of TEL/AML1 did not aberrantly affect
hESCs by itself, and that in the panel of TEL/AML1-expressing hESC lines I had
enough range of expression to minimise any potential affects resulting from the act
of overexpressing proteins, called ‘transgene toxicity’ (Zafarana et al 2009). In not
generating the system to inducibly expression TEL/AML1 I was not able to fully
control expression, so denying the opportunity to study, for example, the timing of
when TEL/AML1 might have an influence on hESC differentiation. Despite this, the
hESC lines generated provides the basis of a model for TEL/AML1+ leukaemia.
3.3.2 Haematopoietic differentiation of transgenic hESCs
Differentiation of hESC lines was performed using the OP9 co-culture method, first
set out by Nakano and colleagues (Nakano et al 1994), and adapted for hESC
differentiation by James Thomson’s group (Vodyanik et al 2005). I used an
established protocol for the ‘OP9 co-culture’ method (Vodyanik & Slukvin 2007),
and found this method to give consistent results over several weeks when a staggered
regime was implemented for the splitting of hESCs and OP9 cells, and the seeding,
feeding, and harvesting of co-cultures. I did attempt differentiation by the ‘embryoid
body’ method (Chadwick et al 2003) but found it to be inefficient (data not shown)
and more technically challenging, as well as the cost of supplemental cytokines to be
expensive.
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Differentiation of the various cell lines took place in a series of three ‘trials’, with
each trial differentiating a number of cell lines simultaneously (Figure 3.8C-E). The
TEL/AML1+ cell line T/AD1 from trial one was also used trial two to act as a
reference; whilst the level of differentiation for each cell line did vary, the levels
across the cell lines did appear to follow each other, so using T/AD1 in the second
trial gave an indication of the efficiency in that trial. It is not clear why the level of
differentiation in trial two was much lower compared to either of the other, but since
a fresh vial of OP9 cells was thawed for each trial, it is possible that Trial 2 made use
of an OP9 batch less able to induce hESC differentiation.
Overall there was little difference in the level of differentiation towards CD31+
haemato-endothelial precursors amongst the various cell lines (Figure 3.8F), and no
significant difference in the percentage of CD43+ cells in the CD31+ population
(Figure 3.8G). It had been previously reported that the level of differentiation
depended on the proliferation rates of the cell lines (Vodyanik & Slukvin 2007). In
normal maintenance culture, no differences in growth rates between the transgenic
cell lines were observed. However, in co-culture with OP9 cells, the proliferation
rates of the cell lines did vary; since the same number of cells for each cell line was
seeded onto each OP9 plate, the percentage of TRA-1-85+ (i.e. human) cells in the
total harvested cell suspension could act as a surrogate marker for proliferation. This
value varied from 11% to 82%, but no significant correlation was observed between
the percentage TRA-1-85+ cell count and the level of differentiation, neither for
individual cell lines nor for all cell lines combined (data not shown).
The lack of a significant effect of TEL/AML1 on the differentiation is consistent
with previous observations of the role of TEL and AML1 in embryonic stem cells
and early embryonic development, if it is assumed the influence would be
TEL/AML1 having a dominant negative effect on TEL and/or AML1 (Zelent et al
2004). Whilst ETV6-/- mice are embryonic lethal (due to angiogenic defects in the
yolk sac), ETV6-/- chimeric mice show no defects in haematopoiesis, instead showing
problems associated with the post-natal establishment of haematopoiesis in the bone
marrow (Wang et al 1998a). Similarly, whilst RUNX1-/- mouse embryos and
embryonic stem cells cannot transfer from primitive to definitive haematopoiesis
(Lacaud et al 2002), haploinsufficent ESCs are still capable of definitive
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haematopoiesis, showing accelerated haematopoietic commitment (Lacaud et al
2004). As such, any effects that TEL/AML1 expression might have on the
expression or activity of either TEL or AML1 (Zelent et al 2004) are unlikely to
have a significant effect during haematopoietic differentiation of hESCs.
I intended to use the CD31+CD43+ haematopoietic progenitors for three main
purposes: (1) to study the general haematopoietic capacity of these progenitors by
Colony Forming Unit (CFU) assays; (2) to investigate gene expression changes in
these progenitors by qPCR; and (3) to differentiate these cells towards
B lymphopoiesis by MS-5 co-culture for further analysis. The total number of cells
harvested each time was regularly ~108 cells, of which 40% on average were human
(TRA-1-85+), and of these up to 1% were CD31+CD43+, meaning roughly 400,000
CD31+CD43+ cells were available. However, it was found that the number of cells
that could be harvested from co-cultures (by FACS, sometimes in combination with
MACS) was much lower than should be present in the culture; the actual number of
cells harvested was rarely above 5,000. The likely reason was due to the ‘clumpy’
nature of endothelial cells, which prevents attaining single cell suspensions without
harsh physical detachment, leading to cell death. This meant that there commonly
were only enough cells to use for one of the three purposes above. I decided, given
the small CD31+CD43+ yield, to focus the use of the cells for the MS-5 co-culture, as
it was in B cell differentiation where I expected to be most likely to see significant
differences between the cell lines, given the known impact of TEL/AML1 on B cell
development in a variety of models (Tsuzuki et al 2004; Sabaawy et al 2006; Hong
et al 2008), and B lineage induction only required 1,000 cells per well of a six-well
plate (Vodyanik et al 2006). This unfortunately prevented meaningful numbers of
replicates for the CFU assays and gene expression analysis from being carried out.
One limitation of this study was that the different transgenic hESC lines were
differentiated in three separate trials. The differentiation capacity of T/AD1varied
significantly between the two trials it was used in, indicating that the conditions of
the three trials were not identical, and so limiting the strength of the conclusions that
can be drawn by direct comparison between trials. The differentiation of the
transgenic lines was divided in this way primarily because not all the hESC lines
were ready at the same time. To more reliably compare the differentiation capacity
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of these lines, the eight hESC lines would have to be differentiated at the same time
using the same batch of OP9 cells, but it would then become a very difficult task in
terms of cell culture. If these differentiation experiments were to be repeated and
remain divided into trials, it would be important to ensure uniformity in the OP9
batches used for differentiation, and to use one or more cell lines in all trials, to
allow for a more reliable comparison between the hESC lines.
3.3.3 B cell development from differentiated transgenic hESCs
Since there were not enough cells for analysis of B cell development in the MS-5
co-cultures by flow cytometry, I assessed the level of B lymphopoiesis by qPCR as it
has the advantage of being very sensitive to small amounts of transcript. For the
same reason, it is also more susceptible to contamination, but I found no expression
in MS5 cells of any of the B cell development markers (Figure 3.10B) or the
leukaemia-associated genes (Figure 3.11B). The genes analysed (Vodyanik et al
2006) are used to discriminate between different stages of B cell development (Ghia
et al 1996; LeBien 2000; Hystad et al 2007; Sanz et al 2010).
In the expression of genes for cell surface ‘CD’ markers, there is an upregulation of
CD34 in T/AD1 MS5 co-cultures compared to ΔRHD5 co-cultures (Figure 3.10C),
which might indicate an increase ratio of pro-B to pre-B cells (since it is during this
transition that CD34 expression is lost; Ghia et al 1996) which is consistent with the
pro-B to pre-B blockade observed in a number of mouse models investigating the
effects of TEL/AML1 on B cell development (Tsuzuki et al 2004; Fischer et al
2005). There was no significant difference between the expression of other B cell
markers in T/AD1 compared to GFP1 or ΔRHD5 (Figure 3.10D). Comparison of
these gene expression changes with mouse models of leukaemia is complicated since
most papers analyse B cell development using flow cytometry (as opposed to gene
expression; e.g. Tsuzuki et al 2004, Schindler et al 2009), and the stages of B cell
development in a mouse do not have direct equivalents in humans (Hardy et al 1991;
LeBien 2000). However, if the block in B cell development between the pro-B and
pre-B stages commonly observed in patients (Golub et al 1995) were to be observed
in this model, one might see much higher levels of TdT expression, higher levels of
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VpreB and Rag1, and lower levels of Pax5 as the proportion of pro-B cells compared
to pre-B cells increases (Hystad et al 2007).
Using the same method, I also investigated the expression levels of genes commonly
upregulated with TEL/AML1+ leukaemia. These genes (PIK3C3, TNFRSF7,
SMAD1, and ANGPTL4) were selected from studies of RNA samples from acute
lymphoblastic leukaemia patients of various subtypes analysed by gene expression
microarray (Andersson et al 2005b; Gandemer et al 2007). An increase in expression
of TNFRSF7 and SMAD1 in T/AD1 MS5 co-cultures compared to the ΔRHD5
co-cultures was observed (Figure 3.11C). Amongst these four genes originally
identified by Andersson and colleagues, only the genes also identified in the
microarray by Gandemer (namely PIK3C3 and TNFRSF7) were validated by qPCR
(Gandemer et al 2007). However, Andersson and colleagues found the genes in their
TEL/AML1+ profile to correlate significantly with those identified in a separate gene
expression profiling study of acute lymphoblastic leukaemia subtypes (Ross et al
2003).
Of course, the influence of TEL/AML1 has not been fully revealed by the analysis of
only four genes. Beyond testing the expression of other genes previously associated
with TEL/AML1+ leukaemia, one approach would be to conduct a gene expression
microarray to identify the differentially expressed genes in differentiated transgenic
hESCs. This would have the advantage of a direct list of genes affected by, and
reveal potential functional consequences of, the expression of TEL/AML1. Such an
approach would enable a more directed study of how TEL/AML1 affects
haematopoietic development and early B cells.
Nevertheless, the lack of a strong ‘leukaemia’ phenotype, in terms of a block in
B cell development and expression of genes commonly associated with leukaemia, is
consistent with previous studies in mouse models. Mice receiving bone marrow
transduced with TEL/AML1 do not show symptoms of leukaemia (Andreasson et al
2001; Tsuzuki et al 2004; Fischer et al 2005), but TEL/AML1 in combination with
secondary mutations does give rise to B cell ALL (Bernardin et al 2002; Schindler et
al 2009; van der Weyden et al 2011).
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3.3.4 Conclusions
The results presented in this chapter have not shown that TEL/AML1 alone has a
significant effect on the haematopoietic differentiation of hESCs. According to
previous studies of TEL/AML1+ leukaemia, the properties acquired by TEL/AML1
expression alone have been referred to as a ‘pre-leukaemic state’ (Greaves et al
2003), exemplified by high numbers of quiescent HSCs (Schindler et al 2009) and/or
an impairment – but not a block – of B cell differentiation (Fischer et al 2005). In
this model, I was not able to provide a strong demonstration of either of these two
hallmarks, due to the limited numbers of haematopoietic cells that could be
recovered from the OP9 and MS-5 co-cultures. However, if these technical
difficulties can be overcome, there is no reason why this model could not be used to
demonstrate these effects. Indeed, it is possible that these effects are an artefact of
mouse models, and that one might not observe a similar effect in a human model
such as the hESC model presented in this chapter. Nevertheless, our results are
consistent with previous studies in mice that conclude TEL/AML1 is not sufficient
for leukaemogenesis, and thus likely represents a ‘first-hit’ that gives transformed
cells properties which allow it to acquire further mutations leading to leukaemia.
The strength of the hESC model of leukaemia is its ability to recapitulate
haematopoietic differentiation at various stages. However, the technical challenges
involved in this have impaired the current study, although I would anticipate that
some of these challenges could be overcome with enough time to optimise methods
(for example, the isolation of CD31+CD43+ haematopoietic precursors). Further
technical challenges may be met, such as the culture of B cell precursors once
derived from haematopoietic precursors, although it has been shown that it is
possible to culture B cell progenitors from CD34+ cord blood cells for more than 12
weeks ex vivo, without significant changes to their cell surface markers (Rawlings et
al 1995), and B cells from peripheral blood for extended periods of culture (Wiesner
et al 2008). Whether such results could be gained from hESC-derived B cell
precursors remains to be seen.
In summary, this chapter describes the development of the first model of
TEL/AML1+ leukaemia using hESCs. Combining this study with the work of others
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in haematopoietic differentiation of hESCs, I have shown that
TEL/AML1-expressing hESCs are capable of haematopoiesis and differentiation
towards B lymphocytes. Overcoming the technical challenges of haematopoietic
differentiation of the transgenic hESCs will allow renewed study into TEL/AML1+
leukaemia using a human multipotent system.
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Chapter 4: The role of TEL in TEL/AML1+ leukaemia
4.1 Introduction
One of the most common secondary mutations in TEL/AML1+ leukaemia is the loss
of the untranslocated TEL allele (Raynaud et al 1996; Cave et al 1997). This
frequent bialleic loss of TEL indicates its importance in the context of leukaemia,
and yet there is relatively little known about the role of TEL in normal and malignant
haematopoiesis, particularly its regulatory targets. This knowledge has implications
for deepening the understanding of how leukaemia arises and for the discovery of
drugs that act against dysregulated pathways.
4.1.1 Discovery of TEL
The TEL gene, located at 12p13, was first discovered in the context of Chronic
Myelomonocytic Leukemia (CMML) by Golub and colleagues (1994). In this
disease, the gene coding for platelet-derived growth factor receptor beta (PDGFRβ)
was found to be frequently fused to an unidentified gene as a result of the
t(5;12)(q33;p13) chromosome translocation. It was found that this gene shared the
same DNA binding domain found in members of the ets family, and so it was named
TEL, after ‘Translocation, Ets, Leukaemia’ (Golub et al 1994). The TEL gene was
later renamed ETV6 (after ‘ETs Variant 6’) to avoid confusion with the abbreviation
for ‘telomere’; however, both names are still used interchangeably for both the gene
and the protein, though TEL is more commonly used when describing fusion
proteins.
4.1.2 TEL structure
The ets group of transcription factors are defined by an 80 amino acid DNA binding
domain called ets (Wasylyk et al 1993). The other domain that TEL shares with
many of its family members is the pointed domain, also known as a sterile alpha
motif (SAM), which forms a helix-loop-helix structure to form homo- and
heterodimers (Kim et al 2001). Finally, TEL has a central repression domain, which
is involved in the recruitment of co-repressors (Wang & Hiebert 2001). TEL is
unique amongst its family members as it always acts as a repressor, whereas the rest
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of the ets family can be activators or repressors of gene expression dependent on
context (Mavrothalassitis & Ghysdael 2000; Oikawa & Yamada 2003).
4.1.3 TEL activity
TEL represses the expression of its targets by chromatin condensation, via two
routes. The recruitment of histone deacetylases (HDACs) is mediated by
corepressors N-CoR (Guidez et al 2000), SMRT and mSin3A (Chakrabarti &
Nucifora 1999), which bind to the central region of TEL. Alternatively, L3MBTL,
which causes chromatin condensation independent of HDACs, has a domain similar
to the SAM domain and thus binds to the helix-loop-helix pointed domain (Boccuni
et al 2003). The homodimerisation of TEL, via the pointed domain, increases its
DNA binding affinity (Green et al 2010) and is necessary for its repression activities,
which is likely due to the stabilisation of the repressor-corepressor interactions
(Lopez et al 1999), rather than any intrinsic property of the dimerised pointed
domain.
Despite its apparent importance in the regulation of haematopoiesis and its
involvement in leukaemia and other cancers, little is known about the targets of TEL.
The DNA-binding specificity of the ets family members centres on a GGAA/T
consensus sequence (Karim et al 1990; Nye et al 1992), but appears in vivo to
depend largely on availability of binding sites (Wei et al 2010). TEL has been
demonstrated to bind to and inhibit the promoters for stromelysin-1 (Fenrick et al
2000; Wang & Hiebert 2001) and Bcl-XL (Irvin et al 2003). TEL has also been
shown to repress the expression of TCL1, a gene associated with CML (Fears et al
2002).
TEL is known to bind with other transcription factors to repress their gene
expression. TEL binds with the ets family member FLI-1 to inhibit the
megakaryocytic-specific GPIbα and GPIX promoters, which are normally activated
by FLI-1 (Kwiatkowski et al 1998). TEL also binds to STAT3 and represses its
growth-inhibiting activities (Schick et al 2004). TEL represses the activation of the
MCSFR promoter by AML1 and C/EBPα, and that the HLH pointed domain is
required for full repression (Fears et al 1997).
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Regulation of TEL activity is believed to occur through the Mitogen-Activated
Protein Kinases (MAPK) pathway, after the discovery of MAPK phosphorylation
sites in TEL (Poirel et al 1997). Two phosphorylation sites in particular have been
linked to MAPK-induced regulation, serine-213 and serine-257, which both lie in the
central region between the pointed and ets domains. Serine-257 is phosphorylated in
response to stress by p38-MAPKs (Arai et al 2002), whereas both serine-213 and
serine-257 are phosphorylated by Extracellular signal-Related Kinase (ERK), a
family of MAPKs (Maki et al 2004). The phosphorylation of TEL by p38 or ERK
MAPKs inhibits the gene repression activities of TEL by preventing DNA binding
(Arai et al 2002; Maki et al 2004).
4.1.4 TEL function
ETV6 is expressed in mouse embryos from embryonic day 7 (E7). Expression
increases through E8.5 and E9.5, where it can be observed throughout the embryo
and in the yolk sac. At E12.5, ETV6 is expressed at higher levels in lung, kidney and
liver, as well as neural tissues, before peaking at E17. ETV6 is expressed in many
tissues in the adult mouse, including heart, brain, spleen, lung, liver, skeletal muscle,
kidney, testes, and haematopoietic tissues (Wang et al 1997; Wang et al 1998a).
ETV6-/- mice are embryonic lethal, owing to faulty blood vessel formation in the yolk
sac at around E9.5 (Wang et al 1997). In addition, ETV6 knockout demonstrate
apoptosis in embryonic mesenchymal and neural tissues (particularly cranial nerve
ganglia), indicating that ETV6 expression is required for their survival. To observe
the role of TEL in the adult mouse, chimeric embryos with ETV6-/- ES cells were
generated (Wang et al 1998a). TEL was found not to be required for haematopoietic
commitment nor maturation in these embryos, but rather it is required for the
colonisation of bone marrow and maintenance of haematopoiesis in the adult. It was
later confirmed using conditional ETV6 mutant mice that TEL selectively regulates
adult HSC survival but is unnecessary for lineage-specification (Hock et al 2004).
4.1.5 TEL fusion proteins in leukaemias
The high frequency of chromosome abnormalities involving the short arm of
chromosome 12 (i.e. 12p) had been noted several years before TEL was identified
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(Raimondi et al 1986). After the ETV6 gene had been identified, it was found to be
the gene frequently involved in fusion proteins in leukaemias and other
haematological malignancies (reviewed in Bohlander 2005). The fusion partners of
TEL can be roughly divided into two groups: protein tyrosine kinases, and
transcription factors.
Genes for Protein Tyrosine Kinases (PTKs) that have been described as fusion genes
with TEL include the aforementioned PDGFRβ (Golub et al 1994), ABL1
(Papadopoulos et al 1995), ABL2 (Cazzaniga et al 1999), and JAK2 (Lacronique et
al 1997). The characteristic feature of all these TEL-PTK fusion proteins is that they
conserve the helix-loop-helix domain of TEL (known as pointed, and required for
dimerisation of TEL; Kim et al 2001) and the kinase domain of the PTK partner.
This result in a mechanism of action common to TEL-PTKs fusions; the protein
dimerises via the pointed domains of TEL, which constitutively activates the
auto-phosphorylation activity of the PTK partner, and leads to the phosphorylation
and activation of downstream targets required for cell survival and proliferation.
The most common transcription factor (TF) that has been found in fusions with TEL
is RUNX1, coding for AML1 (Golub et al 1995). Other TF fusion partners are much
rarer; they include MN1 (Buijs et al 1995), MDS1 (Peeters et al 1997), BTL (Cools et
al 1999), and PAX5 (Cazzaniga et al 2001). The TEL/AML1 fusion protein
conserves the pointed domain of TEL; the mechanism of action of TEL/AML1 is
discussed in the Introduction (section 1.8.3). However, the pointed domain of TEL is
not present in the other TEL-TF fusion proteins, and so there is little known about
their mechanism of action.
4.1.6 TEL fusion proteins in other cancers
The above fusion genes are all involved in haematological malignancies, but TEL
fusions have also been described in other cancers. The fusion of ETV6 to the gene
coding for neurotrophic tyrosine kinase, receptor type 3 (NTRK3) has been observed
in mesoblastic nephroma (Knezevich et al 1998a), congenital fibrosarcoma
(Knezevich et al 1998b), and secretory breast carcinoma (Tognon et al 2002).
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Ets family members related to ETV6 also contribute towards gene fusions in prostate
cancer (Narod et al 2008; Clark & Cooper 2009).
4.1.7 Role of TEL in TEL/AML1+ leukaemia
The most common secondary mutation in TEL/AML1+ leukaemia is the deletion of
the second untranslocated ETV6 allele (Raynaud et al 1996; Cave et al 1997). This
loss of heterozygosity has been detected in about 75% of TEL/AML1+ leukaemia
patients (Cave et al 1997; Patel et al 2003). ETV6 deletions do occur in TEL/AML1–
leukaemia, but at a much lower frequency (Attarbaschi et al 2004). Two separate
studies have shown that the gene expression profiles of TEL/AML1– leukaemia with
a ETV6 deletion are similar to the profiles from TEL/AML1+ leukaemia (Yeoh et al
2002; Attarbaschi et al 2004), indicating that the common biology is a result of the
impairment of the TEL gene, in either one or both alleles.
The frequent loss of heterozygosity of TEL in leukaemia (Cave et al 1995) – as well
as ovarian cancer (Hatta et al 1997) – suggests a tumour suppressor role for TEL.
Indeed, the expression of TEL in Ras-transformed NIH-3T3 cells inhibits their
growth and inhibits their tumour invasion in vivo (Fenrick et al 2000), whilst
predisposing them to apoptosis via the repression of Bcl-XL (Irvin et al 2003). It has
been shown that TEL/AML1 has a dominant negative effect on the growth
suppressive activity of wild-type TEL, by heterodimerisation via the pointed domain
(Gunji et al 2004), so providing a further mechanism how the loss of TEL activity
contributes to leukaemia progression. Tsuzuki and colleagues have also shown that
the forced expression of TEL in the TEL/AML1+ cell lines REH slows down
proliferation and cell division (Tsuzuki et al 2007).
However, few of the target genes of TEL are known, particularly in the context of
TEL/AML1+ leukaemia. Using two cell lines derived from the same
TEL/AML1+ ALL patient, one showing complete loss of TEL amongst other
chromosomal changes, Fears and colleagues showed T Cell Leukaemia/Lymphoma
Protein 1 (TCL1) was expressed at a higher level in the TEL-negative cell line, and
that it could be downregulated by overexpression of TEL in these cells (Fears et al
2002).
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4.1.8 Identifying targets of TEL repression
In addition to a core binding sequence (GGAA/T) which defines the DNA binding
activity of the ets domain (Karim et al 1990), recent work has elucidated the
preferred DNA sequences surrounding this motif to which the members of the
ets family binds, including TEL (Wei et al 2010). Using a high-throughput DNA
binding specificity assay, Wei and colleagues defined a series of high affinity
binding sequences for human ets family members, which they then grouped into four
clusters depending on their sequence preference. Representative members of each
group were assessed for in vivo binding specificity using chromatin
immunoprecipitation (ChIP); in the case of the group ETV6 belonged to, ELF1 was
used. They found that whilst the ChIP-determined binding sites were highly enriched
for the binding sequences defined in vitro, only a small fraction of the possible
binding sites for ets family members were occupied by those proteins. This suggests
that the binding of ets family members, including TEL, can be determined by
accessibility to the DNA, regulated by chromatin packaging (Wei et al 2010).
Other researchers have also shown that the targets of TEL are determined by factors
other than sequence specificity. Green and colleagues (2010) showed that the
binding affinity of TEL to sequences is dependent on polymerisation. Monomeric
TEL (in which two point mutations disrupt the activity of the pointed domain) has a
lower affinity than expected for a TEL-specific binding sequence. They explained
this by a C-terminal inhibitory domain (CID) to the DNA-binding ets domain,
reducing its binding to DNA. Conversely, dimers of TEL have a higher affinity to
DNA than monomeric TEL, and that DNA binding stabilises this dimer, evading the
autoinhibition of the CID. Thus, Green and colleagues argued that TEL acts more
readily at promoters with multiple binding sites (Green et al 2010), examples of
which have already been defined, in the promoters of known TEL targets Bcl-XL
(Irvin et al 2003) and stromelysin-1 (Wang & Hiebert 2001).
The examples above demonstrate that, to determine the role activity of TEL in
leukaemia, it is not enough to know to which DNA sequences TEL binds, and that
the activity of TEL, like that of any transcription factor, is context specific –
dependent on factors such as the availability of binding sites through chromatin
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packaging, and polymerisation. In addition, TEL is also known to regulate gene
expression through the heterodimerisation with other transcription factors, including
ets family members (Fears et al 1997; Kwiatkowski et al 1998; Schick et al 2004).
Therefore, to determine the consequences of a loss of heterozygosity of TEL,
I decided to pursue a more direct approach: analysing the changes in global gene
expression caused by TEL using a gene expression microarray.
4.1.9 Use of microarrays to determine gene expression patterns
Gene expression microarrays provide the opportunity to determine on a large scale
what genes are being expressed in a biological sample. Traditionally, mRNA
extracted from cells is converted into cDNA and labelled with a fluorescent dye (e.g.
Cy3); today, RNA synthesised from the extracted mRNA can be used instead of
mRNA, though this does depend on a high quality of RNA. The labelled cDNAs or
mRNAs are then hybridised with unique DNA probes printed onto a chip in spots;
each probe unique to one gene. The levels of expression of genes represented on the
chip can then be determined by measuring the fluorescence intensity of each probe
spot, which is proportional to the amount of hybridised labelled cDNA.
These raw intensity values need to be corrected to counteract factors such as the
concentration of the starting material, the intensity of the dye, the background
fluorescence of the chip, and other factors that might influence the measurement and
interpretation of fluorescence intensity values (Quackenbush 2002). Part of this
normalisation process can involve adjusting the range of intensity values so that the
average and spread for replicates within each group (e.g. condition or sample type) is
the same. The gene expression values from the different samples, derived from the
normalised intensity data, can be compared to give fold change in gene expression.
Following this, the data can be analysed depending on the question being addressed;
for example, to identify a population of cells, mathematical clustering can be used to
compare the gene expression profile to profiles from known cell profiles. For our
purposes, it was useful to know what kinds of genes were differentially regulated;
these could be identified by linking the gene expression changes to publicly available
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databases for the function of genes (gene ontology), which could identify genes
belonging to common pathways, such as proliferation, or apoptosis.
4.1.10 Studying leukaemia using cell lines
As discussed in the introduction to Chapter 3 (section 3.1.3), many molecular and
cellular aspects of leukaemia have been investigated using cell lines, with the REH
cell line in particular being frequently used to study TEL/AML1+ leukaemia.
Leukaemia cell lines that share specific genetic lesions with acute lymphoblastic
leukaemia patient samples also share gene expression profiles, and this holds true for
REH cells and lymphoblasts from TEL/AML1+ leukaemia patients (Fine et al 2004;
Andersson et al 2005a), endorsing its use as a model.
The REH cell line was used to demonstrate the molecular interactions of TEL/AML1
with its transcriptional corepressors Sin3A (Fenrick et al 1999) and N-CoR (Guidez
et al 2000). The transcriptional profile defined by TEL/AML1 was investigated
using REH cells and patient samples treated with HDAC inhibitors to remove the
effect of gene repression by TEL/AML1 (Starkova et al 2007).
REH cells have been useful in identifying interactions between lymphoblasts and the
stromal microenvironment, including how CXCR4 promotes chemotaxis (Burger et
al 1999; Burger et al 2001), and how bone marrow stroma confers resistance to
chemotherapy via TGFβ and BMP-6 induction of TIEG1 expression (Dosen-Dahl et
al 2008) and compensate for lost asparagines as a result of asparaginase
chemotherapy (Iwamoto et al 2007). In addition, REH cells have been used to
investigate the role of erythropoietin (EPO) signalling (Inthal et al 2008; Torrano et
al 2011), survivin (Diakos et al 2010; Tyner et al 2011), and miRNAs (Gefen et al
2009; Diakos et al 2010) in TEL/AML1+ leukaemia.
Finally, RNA interference (RNAi) has allowed researchers to knock down the
expression of genes, and such approaches have been used frequently to ablate the
expression of TEL/AML1 to investigate if and how it maintains the leukaemia
phenotype of REH cells (Diakos et al 2007; Zaliova et al 2010; Fuka et al 2011a;
Fuka et al 2011b; Zaliova et al 2011); results from these studies have indicated that
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TEL/AML1 is not necessary for the survival of REH cells, suggesting that it
becomes redundant after the initiation of leukaemia.
4.1.11 Aims
Given the loss of the untranslocated ETV6 allele is a frequent feature of TEL/AML1+
leukaemia, it is assumed to be the case that the loss of TEL confers some selective
advantage to pre-leukaemic cells. To investigate this concept further, it was decided
to overexpress TEL in the REH cell line so in effect reversing the progression of
TEL/AML1+ leukaemia. This would give an indication of what role TEL has in
normal and TEL/AML1+ ‘pre-leukaemic’ cells, and how its loss, or the dysregulation
of the genes its controls, might represent a step towards overt leukaemia.
Using viral transduction, the gene expression profile of TEL-expressing REH cells
was revealed using a gene expression microarray, and differentially expressed genes
relevant to ALL were validated. I further investigated the effects of TEL on
proliferation, cell cycle, and apoptosis.
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4.2 Results
4.2.1 Gene expression microarray
As described in the introduction, despite the importance of TEL in both normal and
malignant haematopoietic development, only a few of the targets of its
transcriptional repression activity are known. I wished to address the question of
why the loss of TEL is important in TEL/AML1+ leukaemia. To do this, I decided to
overexpress TEL in the REH cell line, which both carries the TEL/AML1 fusion
gene and also lacks an endogenous TEL allele. By analysing the expression profile
of TEL-overexpressing cells using a cDNA microarray, it could be determined what
function TEL fulfils in these cells, and thus give an indication of the reason why the
loss of TEL in the context of TEL/AML1+ leukaemia is important for the
progression of leukaemia.
To express TEL in REH cells, a Murine Stem Cell Virus (MSCV) oncoretroviral
vector was used (kindly provided by Owen Williams). An Internal Ribosome Entry
Site (IRES) allowed cells expressing TEL to be identified by simultaneous
expression of GFP, with an oncoretroviral vector coding for GFP alone used as a
control. The efficient of viral transduction was high; 48 hours after transduction,
around 99% of cells transduced with either GFP-oncoretrovirus or TEL-GFP-
oncoretrovirus were GFP-positive (Figure 4.1A).
REH cells transduced with either TEL-GFP or GFP oncoretrovirus were sorted by
flow cytometry, with a post-sort purity of 99.7%. (Figure 4.1B). RNA was extracted
from the sorted GFP+ cells, and subjected to a RNA quality control test; Figure 4.1C
shows the fragments of amplified (complimentary) RNA for loading onto the chip
are of similar sizes between samples and within the necessary range (200-1000
nucleotides). Raw data from the microarray was normalised so that median values
and spread of data for both replicates in each group were the same (Figure 4.1D).
The gene expression data from the microarray shows that, upon overexpression of
TEL, there were more genes down-regulated than upregulated (Figure 4.2A). This
might be expected, since TEL is a transcriptional repressor; however, not all the
genes downregulated in the microarray will be direct targets of TEL. Figure 4.2B
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shows the numbers of differentially expressed genes in graphical format, which
illustrates more clearly the difference between the numbers of up- and
downregulated genes and the levels of their expression. A heat map shows the
differentially expressed genes in clusters of red (upregulated) and blue
(downregulated) transcripts (Figure 4.2C)
A list of the top ten upregulated and downregulated genes in response to TEL
overexpression is shown in Table 4.1 and Table 4.2, respectively. A set of genes
were selected because of prior evidence of involvement in cancer or because of
strong differential regulation indicated by the microarray, and are shown in Table
4.3. For reference, the analysis of microarray data gave TEL a fold-change value of
60.6.
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Figure 4.1 – Quality control for gene expression analysis
(A) Histograms showing the expression of GFP in cells transduced with oncoretrovirus coding for GFP (middle
panel) or with oncoretrovirus coding for TEL and GFP (right panel); also shown is the percentage of cells in the
gate displayed, designated GFP-positive. (B) Flow cytometry plots of cells transduced with oncoretroviruses for
GFP (top row) or TEL-GFP (bottom row). (C) Electrophoretic plots to show RNA quality, from top to bottom,
GFP1, GFP2, TEL1, TEL2. (D) Boxplot showing log intensity values from the microarray, normalised within
each condition (GFP or TEL-GFP virus).
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A
up-regulated down-regulated
Differentially expressed (p ≤ 0.05) 710 915
>2-fold 84 361
Figure 4.2 – Gene expression analysis by microarray.
(A) summary of the number of differentially up- and down-regulated genes on TEL overexpression, including
those differentially expressed more than two-fold (B) graph showing the differentially expressed genes along the
x-axis against their fold-change on the y-axis; red dotted line indicates two-fold difference (C) ‘heat-map’
showing the differentially expressed genes; red colouring indicates upregulated genes, blue indicates
downregulated genes, and yellow indicates genes unchanged. Also shown are close-up views of selected regions
of the heat map.
C
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Gene code RefSeq Description Fold-change
H19 NR_002196 H19, imprinted maternally expressed transcript (non-protein coding), non-coding RNA 13.02
AIF1L NM_031426 allograft inflammatory factor 1-like, transcript variant1, mRNA 12.39
VANGL1 NM_138959 vang-like 1 (van gogh, Drosophila), mRNA 10.44
FXYD2 NM_021603 FXYD domain containing ion transport regulator 2,transcript variant b, mRNA 9.39
ADARB2 NM_018702 adenosine deaminase, RNA-specific, B2 (RED2homolog rat), mRNA 5.40
RPA4 NM_013347 replication protein A4, 34kDa, mRNA 5.33
MPO NM_000250 myeloperoxidase, nuclear gene encodingmitochondrial protein, mRNA 5.12
IKZF2 NM_001079526 IKAROS family zinc finger 2 (Helios), transcriptvariant 2, mRNA 5.02
CTGF NM_001901 connective tissue growth factor, mRNA 4.94
EPAS1 NM_001430 endothelial PAS domain protein , mRNA 4.77
Table 4.1 – Top ten genes up-regulated on TEL overexpression
(excluding TEL, which had a fold change value of 60.6)
Gene code RefSeq Description Fold-change
TTBK1 NM_032538 tau tubulin kinase 1, mRNA -56.64
C6orf222 NM_001010903 chromosome 6 open reading frame 222, mRNA -49.98
CLIC5 NM_016929 chloride intracellular channel 5, transcript variant 2,mRNA -46.16
CNN1 NM_001299 calponin 1, basic, smooth muscle, mRNA -27.70
C21orf90 NR_026547 chromosome 21 open reading frame 90, transcriptvariant 1, non-coding RNA -26.48
OSTalpha NM_152672 organic solute transporter alpha, mRNA -22.25
FAM69C NM_001044369 family with sequence similarity 69, member C, mRNA -19.35
TMEM154 NM_152680 transmembrane protein 154, mRNA -18.11
FLJ32810 NM_152432 Rho-type GTPase-activating protein FLJ32810,mRNA -15.15
ANGPTL4 NM_139314 angiopoietin-like 4, transcript variant 1, mRNA -14.87
Table 4.2 – Top ten genes down-regulated on TEL overexpression
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Gene code RefSeq Description Fold-change
CDKN1B NM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1),mRNA 1.66
BCL-2 NM_000633 B-cell CLL/lymphoma 2, nuclear gene encodingmitochondrial protein, transcript variant alpha, mRNA -1.83
EPOR NM_000121 erythropoietin receptor, mRNA -1.80
ANGPTL4 NM_139314 angiopoietin-like 4, transcript variant 1, mRNA -14.87
IKZF2 NM_001079526 IKAROS family zinc finger 2 (Helios), transcript variant2, mRNA 5.02
CLIC5 NM_016929 chloride intracellular channel 5, transcript variant 2,mRNA -46.16
TTBK1 NM_032538 tau tubulin kinase 1, mRNA -56.64
NETO1 NM_138999 neuropilin (NRP) and tolloid (TLL)-like 1, transcriptvariant 1, mRNA -11.75
Table 4.3 – List of genes from microarray whose expression are validated in this chapter
4.2.2 Ingenuity Pathway Analysis
To identify the cellular functions affected by the gene expression changes as a result
of TEL overexpression, the data was further analysed by Ingenuity Pathway Analysis
(IPA) software. Functional analysis in the IPA depends upon knowledge about
which genes are involved in a particular function (for example, ‘differentiation of
B lymphocytes’), and whether these genes positively or negatively affect this
function. By comparing these genes set with the differentially expressed genes in our
microarray dataset, it can be predicted what functions are being affected and in
which direction (i.e. whether in our microarray the genes changed suggest an
activation or an inhibition of a particular function).
Table 4.4 lists all the functions predicted to be affected by gene expression changes
observed in the microarray. Each function is accompanied with the following
information:
 Activation state – whether the gene expression changes in our dataset suggest
either a decrease or an increase the function
 z-score – how strong directionally the association is, based upon how many
genes have expression direction consistent with the activation state, and how
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strongly each gene affects the function; negative values indicate the function
is predicted to be decreased, positive values indicate the function is
predicated to be increased (z-scores with absolute values larger than 2 are
considered significantly affected; only these are shown in Table 4.4)
 p-value – the statistical measure of the overlap between the genes associated
with the function and the differentially expressed genes in the microarray
(p-values less than 0.05 are considered statistically significant)
 # genes – how many genes identified in our microarray are known to be
involved in the function, whether they decrease or increase the function, or
have an unknown or ambiguous effect
Functions
Predicted
Activation
State z-score p-value # genes
proliferation of immune cells Decreased -3.372 5.98E-05 75
proliferation of lymphocytes Decreased -3.364 7.84E-05 71
proliferation of blood cells Decreased -3.155 1.46E-04 77
proliferation of T lymphocytes Decreased -3.118 3.66E-03 53
differentiation of leukocytes Decreased -3.105 2.97E-03 59
development of blood cells Decreased -2.918 4.04E-03 59
proliferation of B lymphocytes Decreased -2.795 4.46E-05 34
quantity of osteoclasts Decreased -2.750 8.69E-03 12
protein kinase cascade Decreased -2.667 7.03E-03 33
differentiation of mononuclear leukocytes Decreased -2.650 5.05E-03 49
differentiation of T lymphocytes Decreased -2.649 3.29E-03 35
activation of antigen presenting cells Decreased -2.580 3.15E-03 24
cell movement of endothelial cells Decreased -2.552 8.23E-03 24
differentiation of blood cells Decreased -2.510 3.85E-04 71
differentiation of lymphocytes Decreased -2.509 4.02E-03 46
proliferation of cells Decreased -2.368 1.72E-03 216
haematopoiesis Decreased -2.354 9.03E-05 89
cellular homeostasis Decreased -2.314 9.93E-04 114
differentiation of cells Decreased -2.311 5.70E-04 157
differentiation Decreased -2.233 2.46E-04 169
activation of macrophages Decreased -2.181 2.40E-03 18
function of blood cells Decreased -2.055 5.05E-03 53
proliferation of hepatocytes Decreased -2.015 2.21E-03 16
uptake of anion Increased 2.018 7.05E-03 6
infection by bacteria Increased 2.516 1.25E-03 40
infection by virus Increased 2.749 8.33E-03 105
Table 4.4 – Functions predicted to be affected by TEL overexpression, based upon gene expression
changes from the microarray
p-values are formatted as follows: 5.98E-05 = 5.98 × 10–5 = 0.0000598.
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Table 4.4 indicates that functions predicted to be decreased include the proliferation
of a variety of immune cell types, including T and B lymphocytes. This finding is
significant in our model, since it suggests that in the context of leukaemia, the loss of
TEL might result in an increase in proliferation of lymphoblasts. Several other
functions predicted to be decreased include differentiation of blood cells, including
lymphocytes. However, as leukaemic lymphoblasts are immature cells, it might be
expected that if the loss of TEL contributes to the progression of the disease, that the
overexpression of TEL might increase differentiation, rather than decrease. TEL
appears to reduce the number of osteoclasts, a bone-resorbing haematopoietic cell
derived from the monocyte/macrophage lineage (Boyle et al 2003). In addition, there
are functions that are affected that do not appear to have any direct relevance to
leukaemia; e.g. proliferation of hepatocytes, uptake of anion, infection by bacteria,
infection by virus. These may be indications of other functions of TEL in non-
haematopoietic tissues.
Since TEL is known to affect the function of other transcription factors by
heterodimerisation (Fears et al 1997; Kwiatkowski et al 1998; Schick et al 2004),
the gene expression data was subjected to an analysis for transcription factor activity.
IPA compares the gene expression data with the known targets of a database of
transcriptional regulators, in an attempt to identify which gene expression changes
might be associated with the inhibition or activation of a transcriptional regulator.
This produces a list of transcription factor proteins whose activities might be
affected; note that this list is not dependent on any gene expression changes of these
transcription factors, simply their respective targets. The output is a z-score for the
direction in which the transcription factor is affected (i.e. decreased or increased),
and a p-value to indicate the statistical significance of the overlap between the
known targets of the transcription factor and the differentially expressed genes in the
microarray dataset.
Table 4.5 shows the list of transcription factors predicted to be affected based upon
the gene expression changes observed in our microarray. Transcription factors
known to be regulated by heterodimerisation with TEL, for example STAT3 (Schick
et al 2004) and FLI1 (Kwiatkowski et al 1998), are not seen in this list. However, the
list of transcription factors might represent new partners of TEL. Of particular note is
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the transcription factor SPI1 (also known as PU.1), which is another member of the
ets family along with TEL and FLI1. PU.1 is known to be involved in both normal
haematopoiesis and leukaemia (Gupta et al 2006; Kastner & Chan 2008; Gupta et al
2009).
Transcription Regulator Predicted Activation State z-score p-value
WT1 Inhibited -2.671 2.70E-02
RELA Inhibited -2.618 7.12E-02
EP300 Inhibited -2.513 1.27E-01
Nfat family Inhibited -2.238 5.75E-03
HMGB1 Inhibited -2.216 9.47E-02
SPI1 Inhibited -2.175 1.07E-01
MYCN Inhibited -2.128 5.02E-01
HOXA9 Inhibited -2.072 2.49E-02
FOXC2 Inhibited -2.069 9.23E-02
NfkB-RelA Inhibited -2.012 1.39E-02
ESR1 Activated 2.064 7.81E-02
SMAD2 Activated 2.076 3.41E-01
SMARCA4 Activated 2.096 7.52E-02
PPARD Activated 2.619 2.58E-01
Table 4.5 – Transcription factors predicted to be affected by TEL overexpression, based upon gene
expression changes from microarray
In bold are predictions deemed statistically significant (p < 0.05)
In light of the importance of proliferation indicated by IPA I decided to further
investigate the effect on proliferation of overexpression of TEL in REH cells.
4.2.3 Effects of TEL transduction on proliferation
Previous work on the role of TEL in leukaemia has indicated that a loss of TEL
results in an increase in the proliferation (Fenrick et al 2000; Tsuzuki et al 2007).
Analysis of the gene expression data indicated that a gene involved in proliferation
and cell cycle control, namely p27-KIP1 (CDKN1B), was differentially expressed
(Table 4.3). p16-INK4A (CDKN2A), another gene involved in cell cycle control, has
been previously shown to be a common secondary mutation in acute lymphoblastic
leukaemia, as described in the Introduction chapter (section 1.9.2). However, when
the expression of these genes was analysed by qPCR, using the same RNA as used in
the microarray, I found no evidence of differential expression of either of these genes
(Figure 4.3A). Nevertheless, I decided to continue to investigate further the role of
TEL on the proliferation of REH cells.
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The effects of oncoretroviral transduction of TEL on proliferation were studied by
analysing DNA content by the double stranded DNA stain DAPI and analysed by
flow cytometry. DNA content histograms were deconvoluted by using FlowJo
software, giving an estimate of the numbers of cells in the stages of cell cycle as
shown in Figure 4.3B. Cells in a sub-G1 position on the DNA histogram represent
apoptotic cells undergoing DNA fragmentation.
Frequencies calculated using the FlowJo software were compiled from
GFP-transduced or TEL-GFP-transduced REH cells at 24 hour intervals over
96 hours. The expression of TEL in REH resulted in only subtle effects on cell cycle
progression, with a small increase in the numbers of cells in G1 phase (Figure 4.3C),
and small decreases in the numbers of cells in S (Figure 4.3D) and G2 phases
(Figure 4.3E). Also, there was a small increase in the numbers of sub-G1 cells
(Figure 4.3F) cells. Further replicates would have to be performed to show whether
this is reproducible and statistically significant, but they indicate the expression of
TEL results in only a slightly reduced proliferation in REH cells, and increased
apoptosis.
I investigated the effect of TEL overexpression on proliferation further using a
different expression method, that of DNA plasmid transfection. This would allow me
to rule out any possibility that the gene delivery method was affecting the results.
4.2.4 Cloning of pCI-TEL-neor
To generate a plasmid to over-express TEL in REH cells, TEL cDNA was inserted
into the multiple cloning site (MCS) of the pCIneo expression plasmid (Promega;
Figure 4.4A), by standard restriction-ligation method using SalI and NotI at the 5’
and 3’ end of TEL, respectively. Digests of both the library plasmid in which the
TEL cDNA was contained and pCIneo was performed (Figure 4.4B), and the
fragments ligated with T4 Ligase, giving rise to plasmid clone, several of which
were assessed to contain both the pCIneo vector and the TEL insert by restriction
digest (Figure 4.4C).
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Figure 4.3 – Effects of oncoretroviral transduction of TEL on cell cycle.
(A) Expression of genes associated with cell cycle control (CDKN1B, upper, and CDKN2A, lower), as analysed
by qPCR. (B) Representative histogram showing DNA content of cells, stained with DAPI after permeabilisation.
Histograms were analysed on FlowJo software and cell cycle populations were fitted to the histogram as shown.
(C-F) Percentage of cells transduced with GFP oncoretrovirus (open blue circles) or TEL-GFP oncoretrovirus
(closed red squares) populating G1 phase (C), S phase (D), G2 phase (E), or sub-G1 (F) against time after
transduction (n=1).
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Figure 4.4 – Cloning of pCI-TEL-neor.
(A) Cloning strategy used to construct the pCI-TEL-neor plasmid. (B) Digest of TEL clone and pCIneo vector
with SalI and NotI restriction enzymes. (C) Plasmid clones after ligation of digested TEL and pCIneo fragments.
Plasmid clones are digested to show presence of both pCIneo and TEL.
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4.2.5 Short term effect of TEL on growth
With the TEL plasmid, I first intended to investigate the short term effect of the
expression of TEL in REH cells. However, without a fluorescently labelled TEL
protein or a plasmid able to express a fluorescent label at the same time, and
knowing the transfection efficiency of REH was less than 100%, it would not be
obvious which cells were expressing TEL and which were not. I decided to
circumvent this problem by co-transfecting TEL with a separate expression plasmid
for a fluorescent protein.
Figure 4.5A demonstrates the phenomena of co-transfection using two fluorescent
plasmids, one for the fluorescent protein Citrine (a Yellow Fluorescent Protein
derivative; Griesbeck et al 2001) and one for Tomato (a DsRed derivative; Shaner et
al 2004). Transfection of REH cells with both plasmids fluorescent plasmids results
in cells that express both fluorescent proteins, and that the expression levels of
Tomato and Citrine increases linearly; i.e. cells expressing high levels of Tomato
express high levels of Citrine, and vice versa. There is also a subtle increase in the
transfection efficiency of both plasmids in co-transfection, compared to when each
was transfected individually (20% to 29% for Tomato, 40% to 43% for Citrine).
These phenomena were exploited to investigate the effect of TEL on the proliferation
of REH cells by co-transfecting REH with both Citrine and TEL plasmids. Based
upon Figure 4.5A, it could be assumed that most Citrine+ cells will also express
TEL, and that levels of Citrine expression could be used as a surrogate marker for
levels of TEL expression.
I assessed the proliferation of REH cells by measurement of DNA synthesis using
labelled nucleotide incorporation. In the current study, EdU taken up by the cell was
labelled with Azide-Alexa647. The intensity of Alexa647 fluorescence in each cell is
proportional to the amount of EdU incorporated into DNA by the cell (and thus the
amount of DNA synthesis) during the incubation period. Thus, mean fluorescence
intensity (MFI) of the fluorophore is a useful statistic to compare overall DNA
synthesis rates; cells that are proliferating at a faster rate have more cells
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synthesising DNA into which EdU is incorporated, resulting in a higher MFI than
slowly proliferating cells.
Figure 4.5B shows the effect that transfection of Citrine and the co-transfection of
Citrine and TEL (with co-transfection of Citrine & empty vector pCIneo as a
control) has on EdU uptake. Cells that were cotransfected with Citrine and either the
TEL plasmid or the empty vector frequently had a Citrine– fraction, the overall
transfection rate of Citrine being roughly 20%. It was found that the MFI of the
fluorescently labelled EdU in the Citrine– fraction varied between samples depending
on what they had been transfected with, even though it was assumed that such cells
would not be carrying any exogenous plasmids. To control for this variation, I used
the ratio between the MFI of the labelled EdU from the Citrine+ and Citrine–
fractions, assuming that the effect that was giving rise to this variation would affect
both fractions equally.
Figure 4.5C shows the MFI ratio was the same between cells transfected with Citrine
and cells co-transfected with Citrine and empty vector pCIneo, indicating that the
presence of the second plasmids had no intrinsic effect on the proliferation rate.
However, the MFI ratio was slightly lower in cells co-transfected with Citrine and
TEL, owing to a low MFI in the Citrine+ population, which I assumed (based upon
Figure 4.5A) has high levels of TEL expression.
One explanation for this reduction in the proliferation rate is that it is caused by the
‘burden’ of overexpressing any protein, regardless of what role it has. However, I did
not believe this to be the case in this instance, since the vector transfected as the
empty vector contains the gene for the protein to confer neomycin resistance
(Neomycin Phosphotransferase), which would also inflict such a ‘burden’ upon the
cells, but there was no change between cells transfected with Citrine alone and those
transfected with Citrine and the empty vector (Figure 4.5C). Therefore, I concluded
that the immediate effect of TEL after transfection (<48hrs) is a subtle reduction in
the proliferation in REH cells.
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Figure 4.5 – Effects of TEL plasmid transfection on DNA synthesis
(A) Cotransfection of REH with two fluorescent protein plasmids (Citrine and Tomato), showing uptake of both
plasmids and expression of both Citrine and Tomato at the same intensity. (B) Flow plots showing EdU uptake
(visualised by azide-Alexa647 staining) and Citrine expression, when REH is transfected with Citrine alone,
Citrine and pCIneo, or Citrine and pCI-TEL-neo. Numbers above gates indicate mean fluorescence intensity of
Alexa647 of the events in the gate. (C) Bar graph showing the ratio between the mean fluorescence intensity
(MFI) of EdU-Alexa647 staining of Citrine-positive cells and that of Citrine-negative cells (shown by gates in
(B)); n=1.
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4.2.6 Long term loss of TEL
REH cells were transfected with TEL or pCIneo, and the cultures were kept under
selection (G418, 600µg/ml) for up to 22 weeks. However, after eight weeks (by
which time all non-transfected REH cells would have been killed), the rates of EdU
incorporation between TEL and pCIneo selected populations was similar (Figure
4.6A), as were the growth rates in culture (Figure 4.6B), and rates of cell death in
response to Staurosporine (Figure 4.6C), a protein kinase inhibitor and apoptosis
inducer (Bertrand et al 1994).
It was discovered by qPCR that the expression of TEL mRNA in the transfected
REH cells decreased dramatically in the population between weeks 4 and 9, and
remained low (Figure 4.6D), despite constant antibiotic selection in culture. This is
consistent with the idea that TEL expression puts REH cells at a selective
disadvantage in culture; since cell culture conditions favour the fastest growing cells,
there is a strong selective pressure for any cells expressing genes which slow down
cell growth (as has been shown for TEL in Figure 4.5) to silence the expression of
these genes, and any cells doing so, by definition, will increase their numbers in the
total population.
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Figure 4.6 – Long term loss of TEL in culture.
(A) Comparing EdU uptake by flow cytometry in REH:pCIneo and REH:TEL cells after 8 weeks post-
transfection in culture under G418 selection. (B) Graph showing growth of REH:pCIneo and REH:TEL cells
seeded in triplicate, 12 weeks post-transfection in culture under G418 selection. (C) Graph showing death of
REH:pCIneo and REH:TEL cells caused by 1µM Staurosporine (STS) after 14 weeks in culture under G418
selection. (D) Graph showing the relative expression level by qPCR of TEL in the bulk culture of REH:TEL over
time (n=1).
A
MFI EdU-azide-Alexa488
REH:pCIneo – 1300.01
REH:TEL – 1190.37
B C Cell Death
Time (hours)
Vi
ab
ili
ty
(%
)
0 24 48
0
20
40
60
80
100
REH:pCIneo +STS
REH:TEL +STS
-STS
-STS
Cell growth
Time (hours)
vi
ab
le
ce
lls
(x
10
6 )
/m
l
0 24 48
0.00
0.05
0.10
0.15
0.20
0.25
REH:pCIneo
REH:TEL
D Expression level of TEL in REH:TEL cellsover time in culture
Time (weeks post transfection)
R
el
at
iv
e
TE
L
ex
pr
es
si
on
(n
or
m
al
is
ed
to
G
AP
D
H
)
0 5 10 15 20 25
0
50
100
150
CHAPTER 4: ROLE OF TEL IN TEL/AML1+ LEUKAEMIA
145
4.2.7 Monoclonal REH:TEL cell lines
In an attempt to avoid the problems with ‘bulk cultures’ observed in Figure 4.6,
I generated monoclonal cell lines to investigate proliferation. Fresh REH cells
recently transfected with TEL or pCIneo were seeded into 96-well U-bottom plates
in limiting dilution to ensure no more than one cell per well. Nine clones were
generated; from TEL-transfected REH cells: T1C8, T1E10, T1G8, T2C5, and
T2D10, and from pCIneo-transfected REH cells: p1C6, p1E9, p2B2, and p2D5.
A growth curve experiment was used to identify the slowest growing
TEL-overexpressing clones (Figure 4.7A), and an estimated doubling time for each
of the clones was calculated from these curves (Figure 4.7B). The doubling times
from the curves vary from 27 hours to 49 hours, 27 hours being the approximate
doubling time for untransfected REH cells (data not shown). However,
unexpectedly, the two fastest growing clones were TEL-overexpressing (T1G8 and
T1C5), and the slowest growing clone was a pCIneo-transfected clone (p2D5), and
there appeared to be no consistent pattern in terms of the doubling times for the other
TEL- or pCIneo-transfected clones.
To resolve this discrepancy, I assessed the transcript expression of TEL in the clones
to see if the difference in growth rates could be attributed to the expression levels of
TEL in the clones. TEL mRNA expression levels were all high in the clones from
TEL-transfected REH (apart from clone T2D10) and low in the clones from
pCIneo-transfected REH cells (Figure 4.7C). The expression levels of TEL did not
appear to correlate with the growth rates of the clones.
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Figure 4.7 – Growth of monoclonal REH:TEL cell lines.
(A) Growth curves over three days calculated by automated cell counts starting with 105 cells. Legend lists cell
lines in order of final cell count on day three, highest to lowest. Mean calculated from three technical replicates,
n=1. (B) Doubling time of cell lines calculated from growth curves (C) Expression of TEL transcript in the
monoclonal cell lines derived from REH transfected with TEL or pCIneo. Transcript expression level is
normalised to GAPDH and compared to Jurkat cells.
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4.2.8 Effects of TEL transduction on apoptosis
The microarray identified BCL-2, a gene associated with the control of apoptosis, as
down-regulated 1.8-fold in TEL-transduced REH cells compared to GFP-transduced
cells (Table 4.3). Analysis by qPCR, using the same RNA as was used in the
microarray, indicated that BCL-2 was down-regulated in TEL-transduced REH cells
compared to GFP-transduced cells (Figure 4.8A), but only by virtue of a high level
of BCL-2 expression in one of the GFP-transduced cells. To further investigate the
effect of TEL on apoptosis, cells were transduced with either GFP or TEL-GFP
oncoretrovirus, and treated with or without Staurosporine (STS), an inhibitor of
protein kinases, and a potent inducer of apoptosis (Jacobson et al 1993). The cells
were stained with an antibody for Annexin-V and DAPI and analysed by flow
cytometry to distinguish between live cells, and cells in the early or late stages of
apoptosis (Figure 4.8B). The experimental schedule is shown in Figure 4.8C; briefly,
REH cells were transduced with either GFP- or TEL-GFP-oncoretrovirus, and 24
hours later incubated with or without staurosporine, with samples taken at 24 hour
intervals from before the transduction to two days after staurosporine treatment.
The frequencies of the populations in each condition are shown in Figure 4.8C. In
the absence of staurosporine, the transduction of TEL did not increase either of the
apoptotic cell populations compared to GFP-transduced cells. Staurosporine induced
apoptosis in both GFP- and TEL-transduced cells, indicated by the dramatic decrease
in live cells and the increase in the early and late apoptotic populations; however,
there appeared to be no difference in the numbers of cells present in the apoptotic
cell fractions between the GFP- or TEL-transduced cells, indicating that TEL did not
have a significant effect on apoptosis in REH cells.
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Figure 4.8 – Effects of oncoretroviral transduction of TEL on apoptosis.
(A) Expression of BCL-2, a gene associated with cell cycle control, as analysed by qPCR. (B) Flow cytometry
histogram showing cells stained with Annexin-V antibody and DAPI to distinguish between live cells, cells in
early apoptosis, and cells in late apoptosis. (C) Experimental set up; red arrow heads indicate when samples were
taken for analysis, and black arrows indicate when cells were either transduced with GFP or TEL oncoretrovirus,
or treated with staurosporine (STS; 1µM). (D) Frequencies of live cells, cells in early apoptosis, and cells in late
apoptosis, as defined in (B) ‘GFP’ and ‘TEL’ indicate cells transduced with GFP- or TEL-oncoretrovirus,
respectively, and ‘-‘ and ‘+ STS’ indicated cells cultured in the absence or presence of 1µM staurosporine,
respectively; n=1.
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4.2.9 Further investigation of genes identified in microarray
In addition to identifying genes associated with proliferation and apoptosis, the gene
expression microarray indicated other differentially expressed genes that have
previously been connected to leukaemia, namely EPOR (erythropoietin receptor),
ANGPTL4 (Angiopoietin-like 4), and IKZF2 (Helios; Table 4.3). Using the same
RNA samples as were used in the microarray, the differential expression of these
genes was further investigated by qPCR in Figure 4.9A. Despite being identified in
the microarray as genes with differential expression, by qPCR no difference was
observed in the expression of the genes in the GFP-transduced versus the
TEL-transduced cells (Figure 4.9A).
Many of the genes identified in the microarray have not been previously linked to
leukaemia, namely CLIC5, TTBK1, and NETO1. Each of these genes were strongly
differentially expressed (Table 4.3), and so warranted further validation by qPCR.
CLIC5 (chloride intracellular channel protein 5) is a chloride ion channel found on
internal membranes, that was originally identified in the microvilli of the placenta
and found to associate with the actin cytoskeleton (Berryman & Bretscher 2000).
CLIC5 has since been found in the cilia of hair cells of the inner ear, and is essential
for the functions of the cochlea for hearing and the vestibular system for balance
(Gagnon et al 2006). It is also highly expressed in skeletal muscle, and has a role in
proliferation and differentiation of myoblasts (Li et al 2010). High expression of
CLIC5 has been shown to be associated with TEL/AML1+ leukaemia compared to
other subtypes of ALL (Ross et al 2003), and also presented on murine follicular
dendritic cells, which help form germinal centres, sites of rapid B cell proliferation
(Huber et al 2005). Recently it has been identified as part of a multigene predictor of
triple-negative breast cancer patients who are at low risk of metastasis (Yau et al
2010).
TTBK1 (tau tubulin kinase 1) is a brain-derived kinase that phosphorylates tau,
β-tubulin, MAP2 and α-casein (Takahashi et al 1995). Variants of TTBK1 are
associated with Alzheimer’s disease (Vazquez-Higuera et al 2011; Yu et al 2011),
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and transgenic mice expressing human TTBK1 show impaired memory (Sato et al
2008).
NETO1 (neuropilin and tolloid-like 1) is a transmembrane receptor that interacts
with the NMDA receptor at neuron synapses, and is involved in memory and
learning (Ng et al 2009). Deletion of the chromosome arm 18q where the NETO1
locus is situated has been associated with autism (O'Donnell et al 2010). NETO1
itself is a receptor for Semaphorin-3F (Sema3F; Gay et al 2011). Semaphorins are a
class of signalling proteins involved in axonal guidance during neural development.
SEMA3F has no known connection to leukaemia, but semaphorin family members
have been linked to leukaemia in the past; for example, SEMA4D (also known as
CD100) has been shown to help promote proliferation of B cell Chronic Lymphoid
Leukaemia cells (Deaglio et al 2005). NETO1 has been shown to be upregulated in a
human B cell line in response to hypoxic conditions (Kim et al 2006), purported to
confer survival to leukaemia cells (Benito et al 2011).
Out of these three genes, two (CLIC5 and NETO1) were indicated by qPCR as being
downregulated in the TEL-transduced REH cells compared to the GFP-transduced
cells (Figure 4.9B). The expression of TTBK1 was not shown to be different
between TEL-transduced and GFP-transduced cells.
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Figure 4.9 – qPCR data from other genes.
(A) Expression of EPOR, ANGPTL4, and IKZF2, by qPCR. (B) Expression of CLIC5, TTBK1, and NETO1, by
qPCR.
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4.3 Discussion
The data presented in this chapter describes the investigation of the role of TEL
overexpression in the REH cell line, a model cell line of TEL/AML1+ leukaemia.
RNA extracted from REH cells after TEL or GFP transduction was run on a gene
expression microarray. Of the differentially expressed genes, there were several
genes involved in proliferation and apoptosis, two important factors in the
development and progression of cancer.
I first investigated the effects of TEL on proliferation. REH cells transduced with
oncoretroviruses expressing TEL and GFP only showed subtle changes in the
progression of the cell cycle, as demonstrated by a slight decrease of cells in S and
G2 phases, compared to those transduced with GFP alone. I decided to further pursue
the study of proliferation in REH by plasmid transfection. The early effects of the
transfection of a TEL expression plasmid were to slow down proliferation compared
to transfection with the empty vector, as demonstrated by reducing incorporation of
EdU, a nucleotide analogue. However, this effect was lost over time in the bulk
culture of TEL-transfected cells, concurrent with a loss of TEL expression,
indicating a strong selective pressure of TEL-transfected REH cells to silence their
TEL expression. The generation of monoclones gave conflicting results with regards
to TEL mRNA and protein levels, as well as growth rates.
I next investigated the role of TEL in apoptosis. Despite a slight increase in sub-G1
cells by cell cycle analysis, TEL transduction had no effect on cell death in response
to staurosporine, as shown by Annexin-V staining. Finally I confirmed the
differential expression of two sets of other genes from the microarray, one set of
three genes that have previously been linked to leukaemia, and another set that have
not had any connection to leukaemia before.
4.3.1 Gene expression microarray
There have been many examples of the use of gene expression microarrays to study
acute lymphoblastic leukaemia. These have been used to identify the molecular
subclasses of leukaemia and discover new subclasses (Fine et al 2004; De Pitta et al
2005; Den Boer et al 2009), and to generate a set of genes that can discriminate
CHAPTER 4: ROLE OF TEL IN TEL/AML1+ LEUKAEMIA
153
between specific groups of ALL patients, for example TEL/AML1+ patients
(Gandemer et al 2007). The findings from such studies are useful in discovering
what makes the subtypes different, which could be used in the future either for a
more detailed diagnosis or for ‘personalised treatment’ for a specific subtype.
However, if one hopes to answer a fundamental question of leukaemia – ‘what
makes leukaemia different to normal haematopoiesis?’ – then it would be more
appropriate to look at the differences between leukaemic and normal blood cells.
Analysing gene expression data to discriminate between different subtypes of ALL
will, by definition, ignore gene expression patterns that are common to many of
these subtypes. There are a few examples of studies that aim to identify the gene
expression differences between leukaemic and normal haematopoietic cells
(Andersson et al 2005b; Andersson et al 2010). Combining the results of these
studies with those looking at specific subtypes will shed light on how specific causes
can lead to common outcomes of malignant haematopoiesis. Similarly, the intention
of this study was to investigate how the loss of TEL fits into the bigger picture
molecular pathogenesis of leukaemia.
The differentially expressed genes were analysed by Ingenuity Pathway Analysis
(IPA), which is designed to link genes with their known functions and interactions.
Analysis of predicted perturbed functions in response to TEL overexpression
identified decreases in several functions such as ‘proliferation of immune cells’, and
‘proliferation of lymphocytes’ (Table 4.4). This indicates that TEL has a role of
suppression of proliferation in haematopoietic cells including B lymphocytes, which
fits with the hypothesis that the loss of TEL is an important step in the progression of
leukaemia, allowing lymphoblasts to proliferate unhindered. Genes whose
differential expression identifies such perturbed functions would be interesting
candidates for further analysis. In addition, other functions affected in this model,
such as ‘activation of antigen presenting cells’ and ‘activation of macrophages’ may
represent new functions for TEL. Other functions affected by TEL overexpression
include decreases in ‘quantity of osteoclasts’ and ‘cell movement of endothelial
cells’, and increases in ‘uptake of anion’, ‘infection by viruses, and ‘infection by
bacteria’ (Table 4.4). These may represent functions of TEL in other cells, but could
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also be a result of ‘false positives’ in the differentially expressed genes from the
microarray, and so not represent a physiological function of TEL.
Transcription factor analysis identified transcriptional regulators whose targets were
differentially expressed in the microarray, and therefore suggests transcription
factors whose activity may have been affected as a result of the overexpression of
TEL (Table 4.5). Of particular note is the prediction of a decreased activity in the ets
family member PU.1 (coded by the gene SPI1), which is involved in both normal
and malignant haematopoiesis (Gupta et al 2006; Kastner & Chan 2008; Gupta et al
2009). The transcription factors predicted to be inhibited may represent new targets
of TEL, and could be further investigated by protein binding studies.
I did not identify in the microarray genes previously shown to be regulated by TEL,
such as stromelysin-1 (Fenrick et al 2000; Wang & Hiebert 2001), Bcl-XL (Irvin et al
2003), and TCL1 (Fears et al 2002). It is possible that any differential expression of
these genes did not meet the threshold of statistical significance, or are not expressed
in REH cells. The expression of these genes could be analysed by qPCR.
The microarray identified some differentially expressed genes that have already been
linked to TEL/AML1+ leukaemia: for example, EPOR (Ross et al 2003; Fine et al
2004) and ANGPTL4 (Andersson et al 2005b). This was promising as it showed not
only that our model was relevant to leukaemia, but it also suggests that the loss of
functional TEL is a ‘driver’ mutation in TEL/AML1+ leukaemia progression; that
genes significantly associated with TEL/AML1+ leukaemia are in fact the result of
the loss of TEL. To identify further changes specific to TEL/AML1+ leukaemia that
could be caused by TEL, these results with other gene expression microarrays could
be compared using a computational biology approach.
However, many of the highest deregulated genes have not been previously associated
with leukaemia. I analysed three of the genes, CLIC5, NETO1, and TTBK1, all of
which have had some involvement in neurons, neuronal development, or memory.
TEL has been implicated in neuronal development and survival; TEL is expressed in
the embryonic brain and TEL-/- mouse embryos have defects of the neural tube and
ganglia (Wang et al 1997). Both CLIC5 and NETO1 were confirmed as being
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downregulated on overexpression of TEL (Figure 4.9B), which might suggest they
are targets of TEL, or that they could be downregulated by an indirect mechanism.
Whether either of these genes has any involvement in leukaemia is unconfirmed, but
could be further investigated. For example, NETO1 is a receptor for the signalling
protein Semaphorin-3F (Gay et al 2011), whose family members have been reported
to be involved in proliferation of B-CLL cells (Deaglio et al 2005). To determine
any effect of the loss of NETO1 in TEL/AML1+ leukaemia and in particular in the
role of the loss of TEL, using recombinant semaphorin-3F and anti-NETO1 blocking
antibodies, the proliferation of TEL-transduced REH cells in the presence of
semaphorin-3F could be assessed.
Nevertheless, out of the probes that were identified as differentially expressed in the
microarray, it would not be expected that all of these are indeed differentially
expressed in vivo. When comparing two groups for differentially expressed probes, a
statistical significance threshold of p = 0.05 allows for 5% of the probes to be
different purely by chance, or 1 in 20. For the 44,000 probe microarray, this equates
to 2,200 probes that would be appear to be ‘differentially expressed’ by chance. Our
microarray results show that roughly 1,600 probes are differentially expressed,
meaning I cannot be confident that the genes that represent these probes are
genuinely differentially expressed genes. A correction to adjust the p-values to take
this into account was not successful due to the small sample size in each group (Peter
Ashton, personal communication).
It was therefore decided to validate the differential expression of some of the genes
directly by qPCR. Out of the eight genes I chose to validated that were identified as
differentially expressed in the microarray, only three (BCL-2, CLIC5, and NETO1)
were found to be differentially expressed in the qPCR. Therefore, I cannot be
confident that the differentially expression of the probes identified in the microarray,
and the subsequent analysis, is reliable. The small sample size is a limitation of this
study; more replicate samples for each group would increase the statistical power of
the microarray analysis and subsequent validation by qPCR.
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4.3.2 The role of TEL in proliferation
As proliferation was predicted to be one of the main functions affected by the
overexpression of TEL, and since uncontrolled growth is the defining feature of
leukaemia and cancer, I decided to study the effects of TEL on proliferation of REH
cells.
There have been previous studies into the influence of TEL on cell growth in the
past. Fenrick and colleagues (2000) studied the effects of TEL on Ras-transformed
3T3 (fibroblast) cells. These transformed cells normally display growth in semi-solid
media (agar), but the expression of TEL slowed down this growth considerably. In
adherent cell cultures, TEL expressed in non-transformed 3T3 cells had no effect on
proliferation, but the proliferation of Ras-transformed cells was slowed down by
TEL expression. (Fenrick et al 2000). The growth inhibitory effect of TEL on
3T3 cells was also shown by Gunji and co-workers (2004).
Fears and colleagues (2002) derived two cell lines from samples taken from the same
TEL/AML1+ leukaemia patient, one at initial diagnosis (AT-1), which was positive
for TEL, and one at relapse (AT-2), which was negative for TEL. They showed that
the AT-2 (TEL-negative) cell line grew at a faster rate, although it was not discussed
whether this was due to the loss of TEL or caused by other genetic abnormalities that
arose in the AT-2 cell line, which includes a translocation involving chromosomes 1
and 17 (Fears et al 2002).
Tsuzuki and co-workers (2007) transduced REH cells with retroviruses containing
either GFP alone or TEL and GFP. By tracking the changes in the GFP+ population
amongst all cells transduced, they showed that TEL-GFP-transduced cells lost their
GFP expression quicker than cells transduced with GFP alone, and that cell division
occurs at a slower rate (Tsuzuki et al 2007).
However, I found that the expression of TEL on the proliferation of REH cells had
only a subtle effect of slowing down proliferation. I used a variety of different
methods of measurement, including doubling time, growth curves, DNA synthesis
analysed by EdU incorporation, and cell cycle analysis by DNA content. I also could
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not confirm differential expression of the cell cycle genes CDKN1B and CDKN2A by
qPCR (Figure 4.3A).
By oncoretroviral transduction, I measured the effects of TEL on the cell cycle, and
only found a slight reduction in the numbers of cells in S phase of 5-7 percentage
points (Figure 4.3D), and a similar reduction of cells in G2 phase of 2-3 percentage
points (Figure 4.3E). By plasmid transfection, I observed a modest decrease in EdU
uptake (Figure 4.5C), but inconclusive results using clones derived from stably
transfected cells when growth rate was assessed with growth curves and doubling
times (Figure 4.7A-B).
This conflicts with previous work on the effects of TEL on cell growth, but might be
explained by the differences between these studies and the work presented in this
chapter. The differences in cell growth of the AT-1 and AT-2 cell lines (Fears et al
2002) may not be solely due to the absence of TEL in the AT-2 cell line; detailed
spectral karyotyping identified a t(1;17)(q36;p13) translocation in the AT-2 cell line
not present in the slower growing AT-1 cell line. Whilst TEL inhibited the growth of
3T3 fibroblast cells (Fenrick et al 2000; Gunji et al 2004), it cannot be ruled out that
this effect is specific to 3T3 or fibroblast cells, and so it cannot be assumed TEL has
the same effect on REH cells. Finally, Tsuzuki and co-workers did show that the
transduction of REH cells with TEL slows down the proliferation of cells using a
competition assay, but there was no further analysis with regards to cell cycle
analysis or EdU uptake (Tsuzuki et al 2007).
I did observe some conflicting data in our results, particularly in the study of the
transduced REH monoclones (Figure 4.7). A growth curve was generated by
counting cells seeded into a cell culture plated over time (Figure 4.7A), and from
these curves, a doubling time for each clone was calculated (Figure 4.7B).
Unexpectedly, the fastest growing clones overall were not the empty vector clones,
but the TEL-transfected T1C5 and T1G8 clones. In addition, the slowest growing
clone, below the rest of the TEL clones, was the empty vector clone p2D5. Despite
the best efforts to ensure a consistent numbers of cells (100,000) at the start of the
experiment, if there were differences between the numbers of cells seeded due to
counting errors, this could explain the discrepancy between the growth curves and
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the doubling times of the clones. These experiments would have to be repeated for
this to be investigated. By qPCR, the TEL-transfected clones expressed high levels
of TEL, with the exception of T2D10 (Figure 4.7C). Low levels of qPCR
amplification could be detected in all of the empty vector clones, which could be due
to contamination, the expression of mutant transcripts in REH cells or none specific
binding of the primers. The expression of TEL in these clones did not appear to
correlate with their growth rate.
In summary, without additional replicates of the experiment, I cannot conclude that
TEL has more than a subtle inhibitory effect on the proliferation of REH cells. One
factor that was not examined was if TEL has an effect on the response of REH cells
to external stimuli that either induce or inhibit proliferation. For example, the
proliferation of REH cells has been shown to be stimulated by IL-3 (Accordi et al
2007) or seratonin (Prada et al 2011), and inhibited by IL-7 (Pandrau-Garcia et al
1994); an experiment using these in combination with TEL expression would reveal
how REH cells respond to such stimuli, and possibly identify a role for TEL in
signal transduction.
4.3.3 The role of TEL in apoptosis
In addition to proliferation, the evasion of apoptosis is an important feature of cancer
and leukaemia. The microarray also identified several genes involved in apoptosis,
so I decided to investigate further what role the expression of TEL has on the death
of REH cells.
There have been previous studies of the influence of TEL on apoptosis. Irvin and
colleagues (2003) found that TEL-transduced 3T3 fibroblast cells were much more
sensitive to apoptosis induced by serum-starvation than control 3T3 cells, and that
this correlated with a repression of the anti-apoptotic gene Bcl-XL by TEL. Yamagata
and co-workers (2006) discovered that the expression of TEL in the murine myeloid
cell line 32Dcl3 increase the sensitivity of these cells to apoptosis induced by G-CSF
through the upregulation of p53.
However, in REH cells overexpressing TEL, (Figure 4.8) I did not observe a
significant effect on cell death. When analysing the cell cycle profile TEL
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oncoretrovirus-transduced cells, I only saw a small increase in the number of the
‘sub-G1’ (apoptotic) cells of 1-2 percentage points (Figure 4.3F). However, when I
analysed TEL plasmid-transfected cells for Annexin-V staining (a marker of
apoptosis), I saw no difference in the apoptosis response to the apoptosis inducer
staurosporine (Figure 4.8D).
One explanation for the discrepancy between our results and that of previous work
(Irvin et al 2003; Yamagata et al 2006) could be that, similar to the work in studying
the effects of TEL in 3T3, the increase in sensitivity to apoptosis is due to cell-
specific effects. However, since apoptosis can be induced in different ways, it cannot
be ruled out that TEL does not have the influence on staurosporine-mediated
apoptosis that it might on other means of stimulating cell death.
As described in Introduction chapter (section 1.5.1), apoptosis triggered by intrinsic
signals is dependent on the balance between anti-apoptotic and pro-apoptotic signals
of the bcl-2 family of mitochondrial proteins (Tsujimoto 2003; Yamagata et al
2006). Although the apparent downregulation of BCL-2 in TEL-expressing cells
might only be due to a higher level of TEL expression in one of the GFP-transduced
clones (Figure 4.8A), a downregulation of BCL-2 might be expected to lead to
increased levels of apoptosis. However, the microarray indicated the downregulation
of a pro-apoptotic bcl-2 family member, BAK1, on TEL overexpression (data not
shown). The level of differential expression was low (1.16-fold down regulation),
which I did not confirm by qPCR, but the downregulation of BAK1 might have been
enough to balance out any real downregulation of BCL-2, and so lead to no net effect
on apoptosis of TEL overexpression.
As described in the Introduction chapter (section 1.5.2), the elimination of
self-reactive B cells is a critical stage in B cell development. Apoptosis of immature
self-reactive B lymphocytes is believed to occur via the B-cell receptor (Niiro &
Clark 2002), and acts via both caspase-dependent and -independent pathways
(Berard et al 1999). The mechanism of staurosporine-induced apoptosis is unclear,
but it is believed to act via both caspase-dependent and caspase-independent
pathways (Belmokhtar et al 2001; Zhang et al 2004), the latter which could act
independently of the bcl-2 family proteins (Zhang et al 2004). To fully investigate
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the effects of TEL on apoptosis, a variety of methods to induce apoptosis could be
used, including those relevant to B lymphocytes; for example, activation of apoptosis
via the B-cell receptor by anti-IgM antibody, and apoptosis via Fas by anti-Fas
antibody (Graves et al 1998).
4.3.4 Conclusion
The data presented in this chapter has not demonstrated more than subtle effect of
TEL on proliferation or apoptosis of the TEL/AML1+ cell line REH. This is in
conflict with previous work which has shown that forced TEL expression decreases
proliferation of cells and increases apoptosis.
One possible reason for our observations, as outlined above, could be that I did not
consider the use of methods to induce or inhibit proliferation, nor a variety of
methods to induce apoptosis, which could have revealed an influence of TEL that I
did not observe in this study. Another limitation of this study is the low number of
replicates used for the experiments. If the effects of TEL on proliferation and
apoptosis truly are as subtle as our results suggest, more replicates would increase
the statistical power of the data.
It may be that the loss of TEL is not in fact a ‘driver’ mutation of TEL/AML1+
leukaemia, or is only partially involved. It is possible that the loss of TEL is only one
mutation in a multi-step process to leukaemia, all of which are necessary but not
sufficient to bring about overt leukaemia. To this end, it would be necessary to
investigate how TEL along with other common mutations (outlined in the
Introduction, section 1.9) influence leukaemia.
However, given the frequency of the loss of the untranslocated ETV6 allele observed
in TEL/AML1+ leukaemia patients (Cave et al 1997; Patel et al 2003), it seems
unlikely that TEL only has a limited effect influence. To support this, when the gene
expression changes were analysed by the Ingenuity Pathway Analysis, most of the
functions predicted to be affected by TEL overexpression were proliferation of
various subtypes of haematopoietic cells (Table 4.4). It is more likely that the loss of
TEL results in changes in lymphoblasts that have not been studied in this chapter.
Cancer is a disease of many features, with increased proliferation and evasion of
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apoptosis just two such features, which can each be affected in many ways; for
example, a hypothetical cancer promoting mutation might not affect the baseline rate
of proliferation of a cell, but might change its sensitivity to a proliferation-inducing
signal, which in turn means that the cell proliferates faster in response. More
sophisticated experiments than the ones performed in this chapter would have to be
performed to reveal what role TEL has on proliferation and apoptosis. A more
directed approach would be to start with investigating the functions predicted by IPA
to be affected by TEL overexpression (Table 4.4).
Ultimately, some of the roles of TEL may not be revealed by models using cell lines,
and indeed, the limitation all model systems when studying any gene is that they
cannot individually reveal all aspects of what that gene does in an organism. As a
demonstration, mouse models were used to show that TEL is essential for adult
haematopoietic engraftment but dispensable for adult haematopoiesis itself (Wang et
al 1998a; Hock et al 2004), which would not have been possible to show using cell
lines alone. Similarly, whilst important aspects of the role of the loss of TEL in
TEL/AML1+ leukaemia can be revealed using cell lines, such a model would not be
appropriate for the study of, for example, how TEL influences B lymphocyte
development, since cell lines rarely represent more than a ‘snapshot’ of a particular
stage in development.
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Chapter 5: Discussion
The fusion gene TEL/AML1, generated by the t(12;21) chromosome translocation, is
the most common single genetic aberration in childhood leukaemia. However,
despite extensive research using a variety of mouse and human models, it is still not
clear how the activity of TEL/AML1 leads to leukaemia. In addition, the significance
of one of the most frequent secondary mutations, the loss of the remaining
untranslocated TEL allele, is still not known. The aims of this thesis were two-fold:
to generate a new model based on human embryonic stem cells in which the
aetiology of TEL/AML1+ leukaemia might be further investigated (Chapter 3), and
provide an insight into the role of the loss of TEL in the context of TEL/AML1+
leukaemia using a human leukaemia cell line REH (Chapter 4).
A model of leukaemia using hESCs would combine the advantages of in vivo and
in vitro models; it would demonstrate human multipotent haematopoietic
development, and would be amenable to genetic manipulation whilst maintaining a
reproducible genetic background. In Chapter 3 all of these characteristics were
demonstrated in the hES cell line H9 expressing the TEL/AML1 transgene.
Transgenic hESCs could generate haematopoietic progenitors, capable of
differentiation towards a variety of haematopoietic lineages, whilst also maintaining
genetic stability and pluripotency markers when cultured in an undifferentiated state.
To my knowledge there are no published examples of models of TEL/AML1+
leukaemia using hESCs, and thus the work presented in this thesis provides the basis
of first model of its kind.
Differentiation of transgenic TEL/AML1+ hESCs showed that there was no
significant effect of TEL/AML1 on the numbers of haematopoietic precursors
(CD43+CD31+ hESC-derived cells; Figure 3.8). This is consistent with previous
studies concerning the haematopoietic development in TEL and AML1 deficient mice
(Wang et al 1998a; Lacaud et al 2004), demonstrating that any dominant negative
effects that TEL/AML1 might have over TEL or AML1 (Zelent et al 2004) will not
have a significant effect on the differentiation of TEL/AML1+ hESCs.
TEL/AML1-transgenic mice show that the expression of TEL/AML1 increases the
self-renewal capacity of HSCs and an increase in myeloid progenitors with a
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reciprocal decrease in lymphoid progenitors (Schindler et al 2009). Unfortunately,
inefficient recovery of CD43+CD31+ haematopoietic precursors precluded a
thorough analysis by CFU assays of the influence of TEL/AML1 in the
haematopoietic capacity from the transgenic hESCs (Figure 3.9). However, it would
theoretically be possible to conduct a more in depth study of the self-renewal and
differentiation properties of TEL/AML1+ hESC-derived haematopoietic progenitors,
using both an in vivo approach by xenograft repopulation, with additional limiting
dilution and competitive repopulation assays, and in vitro approach with serial
transplantations in methylcellulose-based CFU assays (Schindler et al 2009).
Further differentiation of haematopoietic progenitors towards B cell lineage was
demonstrated in Figure 3.10. A slight increase in CD34 transcript expression was
observed in TEL/AML1+ differentiation cultures, which suggests an inhibition of
differentiation between pro-B and pre-B expression, consistent with murine models
of TEL/AML1+ leukaemia (Tsuzuki et al 2004; Fischer et al 2005). No study of the
proliferative or self-renewal capacity of these B lineage cells was performed, which
would have shed light on whether these cells contained a population of
‘pre-leukaemic’ blasts typical of TEL/AML1+ leukaemia (Morrow et al 2004;
Morrow et al 2007). Nevertheless, such studies could be performed by xenograft as
detailed above or in an in vitro culture system (Rawlings et al 1995). In addition,
harvesting of B lineage cells could enable further phenotypic studies of, for example,
surface expression of B cell markers and immunoglobulin gene rearrangements
(Carpenter et al 2011).
I demonstrated the upregulation of two genes, TNFRSF7 and SMAD1, associated
with TEL/AML1+ leukaemia in the B lineage differentiation cultures (Figure 3.11),
indicating that the association of these genes with TEL/AML1 might be directly
regulated by TEL/AML1 itself. However, if functional effects of TEL/AML1 in
haematopoietic and B-lineage progenitors could be demonstrated using the
experiments suggested above, it could be interesting to conduct a gene expression
microarray to observe the changes involved. This might shed light on the pathways
involved in maintaining the ‘pre-leukaemic’ state observed in TEL/AML1, and could
provide therapeutic targets with which to proactively reduce the risk of progression
to overt leukaemia. In any case it would be interesting to pursue the importance of
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SMAD1 and TNFRSF7 in TEL/AML1+ leukaemia, particularly the latter as previous
studies have demonstrated it has a clear link to leukaemia, as described in the
Introduction chapter (section 1.9.4).
A panel of hESC lines was generated that constitutively expressed TEL/AML1.
Although no adverse effects of the overexpression of TEL/AML1 were observed,
concerns about ‘transgene toxicity’ could be addressed by using homologous
recombination in hESCs, which could insert RUNX1 cDNA in the appropriate intron
of the ETV6 locus, similar to the systems used in some murine models (Schindler et
al 2009; van der Weyden et al 2011). This would enable the expression of
TEL/AML1 from the endogenous ETV6 locus, and so generate a model more closely
replicating the disease.
During the development of this model, I had attempted to set up a tetracycline-
inducible expression system for TEL/AML1. However, in practise no expression
could be induced when tested, and it was decided to switch to a constitutive
expression system. The inducible system would allow the investigation of at what
stage TEL/AML1 can contribute to leukaemogenesis, and so provide evidence as to
the ‘cell of origin’ in leukaemia. Studies in mice with inducible expression of
TEL/AML1 have shown that the presence of TEL/AML1 in HSCs can change the
self-renewal properties of multipotent and lymphoid cells (Schindler et al 2009), but
that TEL/AML1 expression restricted to lymphoid lineages has no effect
(Andreasson et al 2001; Schindler et al 2009).
To elucidate the importance of the loss of TEL in the progression of TEL/AML1+
leukaemia, TEL was overexpressed in the TEL/AML1+ cell line REH (Chapter 4).
A gene expression microarray showed that the presence of TEL had an effect on the
transcription of genes involved in functions of significance to leukaemia; for
example, TEL expression decreased genes involved in the proliferation of
lymphocytes (Table 4.4). In addition, differentially expressed genes included some
genes strongly associated with TEL/AML1+ leukaemia from previous studies (Table
4.3). These two results vindicate the approach taken as they indicate that this model
has some relevance to the clinical TEL/AML1+ disease. Supporting this, it has been
shown that despite concerns that culture adaptation of cell lines can result in cells
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that no longer represent real diseases, leukaemia cells lines have similar
transcriptional profiles to the leukaemia subtypes from which they were derived
(Andersson et al 2005a).
Regarding the genes differentially regulated by TEL overexpression, some genes
have been previously linked to leukaemia, and it might be interesting to use a
computational approach to further compare the data set generated in this thesis with
those of studies of ALL and/or TEL/AML1+ leukaemia. Analysis of gene expression
changes also identified gene expression patterns that were consistent with the
inhibition of various transcription factors (Table 4.5). Since TEL is known to form
heterodimers with other transcription factors and interfere with their transcriptional
profiles (Fears et al 1997; Kwiatkowski et al 1998; Schick et al 2004), this list of
transcription factors could be an interesting starting point for further studies of
functional heterodimer partners of TEL. Finally, through strong differential
expression of genes in the presence of TEL (Table 4.1 and Table 4.2), new potential
targets of TEL were identified, two of which, CLIC5 and NETO1, have been
validated by qPCR (Figure 4.9); it would be interesting to pursue these genes with
further studies as they have not been linked to leukaemia previously. It is our
intention to make this gene expression data set publicly available so that it could be
used by other groups for their own research, and thus would represent the first gene
expression data set looking at the transcriptional consequences of TEL in the context
of TEL/AML1+ leukaemia.
As an example of the further research that could be conducted on genes identified in
the TEL microarray, one could investigate the role of CLIC5 in leukaemia. As
discussed in Chapter 4 (section 4.2.9), CLIC5 is an intracellular chloride channel that
has already been associated with TEL/AML1+ leukaemia (Ross et al 2003) that is
associated with (Berryman & Bretscher 2000) and regulated by (Singh et al 2007)
the actin cytoskeleton. Interestingly, intracellular chloride ion concentration is
known to control, and be controlled by, progression through the cell cycle
(Blackiston et al 2009), evidence of which is observed in various cell types
(Valenzuela et al 2000; Miyazaki et al 2008), including lymphocytes (Bubien et al
1990). Connecting the actin cytoskeleton and proliferation is cell volume (Lang et al
1998), which has also been shown to be connected chloride concentration (Chen et al
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2002). From the data presented in Chapter 4, and from previous gene expression
studies of TEL/AML1 (e.g.Ross et al 2003), it is feasible that the upregulation of
CLIC5 in TEL/AML1+ leukaemia, with the subsequent loss of heterozygosity of
TEL, affects the intracellular chloride concentration, which could lead to a
dysregulation of the cell cycle, possibly mediate by changes in cell volume.
Experiments which could be performed to investigate this hypothesis could include
the overexpression and knockdown of CLIC5, in coordination with the use of
chloride-sensitive dyes, such as MQAE, to measure intracellular chloride
concentration. The intracellular chloride concentration can be altered through the use
of cell medium deficient in chloride (replaced instead with NO3– , e.g. Miyazaki et al
2008). The effect of such alterations on cell volume can be measured using a variety
of techniques (Davis et al 2004), and on cell proliferation and cell cycle progression
through techniques including those demonstrated in this thesis.
Following the study of the transcriptional consequences of TEL overexpression, the
functional effects, namely proliferation and apoptosis, were investigated. It was
found that TEL had no consistent effect on proliferation. Whilst this is conflicting
with other studies of the role of TEL in proliferation (Fenrick et al 2000; Fears et al
2002; Gunji et al 2004; Tsuzuki et al 2007), there are several explanations for the
discrepancies between previous studies and the work presented in this thesis (see
section 4.3.2). In addition, the lack of a functional effect on proliferation may seem
surprising given the transcriptional effect on genes involved with proliferation (Table
4.4), but it is possible that the proliferative effects of TEL could not be demonstrated
in the experiments performed; one aspect that was not investigated was how TEL
affected the proliferation of cells in response to stimulants of growth and/or cell
division in REH cells, and so this would make a good starting point for further
studies. Similarly, no influence of TEL on the induction of apoptosis was observed
(Figure 4.8). Whilst I used an inducer of apoptosis in the form of staurosporine, it is
not clear through which mechanism this chemical causes apoptosis, and so cell-
specific differences in how apoptosis is controlled could account for discrepancies
between this work and previous studies into the role of TEL in apoptosis (Irvin et al
2003; Yamagata et al 2006). It would be interesting to investigate if TEL regulates
apoptosis by stimulating cell death through a better defined pathway, for example, by
the polymerisation and activation of Fas receptor using antibodies.
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In the introduction chapter, three possible models of the role of the loss of TEL in
TEL/AML1+ leukaemia were presented (Figure 1.3). The first showed that the loss
of TEL is both necessary and sufficient for progression of a TEL/AML1+ clone to
overt leukaemia. The second showed that TEL deficiency is necessary for this, but
other events (for example, further mutations) are needed for progression. Finally, the
third showed that, after an event that causes proliferation of the leukaemic clone, loss
of TEL is one of many mutations that could occur during this expansion, but that
TEL deficiency confers a significant proliferative advantage to a clone so that it
becomes the dominant clone in the leukaemia.
The first scenario seems unlikely to be true, based upon previous studies; the number
of genes that are frequently mutated in TEL/AML1+ leukaemia would indicate that
TEL is not the only important factor in progression; similarly, the lack of TEL as a
gene commonly mutated in other leukaemias not only suggest that it is the loss of
both alleles of TEL that is important but also that TEL loss by itself is not sufficient
for increased proliferation and survival. The work presented in this thesis also
supports this view, suggesting that TEL has no more than a subtle effect on
proliferation and survival. This also suggests that the third model is incorrect, in that
TEL deficiency allows enough expansion of a leukaemic clone to ‘out-compete’
other clones, which is not supported by the results.
In light of this, the second scenario appears to be the most likely; that TEL
deficiency is an essential feature of TEL/AML1+ leukaemia, that somehow
predisposes the pre-leukaemic clone to progress to overt leukaemia, but the ‘switch’
to progression appears to be in the form of another event, either another series of
mutations, or possibly an immunological mechanism as put forward by Greaves
(2006). The transcriptional changes observed as a result of the overexpression of
TEL, presented in Chapter 4, provide a starting point for further studies as to how
TEL deficiency poises pre-leukaemic clones for progression to overt leukaemia.
Thus the work presented as a whole in this thesis confirm the view that
Further study of the role of TEL deficiency could be performed in the TEL/AML1
transgenic hESC model. In the TEL/AML1+ background, the knockdown of TEL by
RNA-interference (RNAi) directed at exons 6 to 8 of TEL (so avoiding any
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knockdown of the TEL/AML1 fusion) could replicate TEL deficiency (Figure 5.1).
This would replicate TEL deficiency in the hESC model and thus allow the study of
TEL in a multipotent system, a valid approach given that TEL overexpression
identified gene expression changes consistent with an inhibition of haematopoietic
differentiation in various lineages (Table 4.4). This approach of changing the
expression of genes in a TEL/AML1+ background could be used, in theory, to
investigate the function of any gene in the context of TEL/AML1+ leukaemia. In
particular, such an approach could provide further evidence for the importance of
genes known to affect differentiation (e.g. Ikaros / IKZF1; Mullighan et al 2008), or
indeed investigate genes identified in the TEL overexpression model that have
previously not been linked to leukaemia (e.g. CLIC5 and NETO1). Recently, an
unbiased screen exploiting random insertion mutagenesis in a TEL/AML1-transgenic
mouse revealed a large number of genes that contribute to leukaemia, some of which
were known common secondary mutations in humans, and others which were novel
(van der Weyden et al 2011). Using standard overexpression or knockdown
methods, it would be possible in our hESC model to conduct preliminary studies into
what effects these novel mutations have on haematopoiesis and lymphopoiesis in a
human system, reducing dependence on expensive and time-consuming mouse
models.
Figure 5.1 – TEL knockdown in the TEL/AML1+ hESC model
Upon transfection of TEL/AML1, mRNA from both the TEL locus and TEL/AML1 cDNA is transcribed. RNAi
against exons of TEL not present in TEL/AML1 (i.e. exons 6 to 8) would knockdown the expression of TEL but
leave the expression of TEL/AML1 unaffected, and thus replicate TEL deficiency frequently observed in
TEL/AML1+ leukaemia.
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The work presented in this thesis makes two novel contributions to the field of
TEL/AML1+ leukaemia; firstly, a gene expression microarray data set showing the
role of TEL in this leukaemia subtype; and secondly, a model based on hESCs that
could be used to further investigate the roles of TEL and these differentially
regulated genes in haematopoietic development. Both the gene expression
microarray data set and the influence of TEL/AML1 in haematopoietic development
are consistent with previous studies in the field, and thus are relevant to the study of
ALL. This work has the potential to make further contributions to our understanding
of leukaemia, as well as potential therapeutic targets for the treatment of leukaemia,
and thus warrants further exploitation.
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